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ABSTRACT 
Adaptation of the streptococcal collagen-like protein 1, Scl1, of group A 
Streptococcus to recognize fibronectin type III repeats 
Dudley H. McNitt 
Background: Group A Streptococcus (GAS) is responsible more than 700 million 
infections worldwide each year. Most of these infections start with initial colonization of 
the throat and skin, which is augmented by surface adhesins. The streptococcal collagen-
like protein 1 (Scl1) is a major adhesin expressed by GAS that contains an N-terminal 
sequence-variable (V) domain, protruded away from the cell surface by the collagen 
domain. The Scl-V domain is comprised of three pairs of anti-parallel α-helices 
interconnected by surface-exposed loops. For attachment, GAS adhesins require a portal 
of entry, such as a wound or breach in the epithelium, to enter the body. Within the wound, 
host cells deposit a provisional extracellular matrix (ECM) rich in cellular fibronectin (cFn) 
isoforms that contain fibronectin type III (FnIII) repeats, including unique extra domains A 
(EDA) and B (EDB), that are absent in plasma fibronectin. Tenascin-C (TnC) is another 
ECM component, which is substantially deposited within the wound microenvironment 
and contains FnIII repeats. In addition to healing wounds, EDA/EDB-cFn and TnC are 
found in tumor microenvironments. Our early work showed that the Scl1-V domain binds 
to cFn via EDA. Our work here has focused on understanding this selective binding of 
Scl1 to wound-associated ECM and how this interaction contributes to GAS 
pathogenesis. Hypothesis: The Scl1-V domain has adapted the capability to bind to 
wound-associated FnIII repeats, EDA and EDB in cFn, and in TnC. Results: First, we 
discovered that surface-exposed loops of the Scl1-V domain, surrounding an acidic patch, 
participate in EDA binding. Both structural characteristics were conserved among 
phylogenetically distant Scl1 variants. We next discovered that Scl1 also binds to EDB in 
cFn, as well as to the FnIII repeats in TnC. Using defined recombinant proteins, we show 
that loop-region of the Scl1-V domain mediates Scl1 binding to EDB and to the TnC FnIII 
repeats. Moreover, Scl1-FnIII binding promotes GAS attachment and biofilm formation in 
vitro. We also developed a more complex heterogeneous in vitro matrix-system, 
deposited by cancer-associated fibroblasts, to demonstrate the selective binding of Scl1 
to EDA/EDB-cFn isoforms and to TnC FnIII repeats within this matrix. Conclusions: Scl1 
binds to wound-associated FnIII repeats in both cFn and TnC. This work has implications 
in GAS wound-colonization and infers Scl1-FnIII binding in modulating host wound-
healing responses. This work lays a foundation for the development of strategies to target 
GAS during wound infections, as well as provides a rationale for the use of Scl1 in 
targeting cancerous tissues.  
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FIBRONECTIN BINDING PROTEINS OF GAS: UNIQUE ADHERENCE OF THE SCL1 
ADHESIN TO THE WOUND MICROENVIRONMENT 
(Portions of the introduction have been published in a mini-review; see appendix 2) 
 
Group A Streptococcus epidemiology  
Group A Streptococcus (GAS) is a human-adapted pathogen that is responsible for over 
700 million infections worldwide each year (1). Diseases linked to GAS infection range in 
severity from non-invasive superficial pharyngitis and impetigo to severe and invasive 
diseases like necrotizing fasciitis or streptococcal toxic shock syndrome (1). Additionally, 
post-infectious autoimmune sequelae include rheumatic fever and rheumatic heart 
disease, acute poststreptococcal glomerulonephritis, and pediatric autoimmune 
neurologic disorder associated with streptococci, also known as PANDAS (2-4). Invasive 
and autoimmune diseases account for approximately 500,000 deaths globally each year 
(1). GAS can transiently colonize barrier tissue sites, such as throat mucosa and the 
surface of the skin (5). When the barrier is breached, the resultant wound provides GAS 
with a portal of entry into host tissues and the interstitium. Once inside the wound, GAS 
adheres to exposed extracellular matrix (ECM) and cells, thus enabling colonization of 
the host. These essential first steps of infection that are critical to colonization are 
augmented by several GAS surface adhesins, such as a prominent GAS surface adhesin 
and key virulence factor, the M protein (6). DNA sequence encoding the outermost amino-
terminal end of the M protein is hypervariable and is used for GAS typing, resulting in 
more than 220 emm types of GAS reported globally (7). Two other major GAS surface 
proteins are the streptococcal collagen-like proteins 1 (Scl1/SclA) and 2 (Scl2/SclB), 
which are ubiquitous among GAS strains (8-12).  
 
The streptococcal collagen-like proteins 
Both scl1 and scl2 genes have been identified in many epidemiologically important M 
types of GAS (8-11,13). scl1 expression is positively regulated by the multiple-gene 
regulator, Mga (8,9,14). Mga is a major virulence-associated transcriptional regulator 
expressed in all GAS strains (15-18). It controls the expression of key GAS virulence 
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factors, including the M and M-like proteins, C5a peptidase, Sic, and Scl1 (8,9,19-21). 
Elevated transcription of scl1 has been found in GAS isolates from both non-invasive and 
invasive infections (13,22). Unlike Scl1, expression of full-length Scl2 protein is controlled 
during polypeptide translation by phase variation, which is associated with varying 
numbers of pentanucleotide CAAAA repeats located downstream of the scl2-start codon 
(9-11). Like scl1, scl2 transcription has been observed during GAS infection, but protein 
expression varies between strains due to the aforementioned phase variation (9,23). The 
invasive M3-type GAS strains (24-26) show elevated levels of scl2 transcripts and low 
levels of scl1 transcripts, compared with strains of several other M types (27). 
Both Scl1 and Scl2 proteins have similar structural organization (28) (Fig. 1A). Both 
are homotrimeric, with an N-terminal globular, sequence-variable (V) domain, followed by 
the collagen-like (CL) domain and a C-terminal cell wall-anchoring domain. The CL 
domain of both Scl1 and Scl2 is composed of varying numbers of Gly-Xaa-Yaa collagen 
repeats, analogous to triple-helical mammalian collagen (29,30). Structurally, the triple 
helix is a motif characterized by the association of three distinct polypeptide chains 
wrapped around a common axis, where each chain assumes a polyproline-II (PPII)-type 
conformation (31-34). However, the CL domain does not contain hydroxyproline, which 
provides the main stabilizing contribution to triple-helix structure in mammalian collagens 
(35-39). Indeed, bacteria lack the prolyl-hydroxylase, an enzyme necessary for post-
translational modification of Pro to Hyp. Despite the lack of Hyp, however, Scl1- and Scl2-
CL domains form triple-helix structures with a stability ranging between 35 and 40ºC, 
similar to mammalian collagens (29,40-43). Instead, alternative stabilization mechanisms 
are employed in bacteria that secure triple-helix stability, such as hydration networks, 
electrostatic interactions between side chains, and specific stabilization repeats (30,43).  
The primary sequences of V domains differ both between and within Scl1 and Scl2 
variants originating from strains of different M types (28). Despite sequence differences, 
secondary-structure prediction algorithms identified two conserved α-helices interspaced 
by a hypervariable segment (8,44). This prediction was validated by crystallography data 
of the recombinant protein, corresponding to the Scl2-V domain from an M3-type GAS 
(45,46) (Fig. 1A). The crystal structure showed that the Scl2-V domain folds into a trimeric 
six-helical bundle, forming a cylinder that is 30 Å in diameter and 60 Å in height, which is 
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stabilized by a hydrophobic core and salt bridges. The inner core of this bundle consists 
of a parallel, trimeric structure in which helices are wrapped in a gradual left-handed 
superhelix. Three further helices wrap antiparallel to the internal helices in a left-handed 
 
Figure 1: Scl1 and Scl2 structure. A) Top, Schematic representation of the common domain 
organization of Scl1 and Scl2 proteins. Domains: V, the N-terminal globular sequence-variable domain; 
CL, the collagen-like domain; G+, the C-terminal cell-wall-anchor domain. Bottom insert, Cartoon 
representation of Scl2-V-CL structure. This structure has been obtained by combining the crystal 
structure of the Scl2-V domain, with the modeled structure of the CL domain, generated using the 
structure of the collagen peptide (Pro-Pro-Gly)10 as a template; only the first 15 Gly-X-Y repeats is 
shown for clarity. B), Homology model of the Scl1-V domain. Left, Side view of the Scl1-V domain, 
showing the six-helix bundle fold, with three pairs of anti-parallel α-helices and connecting loop 
segments. The N-terminus and C-terminus of a single presentative α-helix pair is marked. Right, Top-
down view of the Scl1-V domain. The three helix-pairs are shown, wrapped in a left-handed orientation. 
The homology model is based on the crystal structure of the Scl2-V domain originating from M3-type 




direction around the exterior of the central trimer. The pairs of anti-parallel α-helices are 
each connected with PPII-type loop segments. Structural and biophysical data suggested 
that V domains of Scls display dichotomous functions by acting as triple-helix stabilization 
domains through facilitating proper folding and refolding of the collagen triple-helix (47). 
Consistently, recombinant collagen-domain constructs cannot refold following thermal 
denaturation (29,47). In addition to facilitating trimerization of the CL-domain, the V-
domain of Scl1 mediates host-pathogen interaction (48-50).  
 
 
Scl1 binds to several ligands found in tissue and blood, compared with Scl2; the 
latter’s function in GAS pathogenesis is less clear (reviewed in (28)). The collagen domain 
of Scl1 can bind and activate human collagen integrin receptors (48,49,51), whereas the 
V domain is responsible for the majority of ligand binding (44,51-55). Interestingly, Scl1 
mutants of M1-type GAS were attenuated in a mouse skin infection model, but not 
following intraperitoneal inoculation (12), conceivably due to differences in the capacity 
to evade innate immune defenses between wild type and mutant strains (12,56). In 
contrast, Scl1 mutants of two other M types exhibited increased lesion size in mouse skin 
(27). In vitro assays and animal models show that Scl1 contributes to host colonization 
and biofilm formation within tissues by binding to host ECM proteins (27,52,57). Scl1 
binds to wound-enriched isoforms of cellular fibronectin containing the extra domain A 
(58). The ubiquitous presence of Scl1 in GAS strains across different M types and the 
distinctive binding to cellular fibronectin isoforms specific to the wound microenvironment, 
which enables favorable colonization of the first environment encountered by GAS during 
infection. 
 
Extracellular matrix proteins associated with the wound microenvironment 
GAS utilizes a wounded portal of entry to gain access to host tissues, initiating host 
colonization and subsequent infection. One of the essential measures during wound 
healing is the deposition of new distinct matrices that participate in tissue remodeling and 
signal pro-inflammatory responses. These complex processes engage macrophages and 
neutrophils in clearing out tissue debris and keratinocytes in facilitating wound closure 
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(59,60). One of the major constituents of these matrices is fibronectin (Fn) (61-63). Fn is 
a high-molecular weight glycoprotein that exists in two main forms within the body, e.g., 
as a plasma fibronectin (pFn) secreted by hepatocytes into the blood stream and as 
 
Figure 2: Wound-associated extracellular matrix proteins that contain fibronectin type III 
repeats. Schematic of fibronectin, model of EDA, EDB, and tenascin-C. A) Schematic of fibronectin, 
with fibronectin type I, II, and III repeat domains denoted by squares, ovals, and hexagons, respectively. 
Regular Fn domains are shown in light grey and are numbered, constitutively, whereas alternatively 
spliced extra domains A, B and IIICS are shown in dark gray. Scl1-EDA binding is marked with an arrow 
and binding regions for several GAS Fn-binding proteins (PrtF1, FbaA, SOF, etc.) are also indicated. 
B-C) Cartoon representation of the EDA (left) and EDB (right) domains of fibronectin. Models (PDB 
accession code: 1J8K) show the β-sandwich structures of each, with each β-strands marked (A, B, C, 
C’, D, E, F); the C-C’ loop of EDA is shown in ball-and-stick style. D) Schematic representation of full-
length TnC. Depicted are from the N-terminus: assembly domain (triangle), epidermal growth factor-
like repeats (ovals), constitutively expressed fibronectin type III repeats 1-5 and 6-8 (light hexagons), 
alternatively spliced fibronectin type III repeats (dark hexagons), fibrinogen-related domain (circle). 




cellular fibronectin (cFn) secreted by cells within tissues (64). Both forms of fibronectin 
originate from the same gene, FN1, and are composed of three different types of 
repeating domains: types I, II, and III (64,65)(Fig. 2A). cFn-mRNA can be alternatively 
spliced, resulting in more than 20 different isoforms found within the body (65-67). This 
alternative splicing leads to the inclusion of extra domains that are found in cFn, but not 
pFn. The alternatively spliced type III domains are known as extra domain A (EDA/EIIIA) 
and extra domain B (EDB/EIIIB), as well as different combinations of the type III 
connecting segment (IIICS), also known as the variable domain (67).  
The EDA-containing cFn isoforms (EDA/cFn) are highly expressed during 
embryonic development but only at negligible levels within healthy adult tissues (68-70). 
On the other hand, EDA/cFn isoforms are deposited in high quantities within inflamed and 
wounded tissue environments in adults and play essential roles in wound healing (69,71-
73). EDA adopts the prototypical type III repeat structure, which is composed of two β-
sheets, forming a β-sandwich consisting of seven β-strands (i.e. A, B, C, C’, D, E, and F) 
connected by loop segments (74,75)(Fig. 2B). In full-thickness excisional wounds, wound 
healing was delayed in mice lacking EDA, however, others report no differences in wound 
healing between normal and EDA knockout mice (72,76). These differences may be due 
to differences in genetic background of the mice used in each study, in wounding method 
or differences in analysis. Other studies in mice found deletion of EDA protected mice 
from developing lung fibrosis during murine models of pulmonary fibrosis (77), and when 
crossing EDA knockout mice to ApoE knockout mice, EDA deletion results in smaller 
atherosclerotic lesions compared to control mice (78). Dysregulation of EDA splicing, 
resulting in EDA overexpression, results in increased occlusive thrombi during vascular 
damage compared to normal mice (79), and EDA overexpression results in differences in 
behavior compared to normal mice (80).  
An important role for EDA/cFn within wounded tissue is to support host cell 
attachment, achieved by the interactions between the C-C’ loop of EDA and cellular 
integrin receptors, α9β1 and α4β1, as well as α4β7, which binds EDA by an unknown 
mechanism (81-83). Integrin α9β1 is upregulated by keratinocytes during tissue injury 
(71,84). Integrins α9β1, α4β1, and α4β7 through their attachment to EDA/cFn regulate 
7 
 
important repair mechanisms, such as cell migration, angiogenesis, myofibroblast 
differentiation, growth factor secretion, and tissue remodeling (71,73,83,85,86).  
Like EDA, EDB also adopts the prototypical type III repeat structure (Fig. 2C), and 
follows the same expression pattern as EDA, highly expressed during embryogenesis 
and development, but only found in wounded and inflamed adult tissues (69,87). Isoforms 
of cFn that contain EDB are highly expressed in the cerebral spinal fluid of patients 
suffering from bacterial meningitis, compared to non-bacterial meningitis (88). The 
canonical role of EDB is its association with angiogenesis, as it is highly expressed around 
growing vasculature in human tissues during fetal tissue development, in the granulation 
tissue of wounds, and within the stroma around tumors, suggesting an important role for 
EDB containing cFn isoforms in the growth of blood vessels (89). Despite this known 
association, the role of EDB during wound healing is not as well understood as that of 
EDA, as no direct cell binding sites have been identified within EDB (84). EDB knockout 
mice do not exhibit noticeable differences compared to normal mice in studies examining 
behavior, angiogenesis, tumorigenesis, and bone fracture healing (90-92). The lack of 
noticeable changes in these systems may be due to compensation of EDA or other ECM 
proteins (91). Double knockout of EDA and EDB is embryonic lethal in mouse models, 
exhibiting 80% penetrance, with the surviving pups exhibiting severe cardiovascular 
defects (93), suggesting that EDA and EDB may compensate for each other when one 
domain is unable to be expressed. Some studies have however identified important roles 
for EDB in fibronectin structure, using in vitro or ex vivo samples. Inclusion of EDB in cFn 
leads to confirmation changes that expose cryptic sites that facilitate cell attachment to 
cFn (94). In addition, EDB isoforms of cFn contributes to  head-to-tail dimerization of cFn, 
facilitating Fn fibril formation on the surface of cells, supported by the observation that 
mouse embryonic fibroblasts from EDB knockout mice deposit smaller Fn fibrils than 
those from normal mice (90,95). Though EDA and EDB are fibronectin type III repeats 
(FnIII repeats) with highly regulated expression, other ECM proteins within the wound 
microenvironment also contain FnIII repeats.  
Tenascin-C (TnC) is another ECM protein that is highly expressed within the 
wound microenvironment, as a component of the provisional wound matrix, and contains 
FnIII repeats (96). TnC is high molecular weight glycoprotein, and is the founding member 
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of the Tenascin family, that also consists of Tenascin-R, Tenascin-X, and Tenascin-W 
(97). TnC is comprised of distinct regions, starting from the N-terminus, the heptad 
repeats, followed by the epidermal growth factor-like repeats, the FnIII repeats, and a C-
terminal fibrinogen-related domain (Fig. 2D)(98). The FnIII repeats of TnC adopt the 
prototypical FnIII β-sandwich structure, as well as undergo alternative splicing, where the 
first 5 and last 3 repeats are constitutively expressed, and a varying number and 
combination of 9 different FnIII repeats, in humans, can be included between repeats 5 
and 6 (97,99). This results in the potential for over 511 different isoforms of TnC to be 
expressed in tissues, though only 100 variants have been identified in tissues (97). 
Though both Fn and TnC contain FnIII repeats, they originate from different genes, FN1 
and TNC, respectively (100,101). Genetic analysis of animals from different phylum 
reveal that while fibronectin was discovered first, TnC appears first in evolution (100).  
TnC is often co-expressed with Fn in tissues, circulating in blood plasma at low 
levels, but highly expressed in blood and tissues upon inflammation, similar to EDA and 
EDB isoforms of cFn (96,102). Upon inflammation and tissue damage, TnC is deposited 
into the wound from blood plasma, co-localizing with fibronectin fibrils in the provisional 
ECM (103,104). At the same time, TnC mRNA is upregulated within the first 24 hours of 
wounded tissue cells such as keratinocytes and fibroblasts, and is deposited during this 
time (105-107). TnC protein levels will grow into their peak during the beginning of tissue 
building and repair phases of wound healing, deposited by activated fibroblasts, and 
remain high in the tissues for several days to weeks pending the anatomical site and 
nature of the injury (96). As a part of the ECM, TnC plays multiple roles, such as 
supporting other proteins within the ECM, regulating cell attachment to other ECM 
proteins, initiating inflammation via direct binding to TLR4, and is directly bound by cells 
to facilitate wound closure (108) (109-112). The FnIII repeats of TnC are directly bound 
by cells via integrin receptors, due in part to the presence of the RGD motif and an IDG 
motif in the third TnC FnIII repeat, bound by αvβ1 and α9β1 respectively (TnFnIII)(Fig. 2D) 
(113-115). These, and other integrin binding interactions, were found to mediate cell 
motility and survival (115), and are believed to be critical for proper wound healing through 
facilitating keratinocyte and fibroblast proliferation and migration and regulating 
attachment to collagen type I fibers (96,107,116,117). In addition to regulating host cell 
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attachment, TnC Fn III fragments also regulate ECM assembly through direct binding to 
proteoglycans and play important roles in tissue remodeling through mediating 
myofibroblast wound contracture (118,119).  
 
Fibronectin-binding proteins of GAS 
In addition to being a target for host cells, TnC is bound by several pathogens, including 
GAS, as GAS expresses several adhesins that bind to both TnC (120,121) and Fn (122), 
though, there are more examples of those that bind to Fn.  
GAS expresses a number of fibronectin binding proteins, which can be broadly 
divided into two types, those with fibronectin-binding repeat domains, and those without. 
(122,123). The fibronectin-binding repeats are found in several fibronectin-binding 
proteins of GAS, including Protein F1, Protein F2, Serum opacity factor, and fibronectin-
binding protein A (124-129). The unstructured fibronectin-binding repeats of these 
adhesins bind to the N-terminal FnI repeats, through a tandem β-zipper mechanism 
(125,130). The FnI repeats adopt a β-hairpin, a three-stranded antiparallel β-sheet. Upon 
contact with the FnI repeats, the unstructured region(s) of these fibronectin-binding 
repeats fold into a β-strand structure, and this strand will accent the stacked β-strands in 
the FnI repeat (125,130). Through binding to the type I repeats of Fn, these adhesins 
contribute to GAS adherence to both pFn and cFn. These types of repeats have been 
suggested to bind to the FnIII repeats (121), however, no data exists as of this writing that 
demonstrates direct binding to the FnIII repeats by any GAS fibronectin-binding protein 
that contains these unstructured repeats. Several of these adhesins have been shown to 
contribute to both host colonization, as well as to intracellular entry of GAS into cells via 
a bridge mechanism, where GAS adheres to the FnI repeats that are subsequently 
internalized via endocytosized due to interactions between host-cell integrin receptors 
(e.g. α5β1) and the FnIII repeats (131,132), consequently internalizing the attached GAS. 
Deletion of several of these adhesins in GAS has shown to result in decreases in cell-
adherence and virulence compared to WT strains (129,133,134).  
Scl1 of GAS falls into the second category of adhesin, as Scl1 proteins across M 
types do not contain any fibronectin-binding repeat domains (12). Adhesins in this 
category are known to bind within the type I, II, and III repeats of Fn (122), however, Scl1 
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is the only adhesin, as of this writing, shown to adhere to the wound-associated 
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ABSTRACT 
Keratinized epidermis constitutes a powerful barrier of the mucosa and skin, effectively 
preventing bacterial invasion, unless it is wounded and no longer protective. Wound 
healing involves deposition of distinct extracellular matrix (ECM) proteins enriched in 
cellular fibronectin (cFn) isoforms containing extra domain A (EDA). The streptococcal 
collagen-like protein 1 (Scl1) is a surface adhesin of group A Streptococcus (GAS), which 
contains an N-terminal variable (V) domain and a C-terminally located collagen-like 
domain. During wound infection, Scl1 selectively binds EDA/cFn isoforms and laminin, as 
well as low-density lipoprotein (LDL), through its V domain. The trimeric V domain has a 
six-helical bundle fold composed of three pairs of anti-parallel α-helices interconnected 
by hypervariable loops, but the roles of these structures in EDA/cFn binding are unclear. 
Here, using recombinant Scl constructs (rScl) to investigate structure–function 
determinants of the Scl1–EDA/cFn interaction, we found that full-length rScl1, containing 
both the globular V and the collagen domains, is necessary for EDA/cFn binding. We 
established that the surface-exposed loops, inter-connecting conserved α-helices, guide 
recognition and binding of Scl1-V to EDA and binding to laminin and LDL. Moreover, 
electrostatic surface potential models of the Scl1 V domains pointed to a conserved, 
negatively charged pocket, surrounded by positively charged and neutral regions, as a 
determining factor for the binding. In light of these findings, we propose an updated model 
of EDA/cFn recognition by the Scl1 adhesin from GAS, representing a significant step in 
understanding the Scl1–ECM interactions within the wound microenvironment that 





Group A Streptococcus (GAS) is a human adapted pathogen responsible for over 700 
million disease-associated infections across the globe each year and an estimated 
healthcare cost of 224-539 million dollars in the United States alone (1,2). GAS 
asymptomatically colonizes the general population of adults (5-15%) and children (20-
30%), most of the morbidity is associated with superficial infections of the throat and skin 
(3). In addition, bacterial spread may result in severe soft tissue and systemic infections, 
like necrotizing fasciitis and streptococcal toxic shock syndrome (4), or may lead to post-
infectious sequalae, such as acute rheumatic fever and rheumatic heart disease, post-
streptococcal glomerulonephritis, and pediatric autoimmune neuropsychiatric disorders 
associated with streptococcal infections (5,6). For the initial colonization of the human 
host, GAS requires a portal of entry, which is constituted by a breach in the epithelial cell 
lining (thenceforth as wound) that allows the pathogen to spread into deeper tissue and 
blood. GAS expresses numerous surface adhesins that bind to host extracellular matrix 
(ECM) (7). ECM binding facilitates initial localized colonization, during which GAS forms 
tissue microcolonies embedded in glycocalyx (8). The interplay between GAS adhesins 
and host’s ECM-components, stable tissue microcolony formation, and superficial versus 
invasive infection are of significant clinical interest.  
Among prominent GAS surface proteins are the streptococcal collagen-like (Scl) 
proteins 1 and 2 (9-13). Scl1 and Scl2 are homotrimeric proteins that have similar domain 
organization, which is comprised of an N-terminal globular sequence-variable (V) domain, 
a collagen-like (CL) domain, and the C-terminal cell-wall anchoring domain (9,10). The 
CL-domain of both Scl1 and Scl2 consists of varying numbers of Gly-Xaa-Yaa collagen 
repeats that adopt a right-handed triple-helix structure, similar to mammalian collagen 
(14-16); Scl1-CL domain may interact with human collagen-binding integrins, promoting 
GAS internalization (17-19). The outermost-exposed V domains vary in amino acid 
sequence between and within Scl1 and Scl2 variants and are typically associated with M 
type antigen (9,11). Despite significant sequence variation, the V domains of Scl1 and 
Scl2 were predicted to contain two conserved α-helices, spaced by hypervariable regions 
(11,20). Recent reports of a first crystal structure for the Scl2-V domain validated these 
secondary structure predictions (21,22). The recombinant Scl2-V globular domain forms 
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a trimeric structure, which folds into a 6-helix bundle, with 3 pairs of anti-parallel α-helices 
inter-connected by hypervariable loops (22). Despite both Scl1 and Scl2 having similar 
structural organization, they play different roles in GAS pathogenesis (23). While the 
number of Scl2 targets identified remains scanty (24), Scl1 variants from diverse GAS M 
types bind several host proteins. Ligands include tissue components, cellular fibronectin 
(cFn) and laminin (Lm), as well as blood components, low- and high-density lipoproteins, 
and complement Factor H (CFH) and Factor H-related protein 1 (CFHR1), (20,25-28). It 
is not clear how the variable sequences of the Scl1-V domain bind the same ligands, but 
two mutually-exclusive binding patterns were observed. Scl1 proteins from several M-
types bind to ECM proteins, cFn and Lm, and low-density lipoprotein (LDL), but not FH 
and CFHR1; the converse is also true. 
One of the major ECM targets for GAS within wounded tissue is fibronectin (Fn) 
(7). Fn is a high molecular weight glycoprotein that is found throughout the human body 
in two main forms, either as a soluble circulating plasma fibronectin (pFn) secreted by 
hepatocytes or as an insoluble cellular fibronectin (cFn) secreted by a variety of cells 
within tissues (29). All forms of Fn are transcribed from a single gene, FN1, and are 
comprised of three modules of fibronectin repeats: type I, II, and III (29,30). There are 
about 20 isoforms of human cFn that include combinations of the type III repeats, e.g. 
extra domain A (EDA/EIIIA) and B (EDB/EIIIB), and a varied number of V repeats (30,31). 
These isoforms differ by spatial-temporal distribution following injury (32,33). Specifically, 
the EDA-containing isoforms are normally expressed during embryo-genesis, though, 
they are found in negligible levels in most adult tissues, except in healing wounds where 
EDA/cFn is highly upregulated (32,34). The EDA fold is a β-sandwich structure formed 
by seven antiparallel β-strands (i.e. A, B, C, C’, D, E, and F) connected by loops (35,36). 
The C-C’ loop is an important site for cell attachment, via integrin receptors α9β1 and α4β1 
(37,38), and attachment to the C-C’ loop by these integrins has been shown to regulate 
important tissue repair and wound healing functions (39-43).  
Here, we established that surface-exposed loops within V domain structure guide 
Scl1 to bind EDA/cFn, as well as two other Scl1 ligands, laminin and apolipoprotein B100 
(ApoB100) of LDL. A second conserved constituent within variable Scl1-V domain is a 
common topography of the electrostatic surface potential surrounding guiding loops, 
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which includes a negatively-charged patch formed by collective Asp and Glu residues 
contributed by all three monomeric chains. The proposed model accommodates binding 
of common ligands by phylogenetically diverse Scl1 variants. This work implies the 
evolutionary response of the Scl1-V domain to selective pressure, resulting in the 
retention of the conserved structure and function of ligand binding. This underscores the 
importance of Scl1 binding to EDA-containing fibronectins deposited at the pathogen 
portal of entry.  
 
RESULTS 
The globular sequence-variable (V) domains of Scl1 and Scl2 contain conserved 
helix-loop-helix structures – Two streptococcal collagen-like proteins, Scl1 and Scl2, 
display a similar “lollipop-like” structural organization (Fig. 1A), which is comprised of an 
N-terminal globular V-domain head and a C-terminal CL-domain stalk (14). Multiple 
sequence alignments illustrate a significant variations in the V regions, both between and 
within Scl1 and Scl2 families (Fig. 1B). Despite sequence variation, several secondary 
structure prediction algorithms deduced that both Scl1-V and Scl2-V domains contain two 
conserved α-helices inter-connected by hypervariable regions. Crystallography data 
rendered for the recombinant Scl2-V construct, derived from M3-type GAS, revealed that 
rScl2.3-V protein forms a homotrimer, with three pairs of conserved α-helices forming a 
6-helix bundle and hypervariable regions forming surface-exposed loops (PDB accession 
code: 4nsm). To examine the conservation of the helix-loop-helix motif, homology models 
of two sequence-diverse Scl1- and Scl2-V domains were generated (Fig. 1C), using the 
structure of Scl2.3-V domain as template. The homology model structure of Scl1.1-V 
domain from M1-type GAS was based on the consensus- sequence alignment (24% 
sequence identity on 65 amino acid residues), and the model of Scl2.28-V domain from 
M28 GAS was obtained with the same approach (51.5% identity with Scl2.3-V sequence 
on 74 residues). Homology models predict with high confidence that Scl1.1-V (E= 3.5 x 
10-16) and Scl2.28-V (E= 1.8 x 10-40) domains each adopts a similar six-helical-bundle 
trimeric structure, as Scl2.3-V template. The solved crystal structure and homology 
models rendered here show that globular domains of Scl1.1 and Scl2.28 variants can 
trimerize without the presence of the CL-domain, an observation that was also found in 
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Scl2 proteins from other M-types (44). Furthermore, we hypothesized that trimeric rScl1-
V constructs will retain their binding function to ECM ligands.  
 
The conserved structure of Scl1-V domain requires the collagen domain for ligand 
binding – Full-length rScl1 proteins, derived from different GAS M-types, bind to host cFn 
via interactions with EDA, which is mediated by Scl1-V domain (25,45). Here, we 
examined whether the V-domain-alone rScl1 constructs bind to cFn and rEDA. Full-length 
recombinant Scl1 constructs, derived from M1- (rScl1.1FL) and M3-type (rScl1.3FL) 
strains, as well as their corresponding V-domain-only proteins (rScl1.1V and rScl1.3V) 
were immobilized in wells and tested for ECM-ligand binding. Unexpectedly, neither 
rScl1.1V nor rScl1.3V constructs bound rEDA and cFn, while the corresponding full-length 
rScl1FL control proteins bound both ligands (Fig. 2). Thus, while the V domains of Scl1 
proteins can fold independently of their CL domains, there are currently unknown 
structural constraints that require the presence of continuous CL domains for EDA/cFn 
recognition.  
 
The loop region of Scl1-V domain plays a central role in ECM recognition and 
binding - The binding site for the Scl1-V domain within the loop segment located between 
C- and C’-β-strands of the EDA β-sandwich (45). Here, we hypothesized that EDA binds 
to surface-exposed loops of Scl1.1-V domain, which we since identified in the crystal 
structure and deduced in the homology models (Fig. 1C). To test this hypothesis, we 
generated two full-length chimeric rScl.chi proteins: (i) we inserted the 22-amino-acid loop 
sequence of the ECM-binding-positive rScl1.1 variant (residues 25-46 of the V-domain) 
in place of the respective loop sequence of the ECM-binding-negative protein rScl2.28 
(residues 20-45), resulting in the chimeric construct rScl.chi1FL (Fig. 3A); and (ii) the 
reverse was also constructed, by inserting the 26-amino-acid-loop region of rScl2.28-V in 
place of loop sequence of rScl1.1-V, resulting in rScl.chi2FL. To identify the proper site 
for inserting these sequences, we considered secondary structure predictions, computed 
with JPRED; resulting models were then minimized using GROMACS.  
To ensure that we did not substantially alter the overall structure of the chimeric 
proteins, both rScl.chi1FL and rScl.chi2FL were examined by circular dichroism (CD) 
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spectroscopy and electron microscopy of rotary shadowed samples (Fig. 3B). The 
wavelength scans of the original rScl1.1FL and rScl2.28FL proteins each exhibit a positive 
peak of molar ellipticity at 220 nm, [θ]220 (14), which is a characteristics of the collagen 
triple helix (46). The CD spectra of both chimeric proteins, rScl.chi1FL and rScl.chi2FL, 
rendered at 20ºC, show peak ellipticity values at 220 nm (Fig. 3B, solid lines), thus, 
demonstrating that both chimeric constructs adopt triple helix structures. These peaks 
were not observed at 50ºC, indicating that each triple helix unfolded (Fig. 3B, dashed 
lines). The domain organization of both chimeric rScls was further examined via rotary 
shadowing and subsequent electron microscopy. This technique has been used 
previously by our lab and others to investigate the structure of multi-domain collagens, 
containing collagenous and non-collagenous domains (14,47). Both chimeric rScls 
displayed the characteristic two-domain lollipop-like organization, with the CL domain, as 
the stalk, and the globular V-domain head (Fig. 3B). Thus, swapping the loop regions 
between rScl1.1FL and rScl2.28FL did not alter the overall structural organization and 
triple-helices in the chimeric proteins.  
We next examined the binding characteristics of both chimeric proteins to rEDA 
and cFn ligands, with rScl1.1FL and rScl2.28FL serving as positive and negative controls, 
respectively. Binding data show that rScl.chi1FL chimera, containing donor-loop 
sequence of rScl1.1FL, binds both rEDA and cFn, while the reverse construct rScl.chi2FL 
did not bind to either ligand, similar to negative control protein rScl2.28FL (Fig. 3C). These 
data demonstrate the importance of the loop region in ECM binding for Scl1.1FL, and 
hypothetically for other Scl1 variants.  
To assess the importance of the Scl1.1-V loop in rEDA recognition in the context 
of whole-GAS cells, we complemented in-trans the scl1-inactivated mutant (Δscl1) of M1-
type strain (9) for the expression of original Scl1.1 (Δscl1::scl1.1) or chimeric Scl.chi2 
protein (Δscl1::scl.chi2), using plasmids pSL620 and pSL621 (Table 1). The M1-type wild 
type (WT) and Δscl1 mutant strains were used as positive and negative controls, 
respectively (Fig. 3D, left panel). Expression of surface Scl1.1 and Scl.chi2 was assessed 
via western immunoblotting of the cell wall fractions. Additionally, rScl1.1FL protein was 
loaded, as a positive control (rScl1.1FL is smaller on the SDS gel since it is devoid of the 
cell-wall region of native Scl1.1 protein). Western blot analysis detected an 
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immunoreactive band of ~55 kDa, corresponding to the Scl1.1 surface protein (9), in WT 
and both complemented strains but not in Δscl1 mutant complemented with vector alone. 
It should be noted that lower amounts of protein samples, prepared from complemented 
strains (5 µLs versus 25 µLs of WT and Δscl1 mutant samples), were loaded on the SDS 
gel to avoid an overwhelming chemiluminescent signal. This is not surprising since 
Scl1.1FL and Scl.chi2FL proteins are expressed in complemented strains from multicopy 
plasmids. A similar expression pattern was recorded by flow cytometry of GAS cells. 
Approximately 66% of the WT cells had detectable levels of surface Scl1.1 and only 2%-
background level recorded for Δscl1 mutant, compared to 77% and 92% detection 
recorded for trans-complemented Δscl1::scl1.1 and Δscl1::scl.chi2, respectively (not 
shown).  
We next investigated the rEDA binding to whole GAS cells by flow cytometry (Fig. 
3D, right panel). As expected, the WT and Δscl1::scl1.1-complemented cells bind rEDA, 
although, the complemented strain binds ~4 times more ligand due to overexpression of 
the surface Scl1.1 protein. In contrast, neither Δscl1 mutant nor complemented GAS cells, 
overexpressing the Scl.ch2 protein, bind rEDA. Thus, GAS cells that express native Scl1 
adhesin bind rEDA to the cell surface but lose this capacity once cells express a mutated 
variant with loop substitution from Scl2 protein, which does not bind EDA/cFn.  
 
The C-terminus of the loop region of Scl1-V domain plays a central role in ECM 
recognition and binding - We next designed additional chimeric rScl constructs to 
identify the specific region of the loop involved in rEDA and cFn binding. Instead of 
replacing the entire 22 amino acids, the Scl1.1-V loop was substituted into Scl2.28-V loop 
in three segments (Fig. 4A). For the first construct, only the N-terminal 11 amino acids of 
Scl1.1-V loop (residues 25-35) were substituted in place of the first 11 amino acids of the 
corresponding Scl2.28-V sequence (residues 20-30), resulting in construct rScl.chiNFL. 
Similarly, the C-terminal 11 amino acids of Scl1.1-V (residues 36-46) were substituted in 
place of the C-terminal 15 amino acids of Scl2.28 (residues 31-45), resulting in construct 
rScl.chiCFL. The third construct, rScl.chiIFL, contains the internal 11 amino acids of 




All three chimeric rScls, containing partial loop substitutions, were examined by 
CD spectroscopy and electron microscopy to confirm the essential structural 
characteristics (Fig. 4B). The CD spectra of all three chimeric proteins showed peak 
ellipticity values at 220 nm at 20ºC, while these peaks were not observed at 50ºC. Rotary 
shadowing images show that each chimeric rScl adopts a lollipop-like structural 
organization, with both CL-domain stalks and globular V domains. Thus, like whole loop 
substitutions, partial loop substitutions did not impact the structures of the chimeric rScls.  
Binding data to cFn and rEDA indicated that only one of the three chimeras with partial-
loop-substitutions, rScl.chiCFL (C-terminal substitution), binds to cFn and rEDA, similar 
to the whole-loop-substitution construct rScl.chi1FL and the loop donor protein rScl1.1FL 
(Fig. 4C); the other two chimeric proteins, as well as binding-negative control protein 
rScl2.28FL, do not bind to cFn and rEDA. We observed substantially lower O.D. values 
recorded during rEDA binding to rScl.chi1FL and rScl.chiCFL, compared to rScl1.1FL. 
This may reflect less than optimal loop conformation in chimeric proteins associated with 
rScl2 backbone. Additional binding assays were carried out with increasing 
concentrations (0.039 – 5.0 µM) of rEDA ligand and rScl proteins to assess binding 
specificity (Fig. 4D). Concentration-dependent binding of rEDA to rScl.chi1FL, 
rScl.chiCFL, and control protein rScl1.1FL plateaued between 2.5 and 5.0 µM 
concentration. In contrast, neither rScl.chiNFL, rScl.chiIFL, rScl.chi2FL, nor control 
rScl2.28FL showed significant binding to rEDA. Therefore, these data provide evidence 
that the C-terminal 11 amino acids of rScl1.1-V loop are sufficient for conferring EDA/cFn 
binding, when inserted into binding-negative rScl2.28 protein. 
 
Distribution of the charged residues on the surface of V domain hints at a binding 
mechanism for EDA/cFn - Our initial examination of the multiple sequence alignment of 
Scl1- and Scl2-V domains failed to identify any reasonably conserved pattern of residues, 
which could be responsible for EDA/cFn binding (Fig. 1A). Our subsequent experiments, 
employing the chimeric loop sequences, highlighted a pattern of charged amino acids 
(e.g., K45 (Scl1.1), E46, 47 (Scl1.1), and D48 (Scl1.1)) that were present within the uppermost portion 
of the Scl1-V loops and transitioning to inner α-helices, but were absent in the respective 
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regions of the ECM-binding-negative Scl2-V loops (Fig. 1B). Therefore, we sought to 
investigate the surface potentials of the Scl1-, Scl2-, and the chimeric rScl.chi-V domains.  
Electrostatic surface maps were computed from the homology models of the ECM-
binding-positive and binding-negative proteins. Electrostatic maps computed for Scl1.1- 
and Scl2.28-V domains reveal striking differences in the distribution of charges across 
their surfaces. A uniform, negatively-charged electrostatic potential characterizes the 
ECM-binding-negative Scl2.28-V on the frontal apical region of the molecule, opposite to 
the triple helix attachment (Fig. 5, black ovals). These charges are due to acidic residues 
located on the C-terminal part of the first outer α-helix, the loop region, and N-terminal 
part of the second inner α-helix. In this same area, the electrostatic potential map of the 
binding-positive Scl1.1-V domain presents a central negatively charged pocket or cleft 
(Fig. 5, white arrowhead), surrounded by a neutral and basic crown surface. Although 
less pronounced, the same features of electrostatic potential, with a central negatively-
charged region surrounded by a neutral/basic surface are present in maps of the binding-
positive chimeric rScl.chi1 and rScl.chiC-V domains, but not binding-negative chimeric 
rScl proteins. Therefore, the specific charge pattern of the V-domain head strongly 
differentiates between binding-positive and binding-negative V domains. These 
considerations suggest that interactions with partnering molecules occur through 
electrostatic recognition of the observed charge pattern.  
 
Scl1-V-loop is responsible for the ECM binding in phylogenetically distant Scl1 
variants - Phylogenetic analysis of the amino acid sequences of the Scl1-V and Scl2-V 
domains show that both Scl1 and Scl2 form two distinct clusters (Fig. 6A). Within Scl1, 
there are two observed ligand-binding patterns. The first pattern is represented by Scl1 
variants (Fig. 6A, black boxes) that bind host ECM proteins, cFn/EDA and Lm, (25) and 
ApoB100/LDL (20). The second pattern is represented by two Scl1 variants (Fig. 6A, 
black dots) that bind host complement components, CFH and CFHR1 (26,27), suggesting 
the potential for a unique adaptation of Scl1 proteins in M6 and M55 GAS. In contrast, the 
majority of rScl1 constructs investigated, show the former binding pattern and these Scl1 
variants are distributed all over many branches of the Scl1 cluster, highlighting the 
importance of ECM and LDL binding among GAS of various M types (20,25,45,48,49).  
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We next investigated whether the loop region of the phylogenetically distant 
Scl1.28-V variant, found in M28-type GAS, which shares 46% sequence identity with 
Scl1.1-V sequence (Fig. 6A, arrows), will support EDA/cFn binding. To do this, we 
substituted the loop region of Scl1.28-V (residues 25-46) in place of the loop region of 
Scl2.28-V (residues 20-45), resulting in the chimeric construct rScl.chi3FL (Fig. 6B). The 
CD spectra of rScl.chi3FL showed peak ellipticity at 220 nm at 20ºC, but not at 50ºC, and 
rotary shadowed images shows characteristic lollipop-like domain organization (Fig. 6C). 
Binding data to cFn and rEDA show that rScl.chi3FL binds both ligands (Fig. 6D). Thus, 
as in Scl1.1-V, the loop region of the divergent Scl1.28-V variant confers binding to both 
rEDA and cFn. Despite significant efforts, we could not generate a homology model of 
Scl1.28-V domain with a satisfactory global model quality estimation, due to the low 
sequence identity with the template structure of Scl2.28-V domain, close to 12%.  
 
The same structural constraints determine recognition and binding of the Scl1-V 
domain to laminin and apolipoprotein B100/LDL - Here, we sought to understand 
whether the same structural constraints apply during Scl1 binding to Lm and Apo 
B100/LDL (Fig. 7). Both rScl1.1FL and rScl1.3FL bound to Lm and ApoB100, while their 
respective V-domain-only counterparts, rScl1.1V and rScl1.3V, demonstrated negligible 
or no binding to both ligands (Fig. 7A). Chimeric constructs rScl.chi1FL, rScl.chiCFL, and 
rScl.chi3FL also bind to Lm and ApoB100/LDL, whereas binding-negative control proteins 
rScl2.28FL and rScl.chi2FL (reverse loop replacement to that in rScl.chi1FL) did not (Fig. 
7B, C); in addition, both rScl.chiN and rScl.chiI did not bind to Lm and ApoB100/LDL (data 
not shown). Collectively, our data show that: (i) full-length Scl1 protein is required for 
binding to all ligands; and (ii), the C-terminal 11 amino acids of the Scl1-V loop region is 
sufficient to mediate binding of Scl1 to its sequence- and structure-diverse ligands.  
 
DISCUSSION 
Adhesion to Fn is important for the pathogenesis of group A Streptococcus (7) by 
promoting the development of glycocalyx-embedded tissue microcolonies (in vivo 
biofilms) that are seen in clinical specimens collected from cases of pharyngitis and skin 
infections (8,50). We previously reported that the streptococcal collagen-like protein 1 or 
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Scl1 uniquely adheres to cFn isoforms expressed in wounded tissue, and that interactions 
involve the sequence-variable (V) globular domain of Scl1 and extra domain A (EDA) of 
cFn (25,45). Here, we report on the structural determinants involved in Scl1 binding to 
cFn, in the context of diversity among fibronectin-binding proteins of GAS and other 
bacterial pathogens. We also report that the same determinant of the Scl1 adhesin is 
responsible for binding to laminin (Lm) and apolipoprotein B100/low density lipoprotein 
(ApoB100/LDL) complex.  
Several mammalian collagens, such as collagen type I, IV, and X, contain an N-
terminal and/or C-terminal non-collagenous domain, which serves as a nucleation or 
trimerization domain, thereby facilitating proper folding of the three adjacent α-chains into 
a mature collagen triple helix (51). Similarly, bacterial collagen-like proteins contain non-
collagenous trimerization domains, often of unknown functions (14,44). The BclA of 
Bacillus anthracis endospores possess a C-terminal non-collagenous trimerization 
domain, BclA-CTD, for CL-domain folding and increased thermal stability (52). Two 
different recombinant BclA-CTD constructs had the same crystal structure, similar to a 
non-collagenous globular domain of C1q, independent from whether these constructs 
included the continuous CL domain (53,54). Likewise, the N-terminal V domains of Scl1 
and Scl2 assisted in the trimerization of homologous and heterologous CL domains 
(44,55), and the recombinant Scl2-V-only construct formed a trimeric 6-helical bundle 
structure (22). However, here we found that the rScl1-V-only constructs, derived from the 
corresponding full-length rScl1FL proteins, did not bind rEDA, cFn, Lm, and 
ApoB100/LDL. We propose that the triple helix imposes a restraint on the V domain in a 
way to destabilize it and make it more prone to conformational changes. We expect a 
slight effect on the tertiary structure but not on the secondary structure. A reason of the 
restraint may be the one residue stagger of triple helices, whereas the V domains are 
perfectly aligned; these structural features likely distort the V domain slightly, to make it 
more flexible.  
While Scl1 is unique amongst GAS Fn-binding proteins in recognizing the EDA 
type III repeat of cFn, several other bacterial adhesins may in fact recognize the EDA, 
due to their selective binding to cFn but not pFn, such as FimH of pathogenic E.coli, OppA 
and Msp of Treponema denticola, and Tp0155 of Treponema pallidum (56). In addition, 
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numerous bacterial surface proteins bind Fn type III repeats other than EDA that are 
present in both pFn and cFn, including proteins ShdA, ComE1, Pap31, and Ali, that are 
associated with the outer membrane of gram-negative bacteria (57-60) and fibrillar 
surface proteins Embp and PavA-B of gram-positive bacteria (61,62). Two pneumococcal 
Fn-binding proteins, PavA and PavB, bind to multiple FnIII repeats via common epitopes 
located on β-strands B, C, and F, as well as the AB and BC loops (62). This is, however, 
different from the Scl1 binding site on EDA, mapped to C-C’ loop (45). Interestingly, 
PavA/B did not bind the RGD sequence on FnIII10, which is recognized by the integrin 
α5β1, nor to the synergistic sites on repeats III8 and III9 (62), whereas the Scl1 binding site 
on C-C’ loop maps in the vicinity of binding site for integrins α9β1 and α4β1 (38,45). PavA 
and PavB binding to the FnIII repeats was modeled to be largely due to electrostatic 
interactions; however, basic amino acids were primarily responsible for binding, rather 
than negatively charged residues, as modeled here for Scl1-V. Thus, Scl1 remains a 
unique adhesin that targets EDA/cFn isoforms that are expressed at the pathogen portal 
of entry.  
Here, we identified the loop region of the Scl1-V domain, as the structural 
determinant that is central to EDA/cFn recognition and binding. When the 22-amino-acid 
loop sequence of the EDA-binding positive Scl1-V variant, derived from the global M1-
type strain, was transplanted into the corresponding region of the binding-negative Scl2 
protein, the chimeric construct gained EDA-binding activity. When the reverse 
transplantation was performed, ligand binding was lost both in recombinant protein and 
when expressed on the surface of Scl1 mutant GAS. A similar gain-of-binding function by 
the chimeric protein was achieved, when the loop-region from a phylogenetically distant 
Scl1 variant from M28-type GAS was substituted into the Scl2-V loop. A novel ‘catch-
clamp’ Fn-binding mechanism was deciphered for the multifunctional filamentous adhesin 
of S. gordonii, CshA (63). The CshA protein, which also lacks the classical Fn-binding 
repeats, binds both pFn and cFn via its non-repetitive domains 1 and 2. The NR2 globular 
domain has a β-sandwich structure with lectin-like fold, and likely binds glycosylated sites 
on Fn. The Fn-binding site of NR2 domain is capped by a flexible ligand-gating loop, 
which, upon ligand recognition, uncovers a presumed binding cleft. The Scl1-V domain is 
different, because it forms a 6-helix bundle structure, not lectin-like fold, and binds non-
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glycosylated recombinant EDA protein; in addition, the EDA repeat in human cFn is not 
glycosylated (31). The lectin-like domain, containing ligand-gating loop capping the 
ligand-binding cleft, is represented in numerous fibrillar streptococcal adhesins, including 
S. mutans SpaA (64), S. gordonii SspB (65), S. agalactiae BspA (66), and M28-type S. 
pyogenes AspA (67), all correlated with the extended antigen I/II protein family. While the 
detailed Scl1 structure and structural organization is different from those of antigen I/II 
affiliates, there are several intangible similarities, where the elongated CL domain projects 
the globular ligand-binding domain away from the cell surface, with ligand-engaging loop 
placed at the apex of the Scl1-V structure.  
Homology modeling of the Scl1-V domain revealed that electrostatic surface 
potential and distribution of charged residues likely participate in ligand recognition and 
binding. A negatively charged region is formed in the center of the Scl-V trimer of ligand-
binding-positive proteins modelled (Scl1.1, rScl.chi1, and rScl.chiC) that are surrounded 
by neutral and positively-charged residues. In contrast, the electrostatic models of the 
binding-negative Scl-V domains (Scl2.28, rScl.chi2, and rScl.chiN) display a uniform 
negative surface charge throughout the crown of the Scl-V domain. The arrangement of 
the surface potential observed in the Scl1-V domains was associated with a pattern of 
conserved negatively-charged amino acids, primarily E46, 47(Scl1.1) and D48(Scl1.1), located at 
the C-terminus of the loop sequence at the junction with the α-helices forming the inner 
core of Scl1.1-V bundle. This charge distribution is reminiscent of the ligand-gating loops, 
capping negatively-charged binding clefts, proposed in CshA and BspA (63,66). This 
conserved pattern is observed in Scl1 variants that are evolutionarily distant on the 
phylogenetic tree; for example, E48, 50 of Scl1.28 from M28 GAS. Therefore, 
phylogenetically distant Scl1 proteins, which have significant amino-acid sequence 
variation, exhibit conservation in the arrangement of charged amino acids, and similar 
ligand-binding partners.  
We previously reported that Scl1-V domain bound EDA/cFn, Lm and 
ApoB100/LDL, thus, supporting a dichotomous nature of Scl1-ligand binding in tissue and 
blood (23). Here, we established that the same regions of the globular Scl1 domain are 
critical in binding with all three ligands. It is not unusual that bacterial adhesins are multi-
functional and bind several distinct ligands. Such proteins typically contain clearly defined 
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functional domains; for example, the ECM-binding protein of S. epidermidis Embp, 
discussed earlier, contains both the Fn-binding FIVAR domains and the G-related 
albumin binding GA domains (61). The collagen domain in streptococcal surface proteins 
is also found in association with additional domains; for instance, the pneumococcal 
protein PclA (68), harbors both FIVAR and G5 (binds N-acetylglucosamine) domains, in 
addition to the collagen domain (23). The Scl1-V domain is different in that the short 
sequence-variable loop region and a conserved arrangement of the surface potential at 
the apical plane of Scl1-V structure, are involved in binding of assorted ligands that do 
not share substantial sequence nor structural similarities. These data, combined with 
previous molecular evolutionary analysis (9,11), as well as structural and phylogenetic 
analyses (20,22), indicate that retaining the conserved structure of the Scl1-V domain is 
the selective constraint, which influenced sequence variation.  
Our work demonstrates several critical structure-function constraints that 
determine ligand binding capacity by the globular domain of a major group A 
streptococcal adhesin, Scl1. Current prospects for a global GAS vaccine, based on M 
protein, are problematic because more than 240 M-protein types have been reported, 
especially in regions outside North America and Europe, where vaccines are acutely 
needed. The EDA binding to diverse Scl1 variants could be developed into a non-
conventional treatment option for GAS infections. The EDA-derived cyclic peptide bound 
Scl1 with an affinity in the micromolar range (48). The ongoing research explores the 
possibility of designing an improved EDA-derived peptide for targeting diverse GAS 
strains. This work provides an important structural understanding of Scl1 adhesin, which 
is essential during early stages of GAS infection, and lays the foundation for the 
development of non-vaccine inhibitors of Scl1-ligand interactions for the prevention of 
infection progression.  
 
EXPERIMENTAL PROCEDURES 
Production of recombinant streptococcal collagen-like proteins (rScls) – Gene 
cloning and rScl-protein production were performed in Escherichia coli TB1 and BL-21, 
respectively, grown in Luria-Bertani (LB) media (Fisher Scientific) with ampicillin (100 µg 
mL-1) at 37ºC. rScl-encoding clones, which were derived from the original scl alleles, were 
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generated by PCR amplification from GAS genomic DNA; primers contained flanking 
sequences compatible E.coli expression vector pASK-IBA2 digested with BsaI. Clones 
encoding the chimeric rScl proteins were generated using synthetic double-stranded DNA 
fragments (gBlocks; Integrated DNA Technologies) flanked by PflMI and BsaI sites. All 
plasmids were verified by DNA sequencing. Plasmid constructs used in this study are 
described in Table 1 and gBlocks are shown in Table S1.  
All rScl proteins were produced using the Strep-tag II cloning, expression, and 
purifications system (IBA-GmbH, Geottingen, Germany). Proteins were expressed with a 
C-terminal affinity tag and purified on Strep-Tactin sepharose, as described (14,15). The 
full-length (rSclFL) and V-region-only (rSclV) constructs were made, as designated: 
rScl1.1FL and rScl1.1V are derived from Scl1 protein in M1-type strain MGAS6708 (14); 
rScl1.28FL and rScl2.28FL originate from M28 strains MGAS6274 (14); and rScl1.3FL 
and rScl1.3V are derived from M3 strain MGAS315 (48). Both naturally-derived and 
chimeric rScl proteins were expressed in E. coli BL21 periplasm following the induction 
with anhydrotetracycline at 0.2 µg mL-1 for 3 hours. Cells were centrifuged and suspended 
in high sucrose buffer (100mM Tris-HCl, 1 mM EDTA, pH 8.0, 500mM sucrose) or Cell 
Lytic B Buffer (Sigma) for separation of the periplasmic fraction and subsequent affinity 
purification. Purified proteins were analyzed by SDS-PAGE and stained with 
RAPIDstainTM (G-Biosciences); proteins were dialyzed against 25 mM HEPES, pH 8.0, 
and stored at -20oC. Protein concentrations were determined using Qubit fluorometric 
quantitation (ThermoFisher). 
 
Recombinant extra domain A (rEDA) Production - Recombinant EDA (Table 1) was 
produced using the pQE-30 His-tag cloning, expression, and purification system (Qiagen) 
in the E.coli strain JM-109 (Promega), as described (69). E. coli containing rEDA-
encoding plasmid was grown in LB broth supplemented with ampicillin (100 µg/ml-1). 
Protein expression was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside for 3 
hours. Cells were harvested by centrifugation, and pellets were frozen at -20oC for 2 hours 
or overnight. Cells were next suspended in a lysis buffer (50 mM Tris/HCL pH 8.0, 50 mM 
NaCl, 2 mM MgCl2, 2% Triton X-100, 10 mM β-mercaptoethanol, 0.2 mg/ml lysozyme, 1 
EDTA-free protease inhibitor cocktail tablet [per 10 mL] (Pierce), 1 mM phenylmethane 
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sulfonyl fluoride, 10 U/ml DNaseI) and incubated on ice for 20 minutes. Cell lysate was 
centrifuged at high speed (16000g x 20 minutes) and supernatant was collected. 
Supernatant was mixed with Ni-NTA agarose resin (Qiagen) by inversion for 1.5 hours, 
and then poured into a column (Bio-Rad). Sample was washed with 50x resin bed volume 
of the wash buffer (50 mM NaH2PO4, 20 mM imidazole, 500 mM NaCl), and then rEDA 
protein was eluted in elution buffer (50 mM NaH2PO4, 250 mM imidazole, 300 mM NaCl). 
Purified protein was dialyzed against 25 mM HEPES buffer, pH 8.0 and protein 
concentration was measured with Qubit fluorometric quantitation; protein integrity and 
purity were assessed by 15% SDS-PAGE. Protein was stored at -20oC until future use.  
 
Rotary shadowing and electron microscopy – rScl proteins were rotary shadowed and 
analyzed by electron microscopy, as previously described (14). Briefly, recombinant 
proteins were dialyzed against 0.1 M ammonium bicarbonate. rScl samples were mixed 
with glycerol to a final glycerol concentration of 70% (vol/vol) and 100 µl of each sample 
was nebulized with an airbrush onto freshly cleaved mica. Samples were then dried in a 
vacuum and rotary shadowed with carbon/platinum using an electron beam gun titled at 
an angle of 6 degrees, relative to the mica surface, in a Balzers BAE 250 evaporator. The 
replicas were backed with carbon at 90 degrees, and then were floated in distilled water 
and picked up onto bare 600-mesh copper grids. Photomicrographs were taken using a 
FEI G2 electron microscope operated at 120 kV with a 30-µm objective aperture.  
 
Circular dichroism spectroscopy – Circular dichroism spectroscopy of rScl proteins 
was performed as previously described (14). Briefly, protein samples were dialyzed 
against 1x Dulbecco’s phosphate buffered saline, pH 7.4. CD spectra were taken with a 
Jasco 810 spectropolarimeter, in a thermostatically controlled cuvette, with a path length 
of 0.5 cm. Data were acquired at 10 nm per minute. Wavelength scans were performed 
from 240 nm to 190 nm, at either 20ºC, or 50ºC for denaturation.   
 
Protein binding assays – rScl proteins (0.5 µM solutions) were immobilized onto Strep-
Tactin-coated microplate wells for 1.5 h at room temperature and blocked with Tris-
buffered saline supplemented with 1% fetal bovine serum albumin (BSA) overnight at 4ºC, 
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followed by incubation with ECM ligands: cellular fibronectin (cFn) (Sigma), recombinant 
extra domain A (rEDA), murine laminin-111 (Lm) (Sigma), and Apolipoprotein B100 
(ApoB) and low-density lipoprotein (LDL) (Sigma). The no rScl controls were performed 
in BSA-coated wells for each ligand and each antibody used. Final ODs were normalized 
by subtracting the BSA controls in each experimental set-up. 
In regular binding assays, ECM ligands were added to the rScl-immobilized wells 
at 1 µg per well and incubated at room temperature for 1 h. To assess concentration-
dependent binding, rEDA was added to the wells at concentrations ranging between 
0.039-5 µM. Bound ECM ligands were detected with anti-cFn polyclonal antibody 
(Sigma/F3648; 1:4000), anti-His-Tag monoclonal antibody (Proteintech/66005; 1:100), 
anti-Lm polyclonal antibody (Sigma/L939; 1:500), and anti-ApoB (Chemicon/AB742; 
1:500); followed by goat anti-rabbit (Bio-Rad/1721019; 1:2000), anti-mouse (Bio-
Rad/1721011; 1:1000), or rabbit anti-goat (Bio-Rad/1721034; 1:1000) secondary 
antibodies conjugated to horseradish peroxidase (HRP) (Bio-Rad). The HRP substrate, 
2,20-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (Fisher) was used and 
colorimetric reactions were recorded at OD415 nm.  
 
Protein modeling - Multiple sequence alignments of protein sequences were generated 
using MUSCLE and refined manually based on the results of secondary structure 
predictions. Predicted α-helices represent the consensus between PSIPRED, PHD, and 
SSPRO. The phylogenetic tree of Scl1-V and Scl2-V regions was inferred based on 
multiple sequence alignments, using Neighbour-Joining method (adapted from (20)). 
Branch lengths were scaled to the distance computed using the Gonnet250 matrix, and 
bootstrap values (statistical support for given bifurcation) were calculated for all nodes.  
The homology models of Scl1.1-V and Scl2.28-V domains were obtained after 
consensus-based sequence alignment using HMMer, against the amino acid sequence 
of Scl2.3-V domain with solved, crystal structure(22)(PDB accession code: 4nsm). The 
homology models were built with MODELLER (70) and stereo-chemical quality of the 




Complementation of M1 group A Streptococcus– The E.coli shuttle plasmid pSB027 
(72) (Table 1) was used for in-trans complementation. The DNA fragment encompassing 
the scl1.1 coding sequence with upstream promoter was PCR-amplified using genomic 
DNA from the M1-type strain MGAS5005 (WT) with primers 232Reg and 232Rev_BgIII 
(Table S1). The amplified DNA was cloned into pSB027 between BglII and HindIII sites, 
resulting in pSL620 (Table 1). The scl.chi2 sequence was cloned as a synthetic double 
stranded DNA fragment (gBlocks: Integrated DNA Technologies: SL621 gBlock, Table 
S1) between SpeI and PpuMI sites of pSL620, resulting in pSL621 (Table 1). Both pSL620 
and pSL621 were electroporated into MGAS5005 scl1 mutant GAS (9) and 
transformants were selected on BHI agar containing 10 µg/mL-1 chloramphenicol; 
plasmids were verified by DNA sequencing.  
GAS cultures were grown in Todd Hewitt broth (Becton Dickinson and Co) 
supplemented with 0.2% yeast extract (THY medium) and on Brain Heart Infusion agar 
(Becton Dickinson and Co) at 37ºC in an atmosphere with 5% CO2. For antibiotic 
selection, chloramphenicol (5 µg mL -1) was added to the medium.  
 
Western blot analysis - Expression of Scl1.1 and Scl.chi2 proteins was determined by 
western immunoblotting of the bacterial cell-wall protein fraction, as described previously 
(9,10). Briefly, bacterial cultures were grown to an OD600 of 0.5 and cells were harvested 
by centrifugation. GAS cells were next digested with 100 µg lysozyme and 5 U 
mutanolysin and phenylmethylsulfonyl fluoride in a 20% sucrose buffer. 5- 25 µL of the 
sample supernatants were separated by SDS-PAGE and transferred to a nitrocellulose 
membrane. Detection of Scl1.1 and Scl.chi2 proteins was performed using rabbit antibody 
(1:2000) specific to the Scl1.1-V domain (9). Horseradish peroxidase-conjugated goat 
anti-rabbit IgG secondary antibody (Bio-Rad/1721019; 1:2000) was added to blots, 
followed by addition of Clarity ECL substrate (Bio-Rad) for detection. Images were 
acquired using a ChemiDoc Touch Imaging System (Bio-Rad).  
 
Flow cytometry analysis – Determination of Scl-surface expression and rEDA binding 
by GAS cells was measured by flow cytometry. Bacteria grown to an OD600 of 0.5 were 
harvested by centrifugation and washed with flow cytometry buffer (phosphate-buffered 
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saline containing 10% Todd-Hewitt broth with 0.2% yeast extract). For Scl-surface 
detection, the anti-Scl1.1-V antibody (9) was pre-absorbed with MGAS5005 Δscl1 cells 
and then Ab (1:10 dil.) was incubated with GAS cells tested for 30 minutes on ice. Cells 
were next washed and incubated with Allophycocyanin (APC)-conjugated donkey anti-
rabbit antibody (Jackson ImmunoResearch; 1:150).  
For rEDA binding, GAS cells tested were incubated with rEDA for 30 minutes at 
room temperature and bound rEDA was detected with anti-His-Tag monoclonal antibody 
(1:10 dil.) (Proteintech) pre-absorbed with MGAS5005 WT cells. Samples were then 
incubated with goat anti-mouse polyclonal antibody conjugated with Alexa Fluor® 568 
(ThermoFisher; 1:150). Cells were washed and fixed in 0.4% paraformaldehyde and 
stored at 4ºC until analysis. 50,000 events were collected per sample using a BD 
LSRFortessa and data were analyzed with FCS Express Flow 6 software.  
 
Statistical analyses – Statistics was performed using the two-tailed paired Student’s t-
test or Two-way ANOVA analyses. Significance was denoted at levels of *P ≤0.05, **P 
≤0.01, or ***P ≤0.001. Error bars represent standard deviations with analyses based on 
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Table1: Plasmids used in this study. 
Plasmid Description Source 
pASK-IBA2 
E. coli expression vector, 





















































N-terminal His-tag E. coli 
expression vector 
Qiagen 
pQE-EDA pQE-30 encoding rEDA (69) 
pSB027 
E. coli -GAS shuttle 
plasmid encoding GFP 
(72) 
pSL620 
pSB027 encoding scl1.1 















Figure 1. Conserved structure of the Scl1 and Scl2 globular domains. (A) Cartoon model of full-length 
Scl proteins. Globular N-terminal sequence-variable (V) domain, central rod-shaped collagen (CL) domain, 
and C-terminal cell-wall-anchor domain are shown. (B) Multiple sequence alignment of the V regions of 
Scl1 and Scl2 variants. MSA was generated using MUSCLE; amino acid residues are colored according to 
their physico-chemical character: red - negative (D, E), blue – positive (R, K, H), gray - hydrophobic, 
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aliphatic or aromatic (I, L, V, A, M, F, Y, W), and green – polar, Gly, and Pro (S, T, Q, N, G, P). Predicted 
alpha helices: N-terminal helix 1 (grey) and C-terminal helix 2 (blue) are shown below the alignments (H). 
(C) Homology models of the Scl1.1-V and Scl2.28-V domains. Models were generated based on the crystal 
structure of the Scl2.3-V variant (PDB accession code: 4nsm). Modeled alpha helices: N-terminal helix 1 







Figure 2. Full-length Scl1 proteins are required for binding to ECM ligands. Recombinant full-length 
proteins (rScl1.1FL and rScl1.3FL) and their respective V-region-only constructs (rScl1.1V and rScl1.3V) 
were tested for binding to cellular fibronectin (cFn) and recombinant extra domain A (rEDA). (A) ELISA 
binding assay. rScl proteins were immobilized onto Strep-Tactin-coated microplate wells and incubated with 
ECM ligands, cFn and rEDA. Primary anti-ECM Abs and HRP-conjugated secondary Abs were used for 
ligand detection. Graphic bars indicate the mean OD415 nm normalized against control BSA-coated wells. 
Statistical analysis was calculated using Student’s two-tailed t-test from three independent experiments, 
each performed in triplicate wells (N= 3 ± SD); **P ≤0.01, ***P ≤0.001. Solid (rEDA) and dashed (cFn) lines 
indicate threshold OD415 nm ±2SD values recorded for experimentally validated ECM-binding-negative 








Figure 3. Surface-exposed loop of the Scl1.1-V domain is central in ECM recognition and binding. 
Full-length chimeric rScl proteins were generated by exchanging V-region loop sequences between ECM-
binding-positive and binding-negative rScl proteins; the resulting chimeric rScl.chiFL constructs were 
characterized structurally by circular dichroism spectroscopy and electron microscopy, as well as 
functionally for ECM binding. (A) Amino acid sequences of the V domains of native (rScl1.1FL and 
rScl2.28FL) and chimeric (rScl.chi1FL and rScl.chi2FL) proteins. rScl.chi1FL resulted from the insertion of 
22-amino-acids from the ECM-binding-positive variant rScl1.1FL in place of the corresponding loop region 
of the binding-negative variant rScl2.28FL, whereas rScl.chi2FL resulted from the reverse replacement; 
inserted sequences are shown in italics and numbers mark residue number within V-domain. (B) Structural 
characterization of the chimeric rScl.chiFL constructs. Left, CD wavelength scans of folded (20ºC, solid 
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lines) or denatured (50ºC, dashed lines) rScl.chiFL proteins are shown. Right, structural organization 
viewed by electron microscopy of the rotary shadowed rScl.chi1FL and rScl.chi2FL shows characteristic 
two-domain organization; Bars, 50 nm. (C) ECM binding to full-length original and chimeric rScl constructs 
by ELISA. rScl proteins were immobilized onto Strep-Tactin-coated microplate wells and incubated with 
ECM ligands, cellular fibronectin (cFn) and recombinant extra domain A (rEDA). Primary anti-ECM Abs and 
HRP-conjugated secondary Abs were used for ligand detection. Graph bars indicate the mean OD415 nm 
normalized against BSA controls. Statistical analysis was calculated using Student’s two-tailed t-test, from 
three independent experiments, each performed in triplicate wells (N= 3 ± SD); **P ≤0.01, ***P ≤0.001. 
Statistical significance evaluates the differences between ECM binding by chimeric proteins rScl.chi1FL 
and rScl.chi2FL, and the control proteins, rScl2.28FL and rScl1.1FL. Solid (rEDA) and dashed (cFn) lines 
indicate threshold OD415 nm ±2SD values recorded for experimentally validated ECM-binding-negative 
rScl2.28FL control protein. (D) rEDA binding to whole GAS cells. M1-type GAS wild-type (WT), isogenic 
scl1 inactivated mutant (Δscl1), and mutant complemented for the expression of Scl1.1 (Δscl1::scl1.1) and 
Scl.chi2 (Δscl1::scl.chi2) proteins are shown. Left, Western blot detection of Scl1 expression in cell wall 
fractions. 25 µLs of cell wall samples prepared from GAS WT and Δscl1, , and 5 µLs of samples from 
complemented Δscl1::scl1.1 and Δscl1::scl.chi2 cells overexpressing Scl proteins, were loaded per well. 
rScl1.1FL protein was included as a control. Scl1 was detected with anti-Scl1.1-V antibody. Right, rEDA 
binding to whole-GAS cells by flow cytometry. Cells were incubated with rEDA, and binding was detected 
with primary anti-his-tag mAb and secondary Ab conjugated to Alexa Fluor® 568. Binding to WT cells was 
set as 100%. Statistical analysis was calculated using Student’s two-tailed t-test from three independent 








Figure 4. The C-terminal 11 amino acids of the loop segment of the Scl1.1-V domain is central in 
ECM recognition and binding. Chimeric rScl proteins were generated by exchanging portions of the loop 
from ECM-binding-positive rScl1.1-V with respective loop sequences of the binding-negative protein 
rScl2.28FL; the resulting chimeric rScl.chi constructs were characterized structurally by circular dichroism 
spectroscopy and electron microscopy, as well as functionally for ECM binding by ELISA. (A) Amino acid 
sequences of the V domains of native (rScl1.1FL and rScl2.28FL) and chimeric (rScl.chiNFL, rScl.chiCFL, 
rScl.chiIFL) proteins. rScl.chiNFL resulted from the insertion of the N-terminal 11 amino acids of the 
rScl1.1FL-loop sequence in place of the corresponding N-terminal loop region of the rScl2.28FL, whereas 
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rScl.chiCFL resulted from the replacement of the C-terminal 11 amino acids and rScl.chiIFL from the 
replacement of internal 11 amino acids; inserted sequences are shown in italics and numbers mark residue 
number within V-domain. (B) Structural characterization of the chimeric rScl constructs. Left, CD 
wavelength scans of folded (20ºC, solid lines) or denatured (50ºC, dashed lines) rScl.chi proteins are 
shown. Right, structural organization viewed by electron microscopy of the rotary shadowed rScl.chiNFL, 
rScl.chiCFL, and rScl.chiIFL shows characteristic two-domain organization; Bars, 50 nm. (C) ECM binding 
to chimeric rScl constructs by ELISA. rScl proteins were immobilized onto Strep-Tactin-coated microplate 
wells and incubated with ECM ligands, cellular fibronectin (cFn) and recombinant extra domain A (rEDA). 
Primary anti-ECM Abs and HRP-conjugated secondary Abs were used for ligand detection. Graphic bars 
indicate the mean OD415 nm normalized against BSA controls. Statistical analysis was calculated using 
Student’s two-tailed t-test, from three independent experiments, each performed in triplicate wells (N= 3 ± 
SD); **P ≤0.01, ***P ≤0.001. Solid (rEDA) and dashed (cFn) lines indicate threshold OD415 nm ±2SD values 
recorded for experimentally validated binding-negative rScl2.28FL control protein. (D) Concentration-
dependent binding of rEDA to rScl constructs. rScl proteins were immobilized onto Strep-Tactin-coated 
microplate wells and incubated with increasing concentrations of rEDA. Wells were further developed, as 
described above. Statistical analysis was calculated using two-way ANOVA, from two-independent 
experiments, each performed in triplicate wells (N=2 ± SD), *P ≤0.05, **P ≤0.01, ***P ≤0.001. Statistical 
significance evaluates difference between bindings of each rScl1-chimeric protein to binding-negative 








Figure 5. Electrostatic potential surfaces of Scl1-V, Scl2-V, and Scl.chi-V domains. The positive and 
negative charges are colored blue and red, respectively. Exposed loops are outlined by the black ovals in 
side views. Black arrowheads point to negatively charged pockets of the D/E residues, embedded in neutral 
and positively-charged environment, seen within the binding-positive Scl1.1-V and Scl.chiC-V domains. 
Homology models were generated using the crystal structure of the Scl2.3 V domain (PDB accession code-








Figure 6. Conservation of ECM recognition and binding by phylogenetically distant Scl1 variant. (A) 
Phylogenetic tree of Scl1-V and Scl2-V regions. Branch lengths are scaled to genetic distance and 
bootstrap values are shown for all nodes. Scl1 variants with known ECM-binding capacities are boxed, 
while variants known to bind complement components, Factor H and Factor H-related protein 1, are marked 
with dots. ECM-binding-positive variants, Scl1.28 and Scl1.1, and binding-negative variant Scl2.28, used 
for loop switching, are marked by arrows. (B) Amino acid sequences of the V-domains of native (rScl1.28FL 
and rScl2.28FL) and chimeric (rScl.chi3FL) proteins. rScl.chi3FL resulted from the insertion of the 22-
amino-acids from the ECM-binding-positive variant rScl1.28FL in place of the corresponding loop-region of 
the binding-negative variant rScl2.28FL; inserted sequence is italicized and numbers mark residues within 
V-domain. (C) Structural characterization of rScl.chi3FL. Left, CD wavelength scans of folded (20ºC, solid 
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line) or denatured (50ºC, dashed line) rScl.chi3FL protein are shown. Right, structural organization viewed 
by electron microscopy of the rotary shadowed rScl.chi3FL shows characteristic two-domain organization; 
Bar, 50 nm. (D) ECM binding to rScl.chi3FL by ELISA. rScl proteins were immobilized onto Strep-Tactin-
coated microplate wells and incubated with ECM ligands, cellular fibronectin (cFn) and recombinant extra 
domain A (rEDA). Primary anti-ECM Abs and HRP-conjugated secondary Abs were used for ligand 
detection. Graphic bars indicate the mean OD415 nm normalized against BSA controls. Statistical analysis 
was calculated using Student’s two-tailed t-test, from three independent experiments, each performed in 
triplicate wells (N= 3 ± SD); **P ≤0.01, ***P ≤0.001. Solid (rEDA) and dashed (cFn) lines indicate threshold 









Figure 7. Conserved structural constraints and exposed loop of Scl1 proteins determine binding to 
laminin and apolipoprotein B100/low-density lipoprotein. Full-length recombinant Scl1 proteins, 
chimeric rScl proteins, and rScl1-V-only constructs were tested for binding to laminin (Lm), and 
apolipoprotein B100 (ApoB100) and low-density lipoprotein (LDL). rScl proteins were immobilized onto 
Strep-Tactin-coated microplate wells and incubated with ligands. Primary anti-Lm or anti-ApoB100 Abs and 
HRP-conjugated secondary Abs were used for ligand detection. Graphic bars indicate the mean OD415 nm 
normalized against BSA-coated control wells. Statistical analysis was calculated using Student’s two-tailed 
t-test from three independent experiments, each performed in triplicate wells (N= 3 ± SD); *P ≤0.05, **P 
≤0.01, ***P ≤0.001. (A) Full-length Scl1 proteins are required for binding to Lm and ApoB100. Statistical 
significance evaluates the differences between binding by the full-length proteins, rScl1.1FL and rScl1.3FL, 
and their respective V-region only constructs, rScl1.1V and rScl1.3V. Dashed line (ApoB) and solid line 
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(Lm) indicate threshold OD415 nm ±2SD values recorded for experimentally validated binding-negative 
control protein rScl2.28FL. (B, C) Surface-exposed loop of the Scl1-V domain is central in Lm (B) and 
ApoB100/LDL (C) recognition and binding. Dashed (LDL) and solid lines (B – Lm, C – ApoB) indicate 
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ABSTRACT 
The human-adapted pathogen group A Streptococcus (GAS) utilizes wounds as a portal 
of entry into host tissues, wherein surface adhesins interact with the extracellular matrix, 
enabling bacterial colonization. The streptococcal collagen-like protein 1 (Scl1) is a major 
adhesin of GAS, which selectively binds to fibronectin type III (FnIII) repeats, extra 
domains A and B in cellular fibronectin and to several FnIII repeats within tenascin-C. 
Binding to FnIII repeats occurred through a conserved mechanism, involving the Scl1 
globular domain, and facilitated GAS adherence and biofilm formation. Numerous 
extracellular matrix proteins can be targeted by group A streptococcal adhesins to enter 
the human host. The extra domains A and B are unique in that they are alternatively 
spliced in cellular fibronectin and appear transiently in the wound extracellular matrix. This 
Scl1-FnIII binding is therefore a remarkable example of GAS adaptation to this transient 
environment that is initially encountered within the host. Cellular fibronectin isoforms and 
tenascin-C are also present in the tumor microenvironment, and here, we found that Scl1 
mediated GAS attachment and biofilm formation on the extracellular matrices deposited 
by cancer-associated fibroblasts and osteosarcoma cells. These data lay the groundwork 
for the assessment of Scl1 as a cancer-targeting biomolecule. 
 
INTRODUCTION 
Group A Streptococcus (GAS or Streptococcus pyogenes) is an obligate human pathogen 
that is responsible for over 700 million infections worldwide each year (1). Infection by 
GAS can result in diseases that range in severity, from highly prevalent superficial 
infections to fatal conditions (1). GAS infection can also lead to the development of post-
infectious autoimmune sequelae (2-4). Invasive infections and rheumatic heart diseases 
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results in over 500,000 deaths globally each year (1,5), which places GAS among the top 
ten most lethal infectious disease-causing organisms (5). Nevertheless, superficial GAS 
infections account for the vast majority (~95.5%) of the 700 million infections, mostly 
affecting children; GAS also asymptomatically colonizes the throat and skin of 5-25% of 
children of the general population (6). GAS isolates are subtyped based on the 5’-
hypervariable end of the emm gene, encoding the N-terminus of the M-protein, a major 
surface adhesin and virulence factor of GAS (7). There have been over 220 different emm 
types of GAS identified and there is a non-random correlation between certain M-types 
and infection-associated diseases (8). 
 In addition to protein M, GAS express numerous adhesins that contribute to host 
colonization (9). Two ubiquitous surface-associated proteins are the streptococcal 
collagen-like protein 1 (Scl1/SclA) and 2 (Scl2/SclB) (10-14). Scl1 and Scl2 share a 
unique structure that is distinct from other GAS adhesins; both are homotrimeric and have 
similar “lollipop-like” structural organization (15,16). The N-terminal sequence-variable 
(V) globular domain is followed by the collagen-like (CL) domain, and with a LPATG cell-
wall anchoring motif at the C-terminus (11,12). The V-domain of the Scl2 protein from M3-
type GAS has been crystalized (17). It forms a six-helix bundle, where two antiparallel α-
helices in each monomer are joined by surface-exposed loops. (18,19). Regardless of the 
conserved structure, the amino-acid sequences of the V-domains diverge between Scl1 
and Scl2 proteins and also differ among Scl1 and Scl2 variants from strains of different 
M-types (20). The Scl1-V domain binds selected isoforms of cellular fibronectin (cFn) that 
are expressed within wounded tissue (21,22), via the surface-exposed loops of the V-
domain (19).  
cFn is a high molecular weight glycoprotein encoded by the FN1 gene that contains 
three different types of repeating domains (I, II, and III) (23,24). Type I and II repeats 
interact with fibrin, fibronectin and collagen, while the type III repeats contain numerous 
cell-binding sites via integrins and other receptors (25). There are over 20 different 
isoforms of cFn in humans due to alternative splicing of FN1-mRNA, which can lead to 
the inclusion of extra domains. These extra domains are both fibronectin type III (FnIII) 
repeats, known as extra domain A (EDA/EIIIA) and extra domain B (EDB/EIIIB) (26). The 
EDA and EDB repeats vary in sequence but retain the conserved prototypical FnIII-repeat 
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β-sandwich structure (27,28). Spatial and temporal inclusion of EDA and EDB domains 
in cFn is tightly regulated; both are expressed during embryogenesis but are not readily 
detectable in healthy adult tissue (29,30). Conversely, isoforms of cFn that contain EDA 
and/or EDB are expressed in pathological adult tissues, such as within wound beds and 
around tumors (31-33). EDA has been shown to play important roles in wound healing 
(34,35). The role of EDB in the wound microenvironment is not well understood, but it is 
known to be highly expressed during angiogenesis of healing tissues and of tumors (36-
38). Tenascin-C (TnC) is another ECM protein that contains canonical FnIII repeats (39). 
Like EDA and EDB of cFn, TnC is predominately expressed during fetal development and 
is found at negligible levels within normal adult soft tissue (40-42); though, it is highly 
deposited in wound and within tumor stroma (39,43). 
We previously reported that Scl1 binds to the wound-associated fibronectin type 
III repeat, EDA, and this binding contributes to GAS colonization and biofilm formation on 
matrices deposited by normal human dermal fibroblasts (22). In this report, we show that 
Scl1 binds to recombinant EDB and to some FnIII repeats within TnC. Binding was 
conserved across phylogenetically distant Scl1 variants, originating from strains of 
epidemiologically relevant M types. Recognition of both ligands was mediated through 
the Scl1-V-domain loop-region, the same binding mechanism as for the EDA segment 
within cFn (19). Scl1 facilitates GAS biofilm formation on rEDB coatings. In addition, ECM 
deposited by cancer-associated fibroblasts and osteosarcoma cells contains cFn 
isoforms with EDA and/or EDB, and TnC, capable of binding Scl1-expressing GAS to 
facilitate biofilm formation. This work identifies novel wound–associated ECM targets for 
Scl1 that are expressed at the portal of entry for GAS and facilitate host colonization at 
wound sites. The unique binding of Scl1 to EDA, EDB and TnC and may present 
alternative opportunities to target tumors or other disease regions that selectively express 
these ECM variants.  
 
RESULTS 
Scl1 binds to EDB of cFn via surface exposed loops – Previously, we established that 
Scl1 binds to cFn, but not plasma fibronectin (pFn) (21), via the C-C’ loop of EDA (22). In 
addition to EDA, cFn can include another extra domain, EDB, which is also upregulated 
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within wounded tissue (31). EDA and EDB both adopt a typical fibronectin type III repeat 
structure (27,28), comprised of 7 β-strands (A, B, C, C’, E, F, G) that form 2 β-sheets, 
with strands connected by flexible loops (27,28), including the C-C’ loop that mediates 
Scl1 binding to EDA (Fig. 1A). Interestingly, we determined that the commercial cFn 
preparations we used in binding assays contained cFns that included the EDB segment 
(data not shown). Therefore, we hypothesized that Scl1 may also bind to EDB by a similar 
mechanism, involving the surface-exposed loops of Scl1-V domain (19).  
To test our hypothesis, we devised a panel of chimeric rScl constructs to be used 
in binding assays with rEDB protein (Fig. 1B). A chimeric rScl construct was devised, 
wherein we replaced the loop region (22 amino acids) of the EDA-binding-negative 
rScl2.28-V domain, originating from Scl2 of M28-type strain, with that originating from 
EDA-binding-positive rScl1.1 (Scl1 of M1 strain), resulting in rScl.chimera1 (rScl.chi1). 
We correspondingly did the reverse, replacing the loop-region from rScl1.1-V domain with 
the loop from rScl2.28-V domain, resulting in rScl.chi2. We also devised the rScl.chiC 
construct, with a partial loop substitution (11 amino acids) from Scl1.1 that replaced an 
analogous loop sequence of rScl2.28; this loop fragment was responsible for EDA 
recognition. To assess whether this EDB-binding mechanism is true for a different Scl1 
variant, we similarly replaced the whole loop (22 aa) with another EDA-binding-positive 
sequence from a phylogenetically distant Scl1.28 protein, resulting in rScl.chi3. This panel 
of devised rScl constructs was next tested for rEDB binding and compared to our 
previously reported binding data with rEDA (19).  
Both naturally-derived rScl1.1, rScl1.3, rScl1.28 and rScl1.41, as well as the 
chimeric proteins rScl.chi1-3 and rScl.chiC were tested for binding to rEDB by ELISA; 
binding was compared to that of rEDA-binding-negative rScl2.28 control. As it was 
previously established for rEDA binding, all rScl1 proteins, derived from Scl1 variants 
originating from several GAS M-types (M1, M3, M28 and M41), bind rEDB to varying 
degrees, while control rScl2.28 protein did not bind (Fig. 1C). We furthermore 
demonstrate that the Scl1-V loop mediates rEDB binding, as evidenced by rEDB binding 
to the chimeric constructs rScl.chi1, rScl.chi3, and rScl.chiC, and a loss of binding to 
rScl.chi2, harboring a reverse loop substitution. These data reveal that the Scl1 adhesin 
binds to both the EDA and EDB segments that are found within cFn, expressed in the 
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wounded portal of entry, and signify the importance of the Scl1-V loop in EDB/EDA 
recognition and binding.  
 
Scl1 mediates GAS-EDB binding and promotes biofilm formation – We next 
investigated if Scl1 expressed on GAS cells mediates EDB binding, using flow cytometry 
(Fig. 1D). Deposition of rEDB onto the surface of M1 and M41 strains was assessed after 
30-minute incubation. M1 GAS is isolated across the globe and is responsible for both 
superficial and invasive infections, while M41 is historically associated with superficial 
skin infections (5,44) The rEDB binding to GAS WT cells was compared to that measured 
for the corresponding isogenic Scl1-deficient mutant cells, M1Δscl1 and M41Δscl1. We 
also tested rEDB binding to the M1Δscl1 mutant cells complemented in trans for the 
expression of either the original Scl1.1 protein (Δscl1::scl1.1) or the chimeric Scl.chi2 
variant (Δscl1::scl.chi2). There was a significant reduction in rEDB deposition on the 
surface of both isogenic M1Δscl1 and M41Δscl1 mutants, compared to their respective 
WT strains. In addition, restoration of Scl1.1 or Scl.chi2 expression on the surface of the 
M1Δscl1 mutant restored rEDB binding (Fig. 1D). Thus, just like with rScl1-rEDB binding 
above, our data demonstrate for the first time that GAS can bind to EDB containing cFn 
isoforms through surface Scl1.  
Because wounds, which contain isoforms of cFn that contain either EDA and/or 
EDB fibronectin, can serve as a portal of entry for GAS to gain access to host tissues, we 
sought to understand if the GAS-EDB interaction facilitates GAS biofilm formation in vitro, 
which could influence the course of GAS infection. We used rEDB-coated surfaces and 
analyzed biofilm formation by GAS isogenic strains spectrophotometrically, using crystal 
violet staining to assess biomass (Fig. 1E), as well as microscopically, with GFP-
expressing M41 GAS, to examine biofilm morphology and thickness (Fig. 1F). After 24 
hours, there was significantly more stained biomass of WT strains grown on rEDB, 
compared to amounts of biomass of the isogenic M1Δscl1 and M41Δscl1 mutants (Fig. 
1E). These results were further supported through confocal laser scanning microscopy, 
demonstrating that M41 WT biofilm had an average thickness of approximately 18 µm, 
while the M41Δscl1 mutant had an average thickness of approximately 8 µm, a 40% 
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decrease (Fig. 1F, bottom images). Altogether, our data validate GAS capacity for binding 
to the fibronectin type III repeat, EDB, which facilitates GAS biofilm formation.  
 
Scl1 binds tenascin C via surface-exposed loops of the Scl1-V domain – TnC is a 
multi-domain glycoprotein with a central region made of fibronectin type III repeats (Fig. 
2A) (45). Similar to EDA- and EDB-fibronectins, TnC is abundantly deposited within 
wounded tissue (39,46). Here, we hypothesized that Scl1 could bind to TnC. We first 
investigated TnC binding to our panel of rScl1 and rScl2 constructs that we characterized 
previously for binding to cFn (21) and rEDB above (Fig. 1B-C). ELISA binding data 
demonstrate that constructs rScl1.1, rScl1.2, rScl1.12, rScl1.28 and rScl1.41, derived 
from diverse Scl1 variants expressed by M1-, M2-, M12, M28 and M41 GAS, all bind to 
TnC. In contrast, rScl2.4 (Scl2 of M4) and rScl2.28 (Scl2 of M28) constructs demonstrate 
minimal levels of TnC binding (Fig. 2B) and were considered binding-negative controls, 
reminiscent of their lack of binding to cFn, rEDA and rEDB. Based on these results we 
asked if TnC binding occurs via the loop-region of the Scl1-V domain, utilizing the same 
panel of chimeric rScl proteins described above. ELISA binding data demonstrate TnC 
binding to rScl.chi1, rScl.chiC and rScl.chi3, whereas constructs rScl.chi2 and rScl2.28 
are binding-negative (Fig. 2C). Hence, our results establish the same binding pattern 
documented earlier for EDA of cFn and EDB of cFn, pointing towards one conserved Scl1 
binding mechanism to cFn and TnC, which is mediated by the surface-exposed loops 
present in the structure of Scl1-V domain (18,19). 
 
Scl1 binds to the type III repeats of tenascin C – We next tested whether Scl1 binds 
to FnIII repeats within TnC. EDA in cFn interacts with Scl1 (22) and with the α9β1 integrin 
receptor (47), which also binds to the TnFn3 repeat in TnC (48). Therefore, we 
hypothesized that Scl1 specifically binds to the TnFn3 repeat within the TnC molecule 
(Fig. 2D). To test this hypothesis, we produced recombinant fragments of the TnFnIII 
repeats, encompassing repeats 1-5 (rTnFn1-5), repeat number 3 (rTnFn3), and repeats 
6-8 (rTnFn6-8), the later to be used as a binding-negative control. We first tested the 
rTnFnIII constructs for binding to our panel of naturally-derived and chimeric rScl 
constructs (Fig. 2E). Binding to rTnFn1-5 was significantly higher for all naturally-derived 
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rScl1.1, rScl1.28 and rScl1.41 proteins and the chimeric EDA/EDB/TnC-binding-positive 
proteins rScl.chi1, rScl.chiC, and rScl.chi3, as compared to ECM-binding-negative 
rScl2.28 and rScl.chi2 controls. However, binding between rTnFn3 and rScl constructs 
that bind the larger rTnFn1-5 fragment was negligible and inconsistent. Unexpectedly, we 
also recorded a significant binding between control rTnFn6-8 fragment and rScl 
constructs positive for rTnFn1-5 binding (48).In summary, we have demonstrated for the 
first-time direct binding between Scl1 and TnFnIII repeats using recombinant proteins. 
 The α9β1 and α4β1 integrins were historically referred to as “acidic” integrin 
receptors that recognized LDV or similar tripeptide sequences (49), like an IDG sequence 
located in the B-C loop of TnFn3 (Fig. 2D). We reasoned that the Scl1 binding site in TnC 
may overlap with similar LDV-like sequences, particularly located within the exposed 
loops of the rTnFn1-5 (outside Fn3 repeat) and rTnFn6-8 fragments, and the homology 
models of the TnFn1-5 and TnFn6-8 fragments (48) identified several candidate 
sequences within both TnFn1-5 and TnFn6-8 regions (Fig. 2Fi-ii). Specifically, the VDG 
triplet was identified in the C’-E loop of TnFn6, the LDG sequence in the connecting 
segment between repeats TnFn6 and 7, and the LDS sequence in the connecting 
segment between TnFn7 and 8, and VDG sequence in the B-C loop of TnFn8 (Fig. 2Fi). 
Most of these share a DG-dipeptide with C-C’ loop in EDA that is critical for integrin α9β1 
binding (47). We similarly identified several LDV-like tripeptides within TnFn1-5 fragment 
e.g., PEG, LDA, IDS, VDV, LDT, and LEP triplets (Fig. 2Fii). We propose that Scl1 may 
recognize the TnFnIII repeats 1-5 and 6-8 via LDV/IDG-like motifs, similar to some the 
α9β1binding sequence (50).  
 
Identification of Scl1 targets within the ECM deposited by cancer-associated 
fibroblasts – Tumors have many similarities to healing wounds, including extensive ECM 
remodeling (51). ECM deposition and remodeling is due in part to the surrounding stromal 
cancer-associated fibroblasts (CAFs) (38,52,53) that deposit EDA/EDB-fibronectins and 
TnC (52,54-57). Here, we characterized the extracellular matrix deposited by primary 
CAFs as an in vitro model for Scl1 targeting to the tumor microenvironment, expressing 
significant amounts of cFn isoforms that contain EDA and/or EDB, and TnC. CAFs were 
grown to confluency and were subsequently removed non-proteolytically from deposited 
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matrices by EGTA treatment. Matrices were initially visualized using Ponceau S staining, 
showing good overall integrity of a complex fibrillary network, without obvious signs of 
degradation (Fig. 3A). The composition of the matrices was then assayed by ELISA for 
the presence of cFn, EDA, EDB, and TnC, using specific mAbs (Fig. 3B). ELISA data 
shows that CAFs deposit ECM that contains 2-7 fold higher levels of cFn with EDA, EDB, 
as well as TnC, relative to control BSA background. Matrices were also visualized using 
immunofluorescent staining of the specific distribution of ECM components with the same 
mAbs, used in the ELISA. Immunofluorescence imaging revealed a significant presence 
of cFn isoforms that contain EDA and EDB, as well as the presence of TnC within CAF-
deposited ECM (Fig. 3C). We conclude that we developed a suitable in vitro model to test 
Scl1 binding to complex extracellular matrices potentially akin to those generated by 
fibroblasts in wounds and the tumor microenvironment.  
 
Scl1 mediates GAS targeting to cancer-associated fibroblast-derived ECM – We first 
visualized and quantified the GFP-expressing WT and isogenic M1Δscl1 and M41Δscl1 
mutant cells adherence to glass coverslips, containing CAF-deposited matrices, after 1-
hour incubation (Fig. 4A). More fluorescent M1- and M41-WT GAS were seen adhered to 
the CAF-derived ECM on coverslips than their respective M1Δscl1 and M41Δscl1 mutants 
(Fig. 4A, left). The quantification of attached cells revealed that significantly fewer of the 
M1Δscl1 mutant cells, by ~70%, bound the matrices, compared to the WT strain; similarly, 
the M41Δscl1 mutant bound the matrices ~80% less than the WT strain (Fig. 4A, right). 
Therefore, our results show that GAS adheres to the ECM deposited by CAFs, and this 
attachment is mediated through Scl1.  
We next investigated if Scl1 expression facilitates GAS biofilm formation on the 
CAF-deposited matrix, using crystal violet staining and confocal fluorescence microscopy 
(Fig. 4B-C). Crystal violet staining of 24-hour bacterial biomass formed on CAF-derived 
ECM detected significantly more of both M1 and M41 WT GAS, compared to their 
respective M1Δscl1 and M41Δscl1 mutants (Fig. 4B). In addition, we compared biofilm 
thicknesses formed on CAF-derived ECM by GAS M41 WT and M41Δscl1 mutant strains 
(Fig. 4C). As expected, the M41 WT GAS formed biofilms that averaged 20 µm in 
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thickness, while M41Δscl1 mutant strain had a 40% decrease in thickness, averaging 12 
µm.  
 
Scl1 mediates GAS colonization of matrix deposited by osteosarcoma cells – In 
1891, Dr. William B. Coley injected inoperable osteosarcomas with live group A 
streptococci and observed tumor shrinkage and increased survival in some patients (mini-
review by (58)). While the likely success of Coley’s treatment was principally due to the 
stimulation of immune responses by GAS within tumors (59,60), it is possible that Scl1 
indirectly, although relevantly, contributed to treatment success by promoting GAS to 
colonize the microenvironment of osteosarcomas. Here, we applied the same in vitro 
model as above, but using Saos-2 osteosarcoma cell line (61). Saos-2 cells were grown 
to confluency; cells were removed from the matrices that were visualized by Ponceau S 
staining (Fig. 5A) and characterized for ECM composition by ELISA (Fig. 5B). As before, 
Ponceau S staining showed the formation fibrillary matrix characteristic of Fn and TnC 
(Fig. 5A), and ELISA data demonstrated that Saos-2 cells deposited some EDA-
containing cFn, as well as considerable amounts of EDB-rich cFn isoforms and TnC (Fig. 
5B), relative to BSA background.  
To assess if Scl1 promotes GAS attachment and colonization of Saos-2-deposited 
matrices, we performed a 1-hour whole-cell attachment assay, using GFP-expressing M1 
and M41 isogenic GAS strains (Fig. 5C). There were more fluorescent M1 and M41 WT 
GAS on the Saos-2-deposited matrices than the M1Δscl1mutant and M41Δscl1 mutant 
cells (Fig. 5C, top panels). Quantification revealed significant differences in the 
attachment between isogenic strain pairs; there was ~80% reduction in the attachment of 
the M1Δscl1 mutant and ~90% reduction by the M41Δscl1 GAS (Fig. 5C, bottom graph). 
In addition to facilitating GAS attachment, Scl1 contributes to biofilm formation on Saos-
2-deposited matrices (Fig. 5D). Crystal violet staining after 24 hours showed significantly 
larger bacterial biomass grown by both WT strains on Saos-2 matrices, compared with 
their respective Δscl1 mutant counterparts (Fig. 5D). In summary, our data demonstrates 
that Scl1 targets GAS to colonize the complex ECM deposited by cancer-associated 





GAS infections typically start within the wounded portal of entry, which is characterized 
by a microenvironment rich in cFn isoforms that contain either EDA and/or EDB, as well 
as TnC. Here we report that Scl1 of GAS binds multiple wound-associated ECM targets 
that contain FnIII-type repeats and includes EDA and EDB of cFn, as well as FnIII repeats 
in TnC (Fig. 6). These interactions occurred through the same conserved binding 
mechanism mediated by the Scl1-V domain and facilitated GAS adherence and biofilm 
formation.  
Group A streptococcal strains may express numerous Fn-binding proteins on the 
cell surface and at least 11 distinct Fn adhesins have been reported (reviewed in (62)). 
The most common mechanism of Fn binding is via the classical Fn-binding repeats which 
are found in several Fn-binding proteins of GAS, such as protein F1/SfbI and F2/PFBP, 
serum opacity factor SOF/SfbII, FbaA and FbaB, SfbX, and Fbp54 (63-68). During the 
binding process, the Fn-binding repeats of those adhesins, interact with the N-terminal 
fibronectin type I repeats (FnI) through a tandem β-zipper mechanism and contribute an 
additional anti-parallel β-strand within the -sheet structure of the FnI repeats (64,69). 
Scl1, however, lacks the classical Fn-binding repeats and binds, instead, to the FnIII 
repeat EDA, via its globular V domain (22). Scl1-EDA binding mechanism was mediated 
by the C-C’ loop of EDA and surface-exposed loops of the Scl1-V domain (19). Here, we 
determined that several rScl1 variants, with diverse V-domain sequences, bind to FnIII-
derived rEDB polypeptide. Using a series of engineered rScl constructs, we furthermore 
showed that Scl1-EDB binding engaged, like EDA binding, the Scl1-V-domain loops and 
suggests the same conserved binding mechanism. Homology modeling of EDB and 
analysis of the predicted loop sequences imply that the C-C’ loop of EDB is a potential 
Scl1-binding target. To our knowledge, Scl1 is the first bacterial adhesin that directly binds 
the FnIII-EDB of cFn. 
In addition, we show that the Scl1-EDB interaction facilitates GAS biofilm formation 
in vitro on rEDB-coated surfaces. The role of EDB in bacterial infections is beginning to 
be appreciated. Recently, cFns that include the EDB segment were shown to be 
upregulated in the cerebral spinal fluid and serum of patients suffering from 
Staphylococcus aureus meningitis (70). EDB-containing cFns in these patients were 
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released by immune cells during phagocytosis of S. aureus and enhanced bacterial 
removal by phagocytic cells. Phagocytosis of S. aureus in vitro was augmented by the 
addition of exogenous EDB/cFn, which activated the αvβ3 integrin on phagocytic cells. 
However, it was not shown if S. aureus adhered directly to EDB (70). Similarly, EDA/cFn 
isoforms were shown to be elevated in a post-surgical bacteremia model in sheep; 
however, the role of EDA/cFn in facilitating phagocytosis was not investigated (71).  
Other bacterial adhesins may also bind to EDA and/or EDB, like Tp0155 of 
Treponema pallidum and YadA of Yersinia spp. (72). The outer envelope protein Tp0155 
of T. pallidum displayed a selective binding to cFn (referred to in text as insoluble matrix 
fibronectin), but not plasma pFn, which contributed to T. pallidum host-cell adhesion (73). 
YadA of Y. pseudotuberculosis and Y. enterocolitica also demonstrated preferential 
binding to cFn, promoting bacterial cell entry (74,75). Further investigations are needed 
to assess EDA/cFn and/or EDB/cFn binding by these adhesins.  
Two streptococcal proteins have been reported to bind to the FnIII repeats of TnC 
(TnFnIII): protein H (76) and protein F2 (77). The M-like protein H binds factor H and IgG, 
as well as the neural cell adhesion molecule (N-CAM), which contains FnIII repeats (78). 
Protein H binding to N-CAM was competitively inhibited with pFn fragments 
encompassing the FnIII repeat region, as well as with two different FnIII-containing 
recombinant proteins derived from TnC (76). Protein F2 contains the prototypical 
fibronectin-binding repeats, that bind to the N-terminal type I and II repeats of Fn (66,79). 
To our knowledge, direct binding to the FnIII repeats in either fibronectin or TnC by F2 
protein has not been reported. A recent study showed that a protein F2-deficient mutant 
of an M3-GAS strain bound significantly less TnC compared with the wild-type parental 
organism, which was restored by in-trans complementation (77). It should be noted that 
the M3 strain used in this study, MGAS315, does not express Scl1 adhesin (80). Here we 
used defined recombinant TnFnIII fragments, rTnFn1-5 and rTnFn6-8, and show for the 
first time that Scl1 binds directly to TnFnIII repeats of TnC. 
Cellular fibronectin isoforms and tenascin-C are also present in the tumor 
microenvironment. In cancerous tissues, cancer cells activate the surrounding stromal 
fibroblasts, known as cancer-associated fibroblasts (CAFs) (38,81,82). Here, we show 
that cultured CAFs, isolated from a stage IV laryngeal primary tumor, deposit cFn 
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isoforms that contains EDA and/or EDB, as well as TnC in vitro; and that Scl1 facilitates 
GAS adherence to and biofilm formation on CAF-deposited ECM preparations. GAS has 
a known connection to cancer, as an original and major component of Coley’s toxin 
(succinctly reviewed in (58)). Developed by Dr. William Coley, a bone sarcoma surgeon 
(1862-1936), Coley’s toxin was the first use of a cancer immunotherapy in medicine 
(58,83). Coley and colleagues injected live and killed streptococci to treat patients afflicted 
with soft-tissue and bone tumors with relative success (84). Interestingly, we now know 
that osteosarcoma cells upregulate cFn isoforms that contain EDA and/or EDB, and TnC 
expression (85-87). Here we used model osteosarcoma Saos-2 cells to produce matrices 
containing the cFn isoforms that contain EDA and/or EDB, as well as TnC. Scl1 promoted 
GAS colonization and biofilm formation on osteosarcoma-derived matrices. This work 
adds a new dimension to the history of Coley’s toxin, through the capacity of the Scl1 
adhesin to target ECM proteins that are present within the tumor microenvironment; this 
provides a previously unrealized feature in the utilization of GAS in the potential treatment 
of cancer (59,60). 
Understanding of the GAS-fibronectin interaction has evolved since our finding that 
the GAS adhesin, Scl1, selectively binds to cFn, but not pFn, (21) via unique mechanism 
involving the cFn type III repeat, EDA (19,22). Here, we demonstrate that Scl1 also binds 
to EDB in isoforms of cFn, as well as to the FnIII repeats within TnC. All three ECM ligands 
are expressed within wounded tissue, which is typically the first site GAS encounters 
within the host. In each case, surface-exposed loops of the globular sequence-variable 
but structurally-conserved V-domain of Scl1 were responsible for ligand recognition and 
binding. The Scl1 adhesin improves GAS adherence and biofilm formation on 
extracellular matrices rich in cFn isoforms that contain EDA and/or EDB, and TnC. 
Interestingly, the aforementioned ECM components are also constituents of tumor 
microenvironments and our initial experiments suggest Scl1 has the capacity for targeting 
tumors. In summary, the Scl1-V domain has evolved within the wound microenvironment, 





Bacterial strains and growth – Group A Streptococcus (GAS) strains MGAS5005-M1 
and MGAS6183-M41, as well as their scl1-inactivated isogenic mutants were used in this 
study (88,89);Lukomski, 2000 #119973;Han, 2006 #119967}. Briefly, both mutants were 
generated by allelic replacement with nonpolar resistance cassettes, encoding 
spectinomycin (MGAS5005 Δscl1) and erythromycin (MGAS6183 Δscl1) resistance. GAS 
cultures were grown at 37ºC, with 5% CO2 in Todd-Hewitt broth supplemented with 0.2% 
yeast extract, and on Brain Heart Infusion (BHI) agar. For GAS antibiotic selection, 
erythromycin (4 µg ml-1), chloramphenicol (5-10 µg ml-1), and spectinomycin (100 µg ml-
1) were added to the medium.  
 
Complementation of M1 group A Streptococcus – To complement MGAS5005 Δscl1 
with either scl1.1 or scl.chi2 in-trans, the E.coli shuttle vector pSB207 was used (90). 
Briefly, a DNA fragment, encompassing the scl1.1 coding sequence with upstream 
promoter, was PCR-amplified from genomic DNA and cloned into pSB207, generating 
plasmid pSL620 (19). A synthetic double-stranded DNA fragment (gBlocks; Integrated 
DNA Technologies) encoding the scl.chi2 coding sequence was cloned into pSB620, 
generating pSL621 (19). Clones were verified by sequencing and were then introduced 
into MGAS5005 Δscl1 mutant; transformants were selected on BHI agar containing 10 µg 
ml-1 chloramphenicol and GAS cultures were routinely grown in THY broth with 10 µg ml-
1 chloramphenicol.  
 
Recombinant protein production – Production of recombinant streptococcal collagen-
like proteins (rScls). Gene cloning and rScl-protein production were performed in 
Escherichia coli DH5a, TB1 and BL-21 strains grown in Luria-Bertani (LB) media with 
ampicillin (100 µg ml-1) at 37ºC. rScl-encoding clones, which were derived from the 
original scl alleles, were generated by PCR amplification from GAS genomic DNA and 
cloned into the E.coli expression vector pASK-IBA2(15) (16). Clones encoding the 
chimeric rScl proteins were generated using synthetic double-stranded DNA fragments 
(gBlocks; Integrated DNA Technologies), as described previously (19). All plasmids were 
verified by DNA sequencing.  
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All rScl proteins were generated using the Strep-tag II cloning, expression, and 
purification system (IBA-GmbH). Proteins were expressed with a C-terminal affinity tag 
and purified on Strep-Tactin sepharose, as described (15,16). The rScl1.1 protein is 
derived from Scl1 protein in M1-type strain MGAS6708 (15); rScl1.28 originates from M28 
strain MGAS6274 (15), rScl1.41 is derived from M41 strain MGAS6183 (91), rScl1.3 is 
derived from M3 strain MGAS315 (80), rScl1.12 is derived from an M12 strain MGAS6139 
(16), rScl1.2 is derived from an M2 strain MGAS3803 (92), and rScl2.4 is derived from 
M4 strain MGAS321 (16). Both naturally-derived and chimeric rScl proteins were 
expressed in E. coli BL21 periplasm following induction with anhydrotetracycline at 0.2 
µg mL-1 for 3 hours. Cells were centrifuged and suspended either in high sucrose buffer 
(100mM Tris-HCl, 1 mM EDTA, pH 8.0, 500mM sucrose) or Cell Lytic B Buffer (Sigma), 
for separation of the periplasmic fraction and subsequent affinity purification. Purified 
proteins were analyzed by SDS-PAGE and stained with RAPIDstainTM; proteins were 
dialyzed against 25 mM HEPES, pH 8.0, and stored at -20oC. Protein concentrations were 
determined using Qubit fluorometric quantitation.  
 
Recombinant extra domain B (rEDB) production – rEDB was produced using the pQE-
30 His-tag cloning, expression, and purification system in the E. coli strain JM-109, as 
described elsewhere (93). EDB-encoding segment was amplified by PCR from rat cDNA 
and cloned into pQE-30; the resulting construct was a gift from Dr. John Peters. Protein 
expression was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside for 3 hours. 
Cells were harvested by centrifugation, and pellets were frozen at -20oC for 2 hours or 
overnight. Cells were next suspended in a bacterial lysis buffer (50 mM Tris/HCL pH 8.0, 
50 mM NaCl, 2 mM MgCl2, 2% Triton X-100, 10 mM β-mercaptoethanol, 0.2 mg/ml 
lysozyme, 1 EDTA-free protease inhibitor cocktail tablet [per 10 mL], 1 mM 
phenylmethane sulfonyl fluoride, 10 U ml DNaseI) and incubated on ice for 20 minutes. 
Cell lysate was centrifuged at high speed (16000g x 20 minutes) and supernatant was 
collected. Supernatant was mixed 1:1 volumetrically with wash buffer (50 mM NaH2PO4, 
10 mM imidazole, 300 mM NaCl), added to 1 ml of cobalt-agarose resin, and then poured 
into a column. Sample was washed 10x resin bed volume with wash buffer, and then 
rEDB protein was eluted in elution buffer (50 mM NaH2PO4, 150 mM imidazole, 300 mM 
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NaCl). Purified protein was dialyzed against 25 mM HEPES buffer, pH 8.0 and stored at 
-20oC until future use. Protein integrity and purity were assessed by 18% SDS-PAGE and 
concentration was measured with Qubit fluorometric quantitation.  
 
Recombinant tenascin-C fibronectin type III fragments (rTnFnIII) – Recombinant 
tenascin-C fibronectin type III (FnIII) fragments: repeats 1-5, (rTnFn1-5), repeats 6-8, 
(rTnFn6-8), or repeat 3 (rTnFn3) were produced after recloning into pQE-30 His-tag 
vector in the E. coli strain XL1-blue. Sequences for each fragment were PCR-amplified 
from the original constructs cloned in pET15b (rTnFn1-5 and rTnFn6-8) or pET11b 
(rTnFn3) expression vectors (provided by Dr. Harold P. Erickson)(94). Recombinant 
proteins were expressed, purified, and stored as described above with rEDB.  
 
Homology modeling of, EDA, EDB, and TnFnIII domains – The homology models of 
tenascin-C domains from 1 to 5 (TnFn1-5) and from 6 to 8 (TnFn6-8) were obtained after 
consensus-based sequence alignment using the profile hidden Markov models (profile 
HMMs) implemented in the program HHpred (95). For TnFn1-5, best template model was 
identified as the structure of the recombinant four-domain fragment FnIII 7B89 (PDB code 
3t1w, seqid 27.7% with repeats 1-3 and 25.2% with repeats 2-5). In the case of TnFn6-8, 
best template was the structure of human fibronectin domains 12-14 (PDB code 3r8q, 
seqid 34.9%). Once the best templates were identified, homology models were built with 
MODELLER (95). Stereo chemical quality of predicted models was improved by energy 
minimization using GROMACS (96). Validation of the structural quality of predicted 
models was carried out using the PDBsum database at PROCHECK server 
(http://www.ebi.ac.uk/thornton-srv/software/PROCHECK/). 
 
Protein binding assays – rScl proteins (0.5 µM solutions) were immobilized onto Strep-
Tactin-coated microplate wells for 1.5 h at room temperature and blocked with 1xTBS (25 
mM Tris, 150 mM sodium chloride, pH 7.4) supplemented with 1% fetal bovine serum 
albumin overnight at 4ºC, followed by incubation with ECM ligands: rEDB, tenascin-C 
(TnC) purified from glioblastoma cells (Sigma), rTnFn1-5, rTnFn6-8, and rTnFn3. The no 
rScl controls were performed in BSA-coated wells for each ligand and each antibody 
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used. Final OD values were normalized by subtracting the BSA controls in each 
experimental set-up. ECM ligands were added to the rScl-immobilized wells at 1 µg per 
well (except for TnC, incubated at 0.5 µg per well) and incubated at room temperature for 
1 hour. Bound rECM ligands were detected with monoclonal antibodies (mAbs): anti-His-
tag for rEDA and rEDB (Proteintech; 1:1000), anti-TnC BC-24, specific for the epidermal 
growth factor-like repeats, (ThermoFisher; 1:1000), followed by goat anti-mouse 
secondary antibody conjugated to horseradish peroxidase (HRP) (Jackson 
ImmunoResearch; 1:1000). The HRP substrate, 2,20-azino-bis(3-ethylbenzthiazoline-6-
sulphonic acid) (ThermoFisher; ABTS) was used and colorimetric reactions were 
recorded at OD415 nm.  
 
Eukaryotic cell assays 
 
Isolation of cancer-associated fibroblasts (CAFs) – CAFs were isolated from a stage 
IV laryngeal cancer resection obtained from the West Virginia University Pathology 
Laboratory for Translational Medicine in compliance with approved Institutional Review 
Board protocol #1310105737A033 as described previously (97). Briefly, tissue was 
submerged in DMEM/10% FBS containing 1% penicillin-streptomycin-amphotericin B (P-
S-A) (Millipore, 51610420ML) and mechanically digested. Tissue pieces <2 mm were 
placed into a 24-well plate, allowed to adhere for 2-3 min, then covered with media and 
placed in a humidified 37°C incubator with 5% CO2. Emanating CAFs were cultured in 
DMEM supplemented with 10% FBS/1% P-S-A, passaged 2-3 times with Accumax 
(Millipore, SCR006) until acclimated, then passaged with 0.25% trypsin and grown in 
DMEM/10% FBS. CAFs were passaged 5 times before being cryopreserved. Thawed 
CAFs were passaged 2 times prior to use. 
 
Preparation of cancer-cell-derived extracellular matrices – Cancer-associated 
fibroblasts (CAFs) and the osteosarcoma cell line Saos-2 (ATCC® HTB-85) were used to 
produce cell-derived extracellular matrices. Matrices were prepared, as described 
previously (22), Briefly, CAFs and Saos-2 cells were cultured in high-glucose Dulbecco’s 
Modified Eagle Medium with 10% fetal bovine serum and 1% penicillin and streptomycin 
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at 37ºC in an atmosphere of 5% CO2 throughout the experiment. To produce the 
extracellular matrix for specific tests, cells were grown as follows: (i) for matrix 
characterization via immunofluorescence or for GFP expressing GAS (GFP-GAS) 
attachment assays, cells were grown on 15-mm glass coverslips inserted into wells of 
(24-well) tissue culture plates, and (ii) for crystal violet biofilm assay, matrix 
characterization by ELISA or by Ponceau S staining, cells were growth in plastic wells 
without glass coverslips. Cells were seeded at 50,000 cells per well, grown until confluent, 
and then removed through treatment with 5 mM ethylene glycol tetraacetic acid (EGTA). 
Samples were washed gently with PBS and wells or coverslips were subsequently used 
for assessment.  
 
Cell-derived ECM matrix characterization 
 
Ponceau S staining – To visualize the matrices deposited by CAFs and Saos-2 cells, 
Ponceau S solution (0.1% in 5% acetic acid solution) was added to the wells for 20 
minutes. Stain was then removed, and wells were examined microscopically using a Zeiss 
Axiovert 40 CFL microscope with a 20x objective. Image acquisition was done using the 
Zeiss AxioCam Mrc5 camera and images analyzed with Zeiss AxioVision 4.8 software.  
 
Matrix characterization by ELISA – CAFs- and Saos-2-derived matrices were prepared, 
as above, and wells were blocked overnight with 1% bovine serum albumin in 1X TBS. 
The next day, the following mAbs were added to wells for 1 hour at room temperature: 
anti-fibronectin, specific for the fourth fibronectin type III repeat of fibronectin, (Sigma; 
IST4, 1:1000), anti-EDA (Santa Cruz Biotechnology; IST9, 1:1000), anti-EDB containing 
cFn (Sirius Biotechnology; C6, 1:500), or BC-24, (1:1000); a goat anti-mouse secondary 
antibody conjugated with HRP (1:2000) was added for 1 hour, washed, and then 
developed with ABTS substrate. Each antibody was used in triplicate wells, over 3 





Matrix characterization by immunofluorescence microscopy – To visualize the 
matrices deposited on glass coverslips, wells were denuded of cells and blocked 
overnight at 4ºC with 1% BSA/TBS. Anti-ECM antibodies: IST4 (1:100), IST9 (1:200), C6 
(1:100) and BC-24 (1:1000) were added to wells for 1 hour at room temperature, washed 
with TBS, followed by addition of goat anti-mouse secondary Ab conjugated with Alexa 
Fluor 568® (Thermofisher, 1:300). Coverslips were then washed and mounted in ProLong 
Gold (Invitrogen). Matrices were visualized using a Nikon A1R confocal microscope 
equipped with a 60x objective. Images were processed using Nikon NIS-Elements 
Software.  
 
GAS attachment and biofilm assays  
 
Scl1 surface expression and rEDB binding by flow cytometry – Determination of Scl-
surface expression by GAS cells, as well as rEDB binding to whole-GAS cells were 
measured by flow cytometry. Bacteria were grown to an OD600 of 0.5, harvested by 
centrifugation and washed with flow cytometry buffer (phosphate-buffered saline 
containing 10% Todd-Hewitt broth with 0.2% yeast extract). For Scl-surface detection, the 
anti-Scl1.1-V antibody (11), pre-absorbed with MGAS5005 Δscl1 cells, was incubated 
with GAS cells for 30 minutes on ice. Cells were next washed and incubated with 
Allophycocyanin (APC)-conjugated donkey anti-rabbit antibody (Jackson 
ImmunoResearch; 1:150). For ligand binding, GAS cells tested were incubated with rEDB 
for 30 minutes at room temperature. GAS cells were then centrifuged and washed 2x with 
flow cytometry buffer. Bound protein was detected with anti-His-tag mAb (1:750), followed 
by a goat anti-mouse secondary pAb conjugated with Alexa Fluor® 568 (1:150). Cells 
were washed, fixed in 0.4% paraformaldehyde and analyzed. 50,000 events were 
collected per sample using a BD LSRFortessa flow cytometer and data were analyzed 
with FCS Express Flow 6 software.  
 
GAS whole-cell attachment assay – GFP-GAS adherence was studied on glass 
coverslips with rEDB coating and on cancer-cell-derived matrices, as described (21). 1 
ml of GFP-GAS cultures, prepared as above, were seeded into wells and incubated for 1 
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hour at 37ºC, washed with PBS, fixed with 3% paraformaldehyde for 30 minutes, and then 
mounted in ProLong Gold overnight. The total number of GAS cells were counted in 10 
arbitrary fields and the numbers of WT M1 or M41 GAS cells were set as 100%. The 
differences between WT and isogenic scl1 mutants were evaluated statistically.  
 
Crystal violet staining of GAS biofilms  – GAS biofilm formation was tested on rEDB-
coated surfaces and on cancer-cell-derived matrices. Wild-type and isogenic scl1 mutant 
GAS strains were grown to an OD600 of 0.5 and 1-ml aliquots were seeded into 24-well 
culture plates coated either with rEDB (2 µg/well) or in wells containing CAF- or Saos-2-
derived extracellular matrices, prepared as above. GAS biofilms were grown for 24 hours, 
washed with PBS, and stained with 1% (v/v) crystal violet solution (Becton Dickinson) for 
30 minutes at room temperature. Biomass staining was solubilized with 0.5 ml of 90% 
ethanol and assessed spectrophotometrically at OD600nm.   
 
Confocal laser scanning microscopy of GAS biofilms – GAS biofilms were also 
visualized on glass coverslips coated with rEDB (2 µg) or on cancer-cell-derived matrices, 
using isogenic GFP-GAS (21,98). 24-hour biofilms were grown as above, fixed in 3% 
paraformaldehyde for 30 minutes, and mounted in ProLong Gold overnight. Biofilms were 
imaged using a Nikon A1R confocal microscope, with a 100x objective. Images were 
analyzed and deconvoluted using NIS-Elements Software. Conversion to three-
dimensional images was performed with conventional Z-stacks, deconvoluted stepwise 
and transformed using NIS-Elements Software. 
 
Statistical analyses – Statistics were performed using the two-tailed paired Student’s t-
test. Significance was denoted at levels of *P ≤0.05, **P ≤0.01, or ***P ≤0.001. Error bars 
represent standard deviations with analyses based on three independent experimental 
repeats (N=3), each performed in triplicate technical replicates. 
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Figure 1. Scl1-EDB binding mediates GAS adherence and biofilm formation. Recombinant fibronectin type 
III repeat, extra domain B (rEDB) was tested for binding to recombinant streptococcal collagen-like proteins 
(rScl) , as well to whole-GAS cell. Scl1-mediated biofilm formation was studied on rEDB coatings. (A) 
Cartoon representations of the EDB and EDA domains of fibronectin. Structures of EDB (grey – adapted 
from PDB accession code: 5n48), and EDA (blue – adapted from PDB accession code: 1j8k) are shown in 
forward (left) and side (right) views. Left, front view of superimposed β-sandwich structures of EDA and 
EDB, with each β-strand marked (A, B, C, C’, E, F, G) and C-C’ loops shown in stick representation. Right, 
side view of EDB structure, depicting the C-C’ loop in ball and stick representation. The N- and C-terminal 
ends are labeled in both models. (B) Schematic representation of the variable (V) domains in recombinant 
Scl constructs used. Homotrimeric rScl1.1-, rScl1.28 (gray box), and rScl2.28-V domains (white box) consist 
of three conserved pairs of anti-parallel α-helices, with connecting loops (19). Chimeric proteins were 
generated by replacing either the entire (rScl.chi1-3) or partial (rScl.chiC) loop sequences between different 
constructs. (C) rEDB binding to naturally-derived and chimeric rScl constructs. rScl proteins were 
immobilized onto Strep-Tactin coated microplate wells and incubated with rEDB. Primary anti-His-tag mAb 
and HRP-conjugated secondary Ab were used for ligand detection by ELISA. Graph bars indicate the mean 
OD415nm normalized against BSA controls. Statistical analysis was calculated using Student’s two-tailed t-
test from three independent experiments, each performed in triplicate wells (N=3±SD); *P≤0.05, **P≤0.01. 
Statistical significance evaluates the differences in rEDB binding by naturally-derived rScl1 (left 4) and 
chimeric proteins (right 4), as compared to ECM-binding-negative rScl2.28 control protein; rEDB binding by 
rScl.chi2 was compared to that of rScl1.1. Dashed line indicate threshold OD415nm +2SD values recorded 
for binding-negative rScl2.28 control protein. (D) rEDB binding to whole GAS cells. Isogenic M1- and M41-
type GAS strains were used, as well as the M1 isogenic Δscl1 mutant complemented for the expression of 
Scl1.1 (Δscl1::scl1.1) and Scl.chi2 (Δscl1::scl.chi2) proteins. rEDB binding to whole GAS cells was detected 
by flow cytometry with primary anti-His-tag mAb; binding to GAS WT cells was set as 100%. Statistical 
analysis was calculated using Student’s two-tailed t-test from three independent experiments (N=3±SD); 
*P≤0.05. (E) Assessment of biofilm formation on rEDB-coated surfaces. Isogenic M1- and M41-type GAS 
strains were compared. Biofilm formation was evaluated spectrophotometrically following crystal violet 
staining. Graphic bars indicate the mean OD600nm normalized against BSA controls. Statistical analysis was 
calculated using Student’s two-tailed t-test from three independent experiments (N=3±SD); *P≤0.05. (F) 
Microscopy imaging of GAS biofilms formed on rEDB coating. GFP-expressing M1 WT and Δscl1.1 mutant 
strains were grown on rEDB-coated glass coverslips for 24 h. Two-dimensional orthogonal views of GAS 
biofilms are representative of Z stacks from 10 fields within a single experiment. Average vertical thickness 









Figure 2. Scl1 of GAS binds to the fibronectin type III repeats in tenascin C (TnC). For ligand binding by 
ELISA, rScl proteins were immobilized onto Strep-Tactin coated microplate wells and incubated with full-
length TnC (B-C) or recombinant TnC fragments (E) comprising of the fibronectin type III repeats (rTnFnIII). 
Primary anti-ECM mAb and HRP-conjugated secondary Ab were used for ligand detection. Graph bars 
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indicate the mean OD415nm normalized against BSA controls. Statistical analysis was calculated using 
Student’s two-tailed t-test from three independent experiments, each performed in triplicate wells 
(N=3±SD); *P≤0.05, **P≤0.01, ***P≤0.001. Statistical significance evaluates the differences in TnC and 
rTnFn binding by rScl1 and chimeric proteins, as compared to ECM-binding-negative rScl2.28 control 
protein; TnC and rTnFn binding by rScl.chi2 was compared to that of rScl1.1. Dashed line indicate threshold 
OD415nm +2SD values recorded for binding-negative rScl2.28 control protein. (A) Schematic representation 
of full-length TnC. Depicted are from the N-terminus: assembly domain (triangle), epidermal growth factor-
like repeats (ovals), constitutively expressed fibronectin type III repeats 1-5 and 6-8 (light hexagons), 
alternatively spliced fibronectin type III repeats (dark hexagons), fibrinogen-related domain (circle). Known 
integrin-binding domains are marked above the model. (B) TnC binding to recombinant Scl1- and Scl2-
derived constructs. rScl panel represents diverse Scl1 and Scl2 variants originating from strains of several 
M-types. (C) TnC binding to rScl chimeric proteins. rScl panel represents constructs shown in Fig. 1B-C 
and described (19). (D) Cartoon representation of the third fibronectin type III repeat of TnC PDB accession 
code: 1TEN). β-strands of the EDB β-sandwich are labelled (A, B, C, C’, D, E, F, G); the B-C loop with LDV 
motif  and the F-G loop harboring the RGD sequence is shown in dark gray. (E) rScl binding to recombinant 
fibronectin type III fragments within TnC. rScl panel represents constructs shown in Fig. 1B-C above and 
previously described (19). (F) Cartoon representations of the homology models of the fibronectin type III 
repeats 1-5 (orange) and 6-8 (gray) of TnC. Models of (i) TnFn6-8 repeats, and (ii) TnFn1-5 repeats. 
Segments harboring the potential LDV-like Scl1-binding motifs are shown in light blue ball and stick 
representation. Model of TnFn1-5 based on PDB accession code 3t1w; model of TnFn6-8 based on PDB 








Figure 3. Characterization of extracellular matrices deposited by cancer-associated fibroblasts (CAFs). 
CAFs were isolated from a stage IV laryngeal primary tumor and grown to confluency; matrices were 
prepared after the removal of cells by treatment with EGTA. Matrices were evaluated for the presence of 
EDA- and EDB-containing fibronectins and TnC. (A) Visualization of the overall structure of ECM deposited 
by CAFs. Ponceau S staining reveals complex fibrillary network of the matrices used in this study. (B) 
Characterization of the ECM deposited by CAFs by ELISA. The presence of total cFn, EDA/cFn, EDB/cFn, 
and TnC was assessed with specific mAbs and secondary HRP-conjugated antibody. Graph bars indicate 
the mean OD415nm. Three independent experiments were performed, each with triplicate wells (N=3±SD). 
Dashed line indicate threshold OD415nm +2SD values recorded for BSA control wells. (C) Immunofluorescent 
visualization of the ECM deposited by CAFs. CAFs were grown on glass coverslips, then cells were 
removed from matrices and incubated with primary mAbs specific for cFn, EDA/cFn, EDB/cFn, and TnC, 
followed by secondary Ab conjugated with Alexa Fluor® 568. Images were taken using confocal microscope 
with 60x objective; representative images are shown from 2 independent experiments, imaging 10 arbitrary 









Figure 4. Scl1-mediated GAS attachment to and biofilm formation on ECM deposited by cancer-derived 
fibroblasts. Wild type (WT) GAS strains M1 and M41, and their isogenic Δscl1 mutants were compared for 
attachment and biofilm formation. (A) GAS adherence to CAF-derived ECM. Isogenic GFP-GAS strains 
were inoculated onto CAF-derived ECM coatings, allowed to attach for 1 hour, and imaged using 
fluorescent confocal microscope with 100x objective. Left, representative images of attached GAS were 
taken in 10 fields, over three independent experiments. Right, quantification of GAS attachment with WT 
binding set as a 100%; bacteria were counted in 10 fields, and the average from all 10-fields was calculated. 
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Statistical significance was calculated using Student’s two-tailed t-test from three independent experiments, 
each performed in duplicate wells (N=3±SD); **P≤0.01, ***P≤0.001. Statistical analysis evaluates the 
difference between adherence to CAF-derived matrices by the WT and their respective isogenic Δscl1 
mutants. (B) Assessment of biofilm formation on CAF matrices. Isogenic M1- and M41-type GAS strains 
were compared. Biofilm formation was evaluated spectrophotometrically following crystal violet staining. 
Graphic bars indicate the mean OD600nm normalized against BSA controls. Statistical analysis was 
calculated using Student’s two-tailed t-test from three independent experiments (N=3±SD); *P≤0.05. (C) 
Microscopy imaging of GAS biofilms formed on CAF matrices. GFP-expressing M1 WT and Δscl1.1 mutant 
strains were grown for 24 h on CAF matrices coated glass coverslips. Two-dimensional orthogonal views 
of GAS biofilms are representative of Z stacks from 10 fields within a single experiment. Average vertical 
thickness is indicated in micrometers below two-dimensional orthogonal views, taken from 10 arbitrary fields 










Figure 5. Scl1-mediated GAS attachment to and biofilm formation on ECM deposited by bone 
osteosarcoma cells. Wild type (WT) GAS strains M1 and M41, and their isogenic Δscl1 mutants were 
compared for attachment and biofilm formation on the ECM produced by osteosarcoma Saos-2 cells. (A) 
Representative image of Ponceau S staining of ECM network deposited by Saos-2 cells. (B) 
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Characterization of the ECM deposited by Saos-2 cells by ELISA. The presence of total cFn, EDA/cFn, 
EDB/cFn, and TnC was assessed with specific mAbs and secondary HRP-conjugated antibody. Graph bars 
indicate the mean OD415nm. Three independent experiments were performed, each with triplicate wells 
(N=3±SD). Dashed line indicate threshold OD415nm +2SD values recorded for BSA control wells. (C) GAS 
attachment on Saos-2-derived ECM. Isogenic GFP-GAS strains were inoculated onto Saos-2-derived 
matrices, allowed to attach for 1 hour, and imaged using fluorescent confocal microscope with 100x 
objective. Top, representative images of attached GAS were taken in 10 fields, over three independent 
experiments. Bottom, quantification of GAS attachment with WT binding set as a 100%; bacteria were 
counted in 10 fields, and the average from all 10-fields was calculated. Statistical analysis was calculated 
using Student’s two-tailed t-test from three independent experiments, each performed in duplicate wells 
(N=3±SD); **P≤0.01, ***P≤0.001. Statistical significance evaluates the difference between adherence to 
Saos-2-derived matrices by the WT and their respective isogenic Δscl1 mutants. (D) GAS biofilm formation 
on Saos-2-derived ECM. Isogenic GAS strains were inoculated onto Saos-2-derived matrices and grown 
for 24 hours. Bacterial biomass was evaluated spectrophotometrically following crystal violet staining. 
Graphic bars indicate the mean OD600nm normalized against BSA controls. Statistical analysis was 








Figure 6. Model of GAS colonization of wound and tumor microenvironments. The wound and tumor 
microenvironments are enriched in isoforms of cellular fibronectin (cFn) that contain extra domain A (EDA) 
and extra domain B (EDB), as well as monomer of tenascin-C (TnC). Left, GAS gains access to the host 
via portal of entry, such as through a breach in keratinized squamous epithelium (SE), into a tissue 
environment that contains keratinocytes (KC), basal lamina (BL) ECM, and dermal fibroblasts (DF). Within 
wound, cells such as DFs deposit cFn isoforms that contain EDA and EDB, as well as TnC. GAS-Scl1 
adhesin binds EDA and EDB of cFn, and TnC within the wound, promoting wound colonization. Right, 
Cancer cells (CC) are surrounded by cancer-associated fibroblasts (CAF), which deposit cFn isoforms that 
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contain EDA and/or EDB, and TnC, recognized by GAS-Scl1. Enlarged insert, close-up view of the wound- 
and tumor-associated ECM 
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DISCUSSION AND PROSPECTS 
 
Our work sought to investigate the interactions between the Scl1 adhesin of GAS and 
wound-associated ECM, and the contribution of these interactions to GAS adherence and 
host colonization. The work presented in detail within preceding chapters elaborates on 
important structural determinants and mechanisms of binding for Scl1 and identifies FnIII 
repeats that are associated with the wound microenvironment, as Scl1 targets. In this 
chapter, we will selectively discuss our research in the context of important implications, 
resulting from Scl1-FnIII binding, in GAS wound colonization and pathogenesis, GAS 
targeting, and application to cancer therapies.  
 
Scl1 is a unique Fn-binding adhesin of GAS that adapted to colonize wound 
microenvironment  
Classical fibronectin-binding proteins of GAS, such as proteins F1 and F2, contain a block 
of fibronectin-binding repeats that recognize and bind to Fn type I repeats present in both 
pFn and cFn (1). These classical Fn-binding adhesins of GAS bind FnI repeats via a β-
zipper mechanism, wherein the Fn-binding repeats adopt a β-strand conformation and 
then align parallel to the outer most β-strand within the FnI structure (2). Scl1 lacks these 
canonical Fn-binding repeats and binds FnIII repeats through a different mechanism. Scl1 
interacts with EDA, EDB, and TnFnIII via surface-exposed guiding loops of the Scl1-V 
domain that surround a negatively-charged cleft bordered by a crown of positive and 
neutral surface charges present in binding-positive Scl1 proteins but not in binding-
negative Scl2 proteins (3). In this regard, Scl1 is similar to streptococcal adhesins, CshA 
of S. gordonii and BspA of S. agalactiae, that exploit a “catch-clamp” Fn-binding 
mechanism (4,5). In “catch-clamp” binding model, a surface-exposed loop caps the 
binding cleft, and guides Fn recognition towards binding cleft. The “catch-clamp” adhesins 
and Scl1-V domain share similar electrostatic surface charge distributions. Future 
crystallization of Scl1 in complex with FnIII ligand will aim to verify binding mechanism.  
Scl1 variants from several different M-types of GAS were shown to selectively bind 
cFn, but not pFn (6), and our initial work showed that Scl1 binds EDA (7). Here, I identified 
that Scl1 also binds to EDB of cFn, as well as to FnIII repeats of TnC. Two other GAS 
100 
 
proteins have been reported to bind to the FnIII repeats of TnC and Fn: the protein H, and 
protein F2. The M-like protein H binds factor H and IgG, as well as the neural cell adhesion 
molecule (N-CAM), which contains FnIII repeats (8). Protein H binding to N-CAM was 
competitively inhibited with pFn fragments encompassing the FnIII repeat region, as well 
as with two different FnIII-containing recombinant proteins derived from TnC (9). Protein 
F2 contains the prototypical Fn-binding repeats (10,11). To our knowledge, direct binding 
to the FnIII repeats in either Fn or TnC by F2 protein has not been reported. We, on the 
contrary, showed direct binding between rScl1 and rFnIII. Scl1 is, therefore, the only GAS 
adhesin with demonstrated binding to EDA, EDB, and to the TnFnIII repeats, which 
promotes GAS attachment and biofilm development within the wound. Additional bacterial 
adhesins may also bind to EDA and/or EDB, like Tp0155 of Treponema pallidum and 
YadA of Yersinia spp. (12). The outer envelope protein Tp0155 of T. pallidum displayed 
a selective binding to cFn (referred to in text as insoluble matrix fibronectin), but not 
plasma pFn, which contributed to T. pallidum host-cell adhesion (13). YadA of Y. 
pseudotuberculosis and Y. enterocolitica also demonstrated preferential binding to cFn, 
promoting bacterial cell entry (14,15). Further investigations are needed to assess 
EDA/cFn and/or EDB/cFn binding by these adhesins.  
 
EDA/EDB cFn isoforms and TnC are expressed during wound healing and are 
accessible to Scl1  
Immediately after the initial wounding (portal of entry), platelets deposit EDA and/or EDB 
containing cFn isoforms within the wound, as a component of the initial clot and first 
provisional matrix during wound healing. These isoforms of cFn are released from 
granules that are formed during the development of platelets from megakaryocytes (16). 
In addition, TnC circulates at low levels in human blood, and is deposited within the 
initial matrix formed during clotting (17,18). Several hours after wounding, fibroblasts 
and endothelial cells begin to deposit large amounts of EDA- and/or EDB-containing 
cFn isoforms, and TnC, within the wound bed as a transitional provisional matrix, 
contributing to proper wound healing (19); macrophages have also been shown to 
release EDA containing cFn within the wound bed to signal pro-inflammatory cytokine 
release (20). These isoforms of cFn are present within healing tissue for up to 2 weeks 
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after wound is healed (19). As we have shown previously (7), and outlined above, Scl1 
binds to EDA and EDB isoforms of cFn, and to all splice-variants of TnC via the 
constitutively-expressed FnIII repeats of TnC. This may enable GAS to colonize the 
immediate wound area (Fig. 1), rather than become invasive and disseminate to other 
tissues. As an example, the M3-type GAS strains that are associated with invasive 
infections (21,22) lack surface Scl1, due to a null mutation within collagen domain, which 
prevents cellular attachment (23). Restoring Scl1-surface expression enables Scl1-
mediated ECM binding in these strains, enhances biofilm formation on ECM coated 
surfaces (24), and decreases overall virulence (25). Therefore, the capacity of Scl1 to 
recognize multiple targets within wound microenvironment augments GAS colonization, 
while decreasing invasive spread and avoiding killing the host. In addition to adhesion, 
we have shown that the Scl1-EDA and -EDB interaction contributes to GAS biofilm 
formation in vitro ((7), current work). GAS biofilms are found in both non-invasive and 
invasive infections (26,27), and are thought to play an immune evasive role and offer 
protection from antibiotics (28,29). Therefore, the Scl1 capacity to recognize and bind 
EDA/ and EDB/cFn, and TnC within the wound facilitates enhanced tissue-microcolony 
formation (Fig. 1), thus, contributing to the pathogenesis of GAS infections. To examine 
the importance of EDA/cFn, EDB/cFn, and TnC in GAS wound-colonization, both in vitro 
and in vivo studies can be conducted. Using cell-derived matrices or organotypic 
cultures with EDA, EDB, TnC, or combinations of the three, could be used to assess 
changes in GAS colonization without these components. Inasmuch as double 
EDA/EDB-knockouts are embryonic-lethal, single knockout mouse lines exist for both 
EDA and EDB, as well as whole TnC knockout animals (30-32), enabling the study of 
EDA, EDB, and TnC during GAS wound infections, assessing differences in wound 
colonization.  
 
Scl1 alters human-cell integrin binding to EDA/cFn 
EDA and EDB are highly included in cFn isoforms expressed within wound beds and 
perform important functions in wound healing (33-36). Inasmuch as, the role of EDA in 
wound healing is well defined, limited knowledge exist for EDB. Multiple cells have been 
shown to bind to EDA via integrin receptors α9β1, α4β1, and α4β7. EDB, on the contrary, is 
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not known to interact with integrin receptors. Both α9β1 and α4β1 bind directly to the C-C’ 
loop of EDA, and this binding regulates important wound-healing functions. Scl1 binding 
 
Figure 1: Modulation of host responses by GAS Scl1 during wound colonization. In this model, GAS 
gains access to the host via the portal of entry, shown here as a breach in protective epidermis ( i.e. skin 
and throat mucosa). The wound microenvironment ECM is enriched with extra domains A (EDA) and B 
(EDB) containing cellular fibronectin (cFn) isoforms, as well as tenascin-C (TnC). Scl1 binds to EDA/cFn, 
EDB/cFn, and TnC within the wound, mediating GAS wound-colonization and biofilm formation. The 
globular V-domain of Scl1 binds to the C-C’ loop of EDA. Neutrophils (NT) and keratinocytes (KC) bind to 
the C-C’ loop of EDA via integrin receptor α9β1, regulating important wound-healing functions. EDA/cFn 
also activates TLR4 on monocytes (MC) and dermal fibroblasts (DF) to stimulate the production of pro-
inflammatory cytokines, TNFα and IL-8, through the NF-κB signaling cascade. The Scl1-EDA/cFn 
interaction may alter several important wound-healing functions. 
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to EDA was also mapped to the C-C’ loop (7), at or near the binding site of host cell 
integrin receptor α9β1 (37). Since Scl1 and integrin α9β1 bind to the same peptide region 
of the EDA segment, Scl1 may compete with α9β1 binding to EDA, impacting functions of 
cells, such as keratinocytes. To this extent, our preliminary unpublished data suggests 
that rScl1 competes in vitro with α9β1 binding to EDA and impedes cell attachment and 
spreading. By competing with the host’s integrins, Scl1 binding to EDA/cFn could lead to 
alterations of the dynamic wound-healing processes, such as changes in angiogenesis, 
dysregulation of α3β1 function, and neutrophil migration to the wound (Fig. 1).  
Wound keratinocytes express α9β1, which exerts a “trans-dominant” inhibitory 
effect on α3β1 during angiogenesis in healing wounds (36). On keratinocytes, α3β1 binds 
to laminin-332, and this binding mediates endothelial cell migration and angiogenesis 
through the secretion of growth factors (38,39). Binding of α9β1 to EDA/cFn controls α3β1-
mediated angiogenesis by modulating growth factor secretion, thereby reducing 
endothelial cell migration and leading to increases in endothelial cell apoptosis during the 
regression of growing blood vessels (36). Inhibition of α3β1 by α9β1 occurs through 
changes in Src-mediated phosphorylation of focal adhesion kinase (36). The temporal 
expression of EDA/cFn, during wound healing, suggests that the α9β1-to-α3β1 integrin 
cross-talk is important for controlling the level of angiogenesis. Therefore, Scl1 binding to 
EDA/cFn, within the α9β1 binding site, may disrupt this inhibition, leading to dysregulated 
α3β1 function (Fig. 1). This could result in: altered angiogenesis, increased keratinocyte 
activation and the development of hypertrophic scars (40), or aberrant tissue remodeling 
due to ECM production and increased MMP9 secretion (36,41). Future in vitro and in vivo 
experiments are needed to test if Scl1 mediates such effects.  
In addition to keratinocytes, the β1 integrin receptors on neutrophils play important 
roles in inflammation and wound healing. Neutrophils are one of the first immune cells to 
enter into infected tissues. Neutrophils have multiple effector functions, such as the 
production of reactive-oxygen species, proteases, antimicrobial peptides and cytokines, 
as well as killing the pathogens by phagocytosis and via neutrophil extracellular traps 
(42). During infection, GAS causes the release of chemoattractants from the site of 
infection, into the blood stream that lead to the extravasation of neutrophils from the blood 
stream into the interstitial tissue, where they migrate through the ECM to the site of the 
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infection (43). The α9β1 expression is upregulated on activated neutrophils, and plays an 
essential role during neutrophil extravasation and in interstitial tissue migration (44,45). 
The α9β1 integrin acts in concert with β2 integrins during the trans-endothelial movement 
of neutrophils from the bloodstream into the interstitial space (46). In vitro studies 
demonstrated that the α9β1 integrin receptor significantly contributes to the passage of 
neutrophils through human-dermal fibroblast-derived matrices, implicating α9β1 in the 
movement of neutrophils through dermal tissue (44). EDA/cFn is highly upregulated in 
damaged tissues (33), as well as increased in the blood in a post-surgical bacteria model 
in sheep (47); in vitro studies have demonstrated co-localization of fibronectin and α9β1 in 
areas of tissue damage in human patients (48). It is possible that the α9β1 integrin receptor 
adheres to EDA/cFn during migration through infected tissue, and Scl1 may disrupt this 
interaction to block neutrophil migration into damaged tissues (Fig. 1).Experiments 
examining neutrophil migration in the presence of Scl1, on ECM coated surfaces could 
address this potential impact of Scl1 on neutrophils.  
 
Perturbation of EDB/cFn and TnC function by Scl1 binding 
The role of EDB in the wound microenvironment is not well understood, as no integrin-
binding sites have been identified directly within EDB. EDB/cFn isoforms are associated 
with angiogenesis during fetal development and within healing tissues (49,50). Inclusion 
of EDB into cFn has been shown in vitro to contribute to head-to-tail dimerization of Fn, 
leading to fibril formation (51). It is possible that Scl1 binding to EDB may block important 
sites necessary for head-to-tail dimerization and prevent or delay fibril formation on the 
surface of cells. Moreover, EDB inclusion into cFn is known to expose cryptic sites that 
are necessary for EDB/cFn attachment to cells (52). Scl1 binding to EDB may alter the 
structural conformation of cFn, preventing full-exposure of those cryptic sites in EDB/cFn 
isoforms. Other bacterial adhesins that bind to the FnIII repeats of Fn have been shown 
to have a such effect on Fn structure (53,54). These potential impacts of Scl1 binding to 
EDB/cFn isoforms require further investigations.  
Similar to affecting EDA/EDB containing cFn isoforms, TnC plays important 
functions in wound healing (outlined in the General Introduction). Scl1 binds within the 
FnIII repeats of TnC. The TnFnIII repeats of TnC have been implicated in facilitating 
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fibroblast proliferation, fibronectin fibril formation, proteoglycan binding and assembly, 
and regulating myofibroblast contracture of wounded tissues (55-58). It is possible that 
Scl1 binding to TnFnIII repeats leads to alterations in fibroblast function, proper matrix 
assembly, fibrotic tissue development, and wound closure. It is important to note that the 
exact motif within the TnFnIII repeat(s) that confers these effects on host cells is not 
known. Specifically, the TnFn3 repeat is suggested to be bound by α9β1 receptor on 
neutrophils during neutrophil migration to damaged tissue (43). Though our data does not 
support rScl1 binding to rTnFn3, it is possible that this lack of rScl1 binding to the 
individual rTnFn3 construct is due to structural differences between the individual repeat 
and when it is embedded within neighboring TnFnIII repeats (e.g. FnIII repeats 1-5 of 
TnC, see Chapter 2). Since the exact binding site(s) within the TnFnIII repeats for Scl1 
have not been identified, these concepts require experimental testing. 
 
Scl1-EDA binding inhibits TLR4 
TLR4 is a member of the pattern recognition receptors that recognize host- and pathogen-
associated molecules linked with damaged and infected tissue, and induce the release of 
pro-inflammatory cytokines (59,60). TLR4 is expressed by immune cells such as 
monocytes, dendritic cells, as well as endothelial cells and fibroblasts within tissues (60). 
On the surface of cells, TLR4 is expressed in complex with two other surface proteins, 
CD14 and MD2, which facilitate proper receptor activation and ligand specificity, 
respectively (61,62). The major agonist for TLR4 is bacterial LPS; however, several host-
derived molecules have also been shown to activate TLR4, including EDA/cFn fragments 
(63-65).  
During wound healing, one of the critical steps is tissue remodeling, fostered by 
matrix metalloproteinases that are secreted by both resident tissue cells and infiltrating 
immune cells (66,67). EDA/cFn fragments, generated by this proteolysis, have been 
shown to activate TLR4 on dermal fibroblasts, as well as monocytes and dendritic cells 
(65,67,68). This interaction induces the NF-κB signaling cascade, promoting pro-
inflammatory responses, such as production of cytokines IL-8 and TNFα (65). In addition 
to cytokines, EDA activation of TLR4 on neutrophils and monocytes was shown to 
facilitate release of leukotriene B4, a chemoattractant for leukocytes, resulting in 
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increased leukocyte migration, both in vitro and in vivo (69). EDA-mediated activation of 
TLR4 is dependent on the TLR4-co-receptor, MD-2, and evidence suggests that 
activation of TLR4 is enhanced by synergy from neighboring Fn domains (65,67,70).  
It is currently not known, whether Scl1 binding to EDA/cFn fragments affects TLR4 
function. In such a scenario, Scl1 may inhibit TLR4 activation, leading to a subsequent 
reduction in pro-inflammatory cytokines and a reduction of neutrophil infiltration to the site 
of infection (Fig. 1). This could serve as a novel Scl1-based mechanism for GAS immune 
evasion. To advance this project, I cloned an rFnIII11-EDA fragment, that was previously 
shown to stimulate TLR4 in vitro (67), into pET21a expression vector in the ClearColi E. 
coli strain, which produces a modified LPS that does not stimulate TLR4 (71). Having an 
LPS-free system, will facilitate our laboratory to study whether Scl1 blocks EDA/cFn 
mediated TLR4 activation, using an in vitro HEK-blue cell system (67). In vivo animal 
experiments, using WT and Scl1 mutant GAS strains could also be performed, looking 
for differences in tissue NF-κB activation and differences in cytokines and leukocyte 
recruitment in tissues.  
Therefore, the Scl1 interaction between EDA and EDB/cFn isoforms, as well as 
TnC, raises an exciting prospect that not only does Scl1 facilitate GAS wound 
colonization, but colonization of GAS via Scl1 may alter wound healing responses via 
competition between Scl1 and host cell receptors. 
 
Utilization of wound-associated ECM proteins to target GAS via Scl1 
Currently, GAS infections are treated either with penicillin or erythromycin in patients with 
a penicillin allergy (72). Alarmingly, several studies documented penicillin treatment 
failure, with up to 30% of pharyngitis patients showing persistence of GAS following 
treatment (73-76). These observations underscore the need for new alternative strategies 
to treat GAS infection. Considerable efforts have been undertaken by research 
laboratories in search of vaccine targets to prevent GAS infections and the development 
of a universal GAS vaccine. The immunogenic surface M protein serves as the basis for 
most GAS vaccine candidates, as it confers M type-specific immunity (77). Historically, 
cross-reactive antibody concerns between M protein and cardiac tissue impeded 
development of GAS vaccines for years; however, current methods utilize peptides 
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corresponding to the N-terminal hypervariable region, thereby avoiding cross-reactive 
portions (78,79). A 26-valent vaccine, which is composed of N-terminal hypervariable 
region peptides derived from 26 different M-protein types, has completed stage I/II clinical 
trials in the United States (80). Still, other challenges exist, such as the high number of M 
protein types, the lack of vaccine protection from throat infections, and differences in M-
type distribution across the globe (81,82). Antibodies against the Scl1 antigen were 
produced by humans and in experimental animals (83). In general, anti-Scl1 antibodies 
could be opsonic or may well block the interactions between Scl1 and EDA/cFn, thus, 
preventing GAS colonization. Although infection with GAS can lead to the production of 
anti-Scl1 antibodies, others have found that recombinant Scl-based collagen proteins are 
non-immunogenic (84). Variability of the amino acid sequence of the Scl1 V-domain 
would face challenges similar to those concerning the M protein-based vaccine. 
Therefore, alternative targeting strategies utilizing Scl1 recognition by EDA, EDB, or 
TnFnIII fragments could overcome the aforementioned hurdles.  
 
EDA-derived peptides for GAS targeting 
Of the known Scl1 ligands, the C-C’ loop of EDA is the best studied peptide sequence 
and can potentially serve as a targeting strategy for Scl1. Inasmuch as utilizing peptides 
derived from the C-C’ loop of EDA is a rational premise for treating GAS infections, there 
are significant challenges that need to be overcome. First, the binding affinities between 
C-C’-loop circular peptide and two different recombinant Scl1 variants, originating from 
M1- and M3-type GAS, were in a range of 40–60 µM KD, as estimated through surface 
plasmon resonance and tryptophan fluorescence binding assays ((24,85) appendix 2 and 
3). This binding is relatively weak, especially when compared with the binding affinity of 
an antibody, typically in the nM range, and mutagenesis approach may improve the 
binding affinity. Second, off-target binding effects of the C-C’ loop peptide directly to host 
cell integrin receptor α9β1 could lead to dysregulation of the dynamic wound-healing 
processes, such as dysregulation in tissue angiogenesis (Fig. 1). Alternatively, peptides 
derived from EDB could be used in targeting Scl1 on GAS. Third, although all strains carry 
the scl1 gene, a small subset of strains do not express Scl1, such as M3-type GAS (24). 
In these strains, however, Scl2 protein would serve as an alternative target. Fourth, the 
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C-C’ loop-peptide could increase bacterial spread via microcolony dispersion. 
Nevertheless, sessile GAS cells will be susceptible to drugs or C-C’ loop-derived peptide 
conjugated to an antimicrobial peptide, like LL-37 (86,87). A similar strategy, utilizing 
peptides derived from EDB and/or TnFnIII repeats to target Scl1 would be feasible.  
 
Anti-Scl1 FnIII-based monobodies for GAS targeting 
Alternatively to the utilization of EDA-derived peptides, the whole EDA or a modified FnIII 
repeat, known as a monobody (88), could be used in targeting Scl1. Monobodies are 
protein constructs that utilize FnIII scaffolds to achieve specific protein binding, as they 
share structural homology to the antigen recognition region of antibodies (Fig. 2), and 
serve as an alternative to antibodies (89,90). While commonly used in medicine, 
monoclonal antibodies are large in size (~150 kDa) limiting their tissue distribution; 
Moreover, monoclonal antibodies are complex to produce (91). Monobodies, however, 
are much smaller (~10-20 kDa) enabling effective tissue distribution, are less complex to 
produce, and can exhibit nM and pM affinities to their designed targets, similar to 
monoclonal antibodies (91-93). The surface exposed loops within the monobody (Fig. 2) 
serve as the ligand-recognition site and can be engineered to bind a multitude of epitopes 
(90). Monobodies serve as diagnostic and therapeutic tools, often via the conjugation of 
markers or drugs (94). Originally, monobodies were developed using the FnIII repeat 
number 10 from fibronectin (95), however, monobodies derived from other fibronectin 
FnIII repeats of both Fn and TnC are currently undergoing clinical trials (94). The EDB of 
cFn could serve as a monobody to target GAS via Scl1, as it offers the benefit of reduced 
off-target binding, compared to EDA, which has the potential to bind to cells expressing 
integrin receptors α4β1, α4β7, α9β1, as well as stimulate TLR4. Conversely, EDA may serve 
as the preferential monobody, as the Scl1-binding site and potential binding affinities have 
been delineated (7,24). The EDA or EDB-derived monobody can be conjugated directly 
to antimicrobial peptides or anti-microbials to treat GAS infection, localizing antibiotics to 






Implications of Scl1 in cancer targeting 
Isoforms of cFn that contain EDA and/or EDB, as well as TnC, are expressed in different 
types of cancer, such as prostate cancer, colorectal cancer, head and neck squamous 
cell carcinoma, cervical cancer, and lung cancer (96-101). Expression and deposition of 
EDA/EDB cFn isoforms, and TnC, is predominantly done by the surrounding stromal cells, 
 
Figure 2: Monobodies to target GAS via Scl1-. A) Cartoon representation of the fibronectin 
type III (FnIII) repeat, extra domain B (EDB), from cellular fibronectin (PDB accession code: 
2GEE); showing the fibronectin-type III repeat β-sandwich structure, with each β-strands 
marked (A, B, C, C’, D, E, F). Loops of EDB that share similar orientation to the antigen-
binding domain of single-chain antibodies are highlighted in blue B) Cartoon representation 
of the antigen-binding domain of a camelid heavy-chain antibody (VHH; PDB accession code: 
1ZVY); showing that both EDB and the antigen-binding domain of antibodies consist of a 
FnIII repeat structure. The antigen-recognition sites are highlighted in blue. C) Schematic, 
depicting the rationale behind monobody targeting of group A Streptococcus (GAS) via the 
streptococcal collagen-like 1 (Scl1) surface adhesin. Due to shared structures, FnIII repeats 
can be engineered to as antibody mimics. Scl1 binds to isoforms of cellular fibronectin that 
contain EDA, EDB, as well as tenascin-C (TnC), which are associated-with the wound 
microenvironment. During host wound colonization, EDB-derived monobodies that are 
conjugated to anti-microbial peptides (e.g. LL-37,in red) can be administered to wound to 




primarily by cancer-associated fibroblasts (CAFs)/myofibroblasts, but also by endothelial 
cells during neovascularization of growing tumors (102,103). Some cancer cells will 
directly produce EDA/EDB cFn, but TnC has been shown to be directly deposited on the 
invasive edge of malignant cancer cells and is found to be deposited in newly localized 
metastatic cancers (104,105). Current research supports a model where cancer 
progression is driven by the surrounding cancer microenvironment, rather than intrinsic 
cancer cell factors (106), as expression of these ECM proteins by CAFs is linked to 
several important pathological mechanisms of cancer, such as the epithelial to 
mesenchymal transition, cell proliferation, and metastasis (107,108). Epidemiological 
studies have found that patients with elevated deposition of EDA/EDB cFn isoforms or 
TnC within their tumors have lower survival rates compared to patients with lower levels 
of EDA and EDB cFn isoforms and TnC (109,110). Thus, these ECM substrates are 
unique targets for the delivery of diagnostics and therapeutics to the tumor sites. Several 
research groups and companies across the world have developed monoclonal antibody-
drug conjugates, peptides and aptamers to target EDA/EDB cFn isoforms and to TnC for 
such purposes (111,112). We have shown that Scl1 specifically targets EDA/EDB, and 
the FnIII repeats of TnC within the matrices deposited by CAFs (Fig. 3). Thus, Scl1 offers 
similar potential as a biomolecule for the selective recognition and targeting of GAS or 
Scl1-functionalized nanomaterials to cancerous tissue.  
 
GAS infection in cancer immunotherapy  
GAS has a historical connection with cancers, particularly sarcomas, as it was noted since 
the early 1800s that patients who develop erysipelas, commonly caused by GAS, 
demonstrated shrinkage of their tumors (113). Currently, there is interest in using 
microbes in the treatment of cancer. Microbes offer advantages to traditional 
chemotherapies, as they can be engineered to favorably colonize the tumor 
microenvironment and lead to the death of cancer cells either directly through toxin 
production or indirectly via immune stimulation (113). While there is renewed interest in 
the utilization of GAS as a cancer-therapy, showing promise in the treatment of pancreatic 
cancer in a murine model (114,115), there are still fears of the development of 
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autoimmune sequalae, such as rheumatic fever, in patients treated with GAS. Other 
candidate bacteria do not share this concern, such as a Salmonella typhimurium and 
Clostridium novyi, and treatments are under development or in clinical trials to evaluate 
 
Figure 3.  Specificity of Scl1-mediated GAS attachment to cancer-associated fibroblast 
matrices. Wild type (WT) M41 was pre-incubated with recombinant ECM ligands prior to attachment 
to CAF-derived ECM. GFP-WT M41 GAS were pre-incubated with recombinantly expressed extra 
domain A, extra domain B, and fibronectin type III repeats of tenascin-C, for 30 minutes prior to 
inoculation onto CAF-derived ECM coatings. GAS were allowed to attach for 1 hour and then 
subsequently imaged using fluorescent confocal microscope with 100x objective. Images were taken 
in 10 random fields over three experiments. Top, representative images Bottom, quantification of GAS 
attachment with WT binding set as 100%; bacteria were counted in 30 fields, and the average from all 
30-fields was calculated. Percentage based on the average number of counted bacteria for the parental 
WT strain. Statistical significance was calculated using a one-way ANOVA from three independent 
experiments, each performed in duplicate wells (N=3±SD); **P≤0.01, ***P≤0.001. Statistical analysis 
evaluates the difference in adherence between WT GAS and WT GAS pre-incubated with ECM. Each 




their efficacy (116,117). Yet, significant challenges remain in the utilization of these 
candidate bacteria in the treatment of cancer, such as the improved bacterial colonization 
and retention within the cancer tissues and the development of multi-tissue specific 
bacteria that can target metastatic cancers (113).  
 
rScl1-functionalized nanoparticles for cancer diagnostics and treatment 
Another approach is the use of rScl1 proteins as targeting biomolecules on the surface of 
nanoparticles for targeted drug delivery to cancer tissues. Nanomaterials offer unique 
advantages, due to their size, durability, surface area, and composition, relative to 
 
Figure 4: Hybrid rScl protein in nanoparticle delivery to tumors. 
Schematic of the design and intended use of recombinant hybrid streptococcal 
collagen-like protein 1 (rScl.hyb1) in the delivery of nanoparticles to tumors 
via recognition of tumor-associated extracellular matrix proteins, isoforms of 
cellular fibronectin (cFn) that contain extra domains A (EDA) and/or B (EDB), 
and tenascin-C (TnC), as well as integrin receptors α2β1 and α11β1 expressed 




bacteria. Moreover, nanoparticles do not pose the same off-target infection risks as 
bacterial-based cancer immunotherapies. Nanoparticles can be loaded with drugs (e.g. 
doxorubicin) or biologicals (e.g. siRNA) for delivery to cancer cells (118,119). However, 
one of the major challenges to nanoparticle cancer therapy is the lack of localization and 
retention of particles within the cancer microenvironment. This is due in part to the lack 
of targets unique to the cancer microenvironment, not present healthy tissue (106). 
Targeting EDA/EDB cFn isoforms and TnC, using rScl-based proteins may solve this 
problem. Other groups have developed aptamers and antibodies that target these ECM 
proteins with the same goal in mind, some of which have been conjugated to 
nanomaterials (111,119,120). Scl-derived proteins may have superior features, like 1) 
Scl1 proteins bind multiple cancer-associated ligands, thereby reducing the number of 
different biomolecules needed to be conjugated to a nanomaterial, and 2) the potential to 
target integrin receptors on tumor cells through incorporation of the α2β1 and α11β1 
recognition motif (e.g. GLPGER) into the CL-domain of Scl proteins (121). As a part of 
my IGERT research, I helped engineer a hybrid rScl protein (rScl.hybrid1; Fig. 4) that 
possess both the EDA/EDB and TnC binding site in the V-domain, as well as integrin 
recognition sequences within the CL-domain. This hybrid protein rScl.hybrid1 offers the 
potential to target TnC, as well as EDA/cFn and EDB/cFn isoforms, highly expressed 
within and around tumor/cancerous tissues, as well as promote internalization via integrin 
receptors α2β1 and α11β1 (Fig. 4)(122,123).  
 
Overall Conclusions 
My work identified important structural determinants that facilitate Scl1 ligand-binding, 
highlighting a binding mechanism that is unique relative to the other Fn-binding proteins 
of GAS. In addition, I discovered that Scl1 binds to the FnIII repeats, EDB of cFn, as well 
as to the FnIII repeats within TnC, increasing the number of known targets for Scl1 that 
are associated with the wound microenvironment. My work adds new evidence in support 
that Scl1 is a wound-adapted adhesin for GAS.  
As GAS is a human-obligate pathogen, it has co-evolved with us over time, evident 
through the plethora of virulence factors that GAS employs during pathogenesis to 
facilitate host colonization (124). Scl1 is a major GAS adhesin, and is under the regulation 
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of one of the major transcriptional regulators, Mga, which controls the expression of 
several other key GAS virulence factors (23,125-129). Scl1 is expressed by almost every 
M type studied (23), and as a surface protein, Scl1 is under selective pressure which 
results in sequence variation within the Scl1-V domain across different M-types of GAS 
(23). Yet, despite this sequence variation, Scl1 proteins from across different M-types 
maintain the capacity to bind to EDA, EDB, and TnC, underscoring both the evolution of 
this adhesin for host adaptation and the importance of these ligands for GAS. The first 
environment GAS will typically encounter within our bodies is wounded tissue. This 
selective binding of Scl1 to FnIII repeats that are highly associated with wounded tissue, 
in addition to the conservation of this interactions across phylogenetically-diverse M 
types, serves as strong evidence that Scl1 has adapted to the wound microenvironment, 
contributing to GAS wound colonization.  
 The work presented here lays the foundation for several future directions to take 
research pertaining to Scl1, having implications in the development of strategies to target 
GAS using FnIII monobody, or the use of Scl1 proteins in targeting cancers for drug 
delivery. Ultimately, the strongest implications of this research are in the roles the Scl1-
EDA/EDB/TnC interactions play in GAS pathogenesis, altering host wound healing and 




1. Yamaguchi, M., Terao, Y., and Kawabata, S. (2013) Pleiotropic virulence factor - Streptococcus 
pyogenes fibronectin-binding proteins. Cell. Microbiol. 15, 503-511 
2. Schwarz-Linek, U., Werner, J. M., Pickford, A. R., Gurusiddappa, S., Kim, J. H., Pilka, E. S., 
Briggs, J. A., Gough, T. S., Hӧӧk, M., Campbell, I. D., and Potts, J. R. (2003) Pathogenic bacteria 
attach to human fibronectin through a tandem beta-zipper. Nature 423, 177-181 
3. McNitt, D. H., Choi, S. J., Keene, D. R., Van De Water, L., Squeglia, F., Berisio, R., and 
Lukomski, S. (2018) Surface-exposed loops and an acidic patch in the Scl1 protein of group A 
Streptococcus enable Scl1 binding to wound-associated fibronectin. J. Biol. Chem. 293, 7796-
7810 
4. Back, C. R., Sztukowska, M. N., Till, M., Lamont, R. J., Jenkinson, H. F., Nobbs, A. H., and Race, 
P. R. (2017) The Streptococcus gordonii adhesin CshA protein binds host fibronectin via a catch-
clamp mechanism. J Biol Chem 292, 1538-1549 
115 
 
5. Rego, S., Heal, T. J., Pidwill, G. R., Till, M., Robson, A., Lamont, R. J., Sessions, R. B., 
Jenkinson, H. F., Race, P. R., and Nobbs, A. H. (2016) Structural and functional analysis of cell 
wall-anchored polypeptide adhesin BspA in Streptococcus agalactiae. J. Biol. Chem. 291, 15985-
16000 
6. Caswell, C. C., Oliver-Kozup, H., Han, R., Lukomska, E., and Lukomski, S. (2010) Scl1, the 
multifunctional adhesin of group A Streptococcus, selectively binds cellular fibronectin and 
laminin, and mediates pathogen internalization by human cells. FEMS Microbiol. Lett. 303, 61-68 
7. Oliver-Kozup, H., Martin, K. H., Schwegler-Berry, D., Green, B. J., Betts, C., Shinde, A. V., Van 
De Water, L., and Lukomski, S. (2013) The group A streptococcal collagen-like protein-1, Scl1, 
mediates biofilm formation by targeting the extra domain A-containing variant of cellular 
fibronectin expressed in wounded tissue. Mol. Microbiol. 87, 672-689 
8. Hemperly, J. J., Murray, B. A., Edelman, G. M., and Cunningham, B. A. (1986) Sequence of a 
cDNA clone encoding the polysialic acid-rich and cytoplasmic domains of the neural cell adhesion 
molecule N-CAM. Proc. Natl. Acad. Sci. U. S. A. 83, 3037-3041 
9. Frick, I. M., Crossin, K. L., Edelman, G. M., and Björck, L. (1995) Protein H-a bacterial surface 
protein with affinity for both immunoglobulin and fibronectin type III domains. EMBO J. 14, 1674-
1679 
10. Jaffe, J., Natanson-Yaron, S., Caparon, M. G., and Hanski, E. (1996) Protein F2, a novel 
fibronectin-binding protein from Streptococcus pyogenes, possesses two domains. Mol. Microbiol. 
21, 373-384 
11. Kreikemeyer, B., Oehmcke, S., Nakata, M., Hoffrogge, R., and Podbielski, A. (2004) 
Streptococcus pyogenes Fibronectin-binding Protein F2: Expression profile, binding 
characteristics, and impact on eukaryotic cell interactions. J. Biol. Chem. 279, 15850-15859 
12. Henderson, B., Nair, S., Pallas, J., and Williams, M. A. (2011) Fibronectin: a multidomain host 
adhesin targeted by bacterial fibronectin-binding proteins. FEMS Microbiol. Rev. 35, 147-200 
13. Cameron, C. E., Brown, E. L., Kuroiwa, J. M. Y., Schnapp, L. M., and Brouwer, N. L. (2004) 
Treponema pallidum fibronectin-binding proteins. J. Bacteriol. 186, 7019-7022 
14. Schulze-Koops, H., Burkhardt, H., Heesemann, J., Kirsch, T., Swoboda, B., Bull, C., Goodman, 
S., and Emmrich, F. (1993) Outer membrane protein YadA of enteropathogenic yersiniae 
mediates specific binding to cellular but not plasma fibronectin. Infect. Immun. 61, 2513-2519 
15. Heise, T., and Dersch, P. (2006) Identification of a domain in Yersinia virulence factor YadA that 
is crucial for extracellular matrix-specific cell adhesion and uptake. Proc. Natl. Acad. Sci. U. S. A. 
103, 3375-3380 
16. Sakai, T., Johnson, K. J., Murozono, M., Sakai, K., Magnuson, M. A., Wieloch, T., Cronberg, T., 
Isshiki, A., Erickson, H. P., and Fassler, R. (2001) Plasma fibronectin supports neuronal survival 
and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-
wound healing and hemostasis. Nat. Med. 7, 324-330 
116 
 
17. Schenk, S., Liénard, D., Gérain, J., Baumgartner, M., Lejeune, F. J., Chiquet-Ehrismann, R., and 
Rüegg, C. (1995) Rapid increase in plasma tenascin-C concentration after isolated limb perfusion 
with high-dose tumor necrosis factor (TNF), interferon gamma (IFNγ) and melphalan for 
regionally advanced tumors. Int. J. Cancer 63, 665-672 
18. Midwood, K. S., Hussenet, T., Langlois, B., and Orend, G. (2011) Advances in tenascin-C 
biology. Cell. Mol. Life Sci. 68, 3175 
19. Barnes, J. L., Torres, E. S., Mitchell, R. J., and Peters, J. H. (1995) Expression of alternatively 
spliced fibronectin variants during remodeling in proliferative glomerulonephritis. Am. J. Pathol. 
147, 1361-1371 
20. Gratchev, A., Guillot, P., Hakiy, N., Politz, O., Orfanos, C. E., Schledzewski, K., and Goerdt, S. 
(2001) Alternatively activated macrophages differentially express fibronectin and its splice 
variants and the extracellular matrix protein βIG-H3. Scand. J. Immunol. 53, 386-392 
21. Musser, J. M., Hauser, A. R., Kim, M. H., Schlievert, P. M., Nelson, K., and Selander, R. K. 
(1991) Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: 
clonal diversity and pyrogenic exotoxin expression. Proc. Natl. Acad. Sci. U. S. A. 88, 2668-2672 
22. Lamagni, T., Darenberg, J., Luca-Harari, B., Siljander, T., Efstratiou, A., Henriques-Normark, B., 
Vuopio-Varkila, J., Bouvet, A., Creti, R., Ekelund, K., Koliou, M., Reinert, R., Stathi, A., Strakova, 
L., Ungureanu, V., Schalen, C., , and Jasir, A. (2008) The epidemiology of severe Streptococcus 
pyogenes disease in Europe. J. Clin. Microbiol.  
23. Lukomski, S., Nakashima, K., Abdi, I., Cipriano, V. J., Ireland, R. M., Reid, S. D., Adams, G. G., 
and Musser, J. M. (2000) Identification and characterization of the scl gene encoding a group A 
Streptococcus extracellular protein virulence factor with similarity to human collagen. Infect. 
Immun. 68, 6542-6553 
24. Bachert, B. A., Choi, S. J., LaSala, P. R., Harper, T. I., McNitt, D. H., Boehm, D. T., Caswell, C. 
C., Ciborowski, P., Keene, D. R., Flores, A. R., Musser, J. M., Squeglia, F., Marasco, D., Berisio, 
R., and Lukomski, S. (2016) Unique footprint in the scl1.3 locus affects adhesion and biofilm 
formation of the invasive M3-type group A Streptococcus. Front Cell Infect Microbiol 6, 90 
25. Flores, A. R., Jewell, B. E., Versalovic, E. M., Olsen, R. J., Bachert, B. A., Lukomski, S., and 
Musser, J. M. (2015) Natural variant of collagen-like protein A in serotype M3 Group A 
Streptococcus increases adherence and decreases invasive potential. Infect. Immun. 83, 1122-
1129 
26. Akiyama, H., Morizane, S., Yamasaki, O., Oono, T., and Iwatsuki, K. (2003) Assessment of 
Streptococcus pyogenes microcolony formation in infected skin by confocal laser scanning 
microscopy. J. Dermatol. Sci. 32, 193-199 
27. Siemens, N., Chakrakodi, B., Shambat, S. M., Morgan, M., Bergsten, H., Hyldegaard, O., Skrede, 
S., Arnell, P., Madsen, M. B., Johansson, L., Juarez, J., Bosnjak, L., Mörgelin, M., Svensson, M., 
117 
 
and Norrby-Teglund, A. (2016) Biofilm in group A streptococcal necrotizing soft tissue infections. 
JCI Insight 1 
28. Sumby, P., Barbian, K., Gardner, D., Whitney, A., Welty, D., Long, R., Bailey, J., Parnell, M., Hoe, 
N., Adams, G., Deleo, F., and Musser, J. (2005) Extracellular deoxyribonuclease made by group 
A Streptococcus assists pathogenesis by enhancing evasion of the innate immune response., - 
29. Ogawa, T., Terao, Y., Okuni, H., Ninomiya, K., Sakata, H., Ikebe, K., Maeda, Y., and Kawabata, 
S. (2011) Biofilm formation or internalization into epithelial cells enable Streptococcus pyogenes 
to evade antibiotic eradication in patients with pharyngitis. Microb. Pathog. 51, 58-68 
30. Tan, M. H., Sun, Z., Opitz, S. L., Schmidt, T. E., Peters, J. H., and George, E. L. (2004) Deletion 
of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood 104, 
11-18 
31. Fukuda, T., Yoshida, N., Kataoka, Y., Manabe, R.-i., Mizuno-Horikawa, Y., Sato, M., Kuriyama, 
K., Yasui, N., and Sekiguchi, K. (2002) Mice lacking the EDB segment of fibronectin develop 
normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. Cancer Res. 62, 
5603-5610 
32. Saga, Y., Yagi, T., Ikawa, Y., Sakakura, T., and Aizawa, S. (1992) Mice develop normally without 
tenascin. Genes Dev. 6, 1821-1831 
33. Ffrench-Constant, C., Van De Water, L., Dvorak, H. F., and Hynes, R. O. (1989) Reappearance 
of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J. Cell Biol. 
109, 903-914 
34. Singh, P., Reimer, C. L., Peters, J. H., Stepp, M. A., Hynes, R. O., and Van De Water, L. (2004) 
The spatial and temporal expression patterns of integrin α9β1 and one of its ligands, the EIIIA 
segment of fibronectin, in cutaneous wound healing. J. Invest. Dermatol. 123, 1176-1181 
35. Muro, A. F., Chauhan, A. K., Gajovic, S., Iaconcig, A., Porro, F., Stanta, G., and Baralle, F. E. 
(2003) Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing 
and normal lifespan. J. Cell Biol. 162, 149-160 
36. Longmate, W. M., Lyons, S. P., Chittur, S. V., Pumiglia, K. M., Van De Water, L., and DiPersio, C. 
M. (2017) Suppression of integrin α3β1 by α9β1 in the epidermis controls the paracrine resolution 
of wound angiogenesis. J. Cell Biol. 216, 1473-1488 
37. Liao, Y. F., Gotwals, P. J., Koteliansky, V. E., Sheppard, D., and Van De Water, L. (2002) The 
EIIIA segment of fibronectin is a ligand for integrins α9β1 and α4β1 providing a novel mechanism 
for regulating cell adhesion by alternative splicing. J Biol Chem 277, 14467-14474 
38. Mitchell, K., Szekeres, C., Milano, V., Svenson, K. B., Nilsen-Hamilton, M., Kreidberg, J. A., and 
DiPersio, C. M. (2009) α3β1 integrin in epidermis promotes wound angiogenesis and 




39. Longmate, W. M., Monichan, R., Chu, M.-L., Tsuda, T., Mahoney, M. G., and DiPersio, C. M. 
(2014) Reduced fibulin-2 contributes to loss of basement membrane integrity and skin blistering 
in mice lacking integrin α3β1 in the epidermis. J. Invest. Dermatol. 134, 1609-1617 
40. Machesney, M., Tidman, N., Waseem, A., Kirby, L., and Leigh, I. (1998) Activated keratinocytes 
in the epidermis of hypertrophic scars. Am. J. Pathol. 152, 1133-1141 
41. Longmate, W. M., Lyons, S. P., DeFreest, L., Van De Water, L., and DiPersio, C. M. (2018) 
Opposing Roles of Epidermal Integrins α3β1 and α9β1 in Regulation of mTLD/BMP-1–Mediated 
Laminin-γ2 Processing during Wound Healing. J. Invest. Dermatol. 138, 444-451 
42. Mayadas, T. N., Cullere, X., and Lowell, C. A. (2014) The multifaceted functions of neutrophils. 
Annu. Rev. Pathol. 9, 181-218 
43. Lindbom, L., and Werr, J. (2002) Integrin-dependent neutrophil migration in extravascular tissue. 
Semin. Immunol. 14, 115-121 
44. Shang, T., Yednock, T., and Issekutz, A. C. (1999) α9β1 Integrin is expressed on human 
neutrophils and contributes to neutrophil migration through human lung and synovial fibroblast 
barriers. J. Leukoc. Biol. 66, 809-816 
45. Taooka, Y., Chen, J., Yednock, T., and Sheppard, D. (1999) The integrin alpha9beta1 mediates 
adhesion to activated endothelial cells and transendothelial neutrophil migration through 
interaction with vascular cell adhesion molecule-1. J. Cell Biol. 145, 413-420 
46. Mambole, A., Bigot, S., Baruch, D., Lesavre, P., and Halbwachs-Mecarelli, L. (2010) Human 
neutrophil integrin α9β1: up-regulation by cell activation and synergy with β2 integrins during 
adhesion to endothelium under flow. J. Leukoc. Biol. 88, 321-327 
47. Rizk, T. A., Rebres, R. A., Vincent, P. A., Charash, W. E., McKeown-Longo, P. J., Lewis, E. P., 
Brien, T. P., Minnear, F. L., Fortune, J. B., and Saba, T. M. (1994) Delayed elevation of ED1-
cellular fibronectin in plasma following postsurgical bacteremia. Am J Physiol 266, L689-L697 
48. Weinacker, A., Ferrando, R., Elliott, M., Hogg, J., Balmes, J., and Sheppard, D. (1995) 
Distribution of integrins αvβ6 and α9β1 and their known ligands, fibronectin and tenascin, in 
human airways. Am. J. Respir. Cell Mol. Biol. 12, 547-556 
49. Castellani, P., Viale, G., Dorcaratto, A., Nicolo, G., Kaczmarek, J., Querze, G., and Zardi, L. 
(1994) The fibronectin isoform containing the ED-B oncofetal domain: A marker of angiogenesis. 
Int. J. Cancer 59, 612-618 
50. Birchler, M., Neri, G., Tarli, L., Halin, C., Viti, F., and Neri, D. (1999) Infrared photodetection for 
the in vivo localisation of phage-derived antibodies directed against angiogenic markers. J. 
Immunol. Methods 231, 239-248 
51. Schiefner, A., Gebauer, M., and Skerra, A. (2012) Extra-domain B in oncofetal fibronectin 
structurally promotes fibrillar head-to-tail dimerization of extracellular matrix protein. J. Biol. 
Chem. 287, 17578-17588 
119 
 
52. Chen, S., Chakrabarti, R., Keats, E. C., Chen, M., Chakrabarti, S., and Khan, Z. A. (2012) 
Regulation of Vascular Endothelial Growth Factor Expression by Extra Domain B Segment of 
Fibronectin in Endothelial CellsVEGF Expression by Fibronectin. Invest. Ophthalmol. Vis. Sci. 53, 
8333-8343 
53. Liang, X., Garcia, B. L., Visai, L., Prabhakaran, S., Meenan, N. A. G., Potts, J. R., Humphries, M. 
J., and Höök, M. (2016) Allosteric Regulation of Fibronectin/α5β1 Interaction by Fibronectin-
Binding MSCRAMMs. PLoS One 11, e0159118 
54. Prabhakaran, S., Liang, X., Skare, J. T., Potts, J. R., and Höök, M. (2009) A Novel Fibronectin 
Binding Motif in MSCRAMMs Targets F3 Modules. PLoS One 4, e5412 
55. End, P., Panayotou, G., Entwistle, A., Waterfield, M. D., and Chiquet, M. (1992) Tenascin: a 
modulator of cell growth. Eur. J. Biochem. 209, 1041-1051 
56. Kusubata, M., Hirota, A., Ebihara, T., Kuwaba, K., Matsubara, Y., Sasaki, T., Kusakabe, M., 
Tsukada, T., Irie, S., and Koyama, Y. (1999) Spatiotemporal changes of fibronectin, tenascin-C, 
fibulin-1, and fibulin-2 in the skin during the development of chronic contact dermatitis. J. Invest. 
Dermatol. 113, 906-912 
57. Day, J. M., Olin, A. I., Murdoch, A. D., Canfield, A., Sasaki, T., Timpl, R., Hardingham, T. E., and 
Aspberg, A. (2004) Alternative splicing in the aggrecan G3 domain influences binding interactions 
with tenascin-C and other extracellular matrix proteins. J Biol Chem 279, 12511-12518 
58. Tamaoki, M., Imanaka-Yoshida, K., Yokoyama, K., Nishioka, T., Inada, H., Hiroe, M., Sakakura, 
T., and Yoshida, T. (2005) Tenascin-C regulates recruitment of myofibroblasts during tissue 
repair after myocardial injury. Am. J. Pathol. 167, 71-80 
59. Medzhitov, R. (2001) Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135-145 
60. Vaure, C., and Liu, Y. (2014) A Comparative Review of Toll-Like Receptor 4 Expression and 
Functionality in Different Animal Species. Front. Immunol. 5 
61. Zanoni, I., Ostuni, R., Marek, Lorri R., Barresi, S., Barbalat, R., Barton, Gregory M., Granucci, F., 
and Kagan, Jonathan C. (2011) CD14 Controls the LPS-Induced Endocytosis of Toll-like 
Receptor 4. Cell 147, 868-880 
62. Vašl, J., Oblak, A., Gioannini, T. L., Weiss, J. P., and Jerala, R. (2009) Novel Roles of Lysines 
122, 125, and 58 in Functional Differences between Human and Murine MD-2. The Journal of 
Immunology 183, 5138-5145 
63. Choi, S.-H., Harkewicz, R., Lee Jee, H., Boullier, A., Almazan, F., Li Andrew, C., Witztum Joseph, 
L., Bae Yun, S., and Miller Yury, I. (2009) Lipoprotein Accumulation in Macrophages via Toll-Like 
Receptor-4–Dependent Fluid Phase Uptake. Circ. Res. 104, 1355-1363 
64. Kim, F., Pham, M., Luttrell, I., Bannerman Douglas, D., Tupper, J., Thaler, J., Hawn Thomas, R., 
Raines Elaine, W., and Schwartz Michael, W. (2007) Toll-Like Receptor-4 Mediates Vascular 
Inflammation and Insulin Resistance in Diet-Induced Obesity. Circ. Res. 100, 1589-1596 
120 
 
65. Okamura, Y., Watari, M., Jerud, E. S., Young, D. W., Ishizaka, S. T., Rose, J., Chow, J. C., and 
Strauss, J. F., 3rd. (2001) The extra domain A of fibronectin activates Toll-like receptor 4. J Biol 
Chem 276, 10229-10233 
66. Xue, M., and Jackson, C. J. (2015) Extracellular matrix reorganization during wound healing and 
its impact on abnormal scarring. Adv. Wound Care 4, 119-136 
67. Julier, Z., Martino, M. M., de Titta, A., Jeanbart, L., and Hubbell, J. A. (2015) The TLR4 agonist 
fibronectin extra domain A is cryptic, exposed by elastase-2; use in a fibrin matrix cancer vaccine. 
Sci. Rep. 5, 8569 
68. Kohan, M., Muro, A. F., White, E. S., and Berkman, N. (2010) EDA-containing cellular fibronectin 
induces fibroblast differentiation through binding to α4β7 integrin receptor and MAPK/Erk 1/2-
dependent signaling. FASEB J. 24, 4503-4512 
69. Lefebvre, J. S., Lévesque, T., Picard, S., Paré, G., Gravel, A., Flamand, L., and Borgeat, P. 
(2011) Extra domain A of fibronectin primes leukotriene biosynthesis and stimulates neutrophil 
migration through activation of Toll-like receptor 4. Arthritis Rheum. 63, 1527-1533 
70. Kelsh, R., You, R., Horzempa, C., Zheng, M., and McKeown-Longo, P. J. (2014) Regulation of 
the innate immune response by fibronectin: synergism between the III-1 and EDA domains. PLoS 
One 9, e102974 
71. Mamat, U., Woodard, R. W., Wilke, K., Souvignier, C., Mead, D., Steinmetz, E., Terry, K., 
Kovacich, C., Zegers, A., and Knox, C. (2013) Endotoxin-free protein production—ClearColi™ 
technology. Nat. Methods 10, 916 
72. Hayes, C. S., and Williamson, H., Jr. (2001) Management of group A beta-hemolytic 
streptococcal pharyngitis. Am. Fam. Physician 63, 1557-1564 
73. Neeman, R., Keller, N., Barzilai, A., Korenman, Z., and Sela, S. (1998) Prevalence of 
internalisation-associated gene, prtF1, among persisting group-A Streptococcus strains isolated 
from asymptomatic carriers. Lancet 352, 1974-1977 
74. Stjernquist-Desatnik, A., Orrling, A., Schalén, C., and Kamme, C. (1992) Penicillin tolerance in 
group A streptococci and treatment failure in streptococcal tonsillitis. Acta Otolaryngol. 492, 68-71 
75. Pichichero, M. E., Casey, J. R., Mayes, T., Francis, A. B., Marsocci, S. M., Murphy, A. M., and 
Hoeger, W. (2000) Penicillin failure in streptococcal tonsillopharyngitis: causes and remedies. 
Pediatr. Infect. Dis. J. 19, 917-923 
76. Kaplan, E., Oakes, J., and Johnson, D. (2007) Unexpected Individual Clinical Site Variation in 
Eradication Rates of Group A Streptococci by Penicillin in Multisite Clinical Trials. Pediatr. Infect. 
Dis. J. 26, 1110-1116 
77. Lancefield, R. C. (1959) Persistence of type-specific antibodies in man following infection with 
group A streptococci. J. Exp. Med. 110, 271-292 
121 
 
78. Cunningham, M. W. (2000) Cross-reactive antigens of group A streptococci. in Gram-positive 
pathogens (Fischetti, V. A., Novick, R. P., Ferretti, J. J., Portnoy, D. A., and Rood, J. I. eds.), 
American Society for Microbiology Press, Washington, D.C. pp 66-77 
79. Dale, J. B. (2008) Current status of group A streptococcal vaccine development. Adv. Exp. Med. 
Biol. 609, 53-63 
80. Steer, A. C., Carapetis, J. R., Dale, J. B., Fraser, J. D., Good, M. F., Guilherme, L., Moreland, N. 
J., Mulholland, E. K., Schodel, F., and Smeesters, P. R. (2016) Status of research and 
development of vaccines for Streptococcus pyogenes. Vaccine 34, 2953-2958 
81. Steer, A. C., Law, I., Matatolu, L., Beall, B. W., and Carapetis, J. R. (2009) Global emm type 
distribution of group A streptococci: systematic review and implications for vaccine development. 
The Lancet Infectious Diseases 9, 611-616 
82. Guirguis, N., Fraser, D. W., Facklam, R. R., El Kholy, A., and Wannamaker, L. W. (1982) Type-
specific immunity and pharyngeal acquisition of group A Streptococcus. Am. J. Epidemiol. 116, 
933-939 
83. Hoe, N., Lukomska, E., Musser, J., and Lukomski, S. (2007) Characterization of the immune 
response to collagen-like proteins Scl1 and Scl2 of serotype M1 and M28 group A Streptococcus. 
FEMS Microbiol. Lett. 277, 142-149 
84. Peng, Y. Y., Yoshizumi, A., Danon, S. J., Glattauer, V., Prokopenko, O., Mirochnitchenko, O., Yu, 
Z., Inouye, M., Werkmeister, J. A., Brodsky, B., and Ramshaw, J. A. (2010) A Streptococcus 
pyogenes derived collagen-like protein as a non-cytotoxic and non-immunogenic cross-linkable 
biomaterial. Biomaterials 31, 2755-2761 
85. McNitt, D. H., Van De Water, L., Marasco, D., Berisio, R., and Lukomski, S. (2018) Streptococcal 
collagen-like protein 1 binds wound fibronectin: implications in pathogen targeting. Curr. Med. 
Chem. 25, 1-1 
86. Nizet, V., Ohtake, T., Lauth, X., Trowbridge, J., Rudisill, J., Dorschner, R. A., Pestonjamasp, V., 
Piraino, J., Huttner, K., and Gallo, R. L. (2001) Innate antimicrobial peptide protects the skin from 
invasive bacterial infection. Nature 414, 454-457 
87. Dorschner, R. A., Pestonjamasp, V. K., Tamakuwala, S., Ohtake, T., Rudisill, J., Nizet, V., 
Agerberth, B., Gudmundsson, G. H., and Gallo, R. L. (2001) Cutaneous injury induces the 
release of cathelicidin anti-microbial peptides active against group A Streptococcus. J. Invest. 
Dermatol. 117, 91-97 
88. Koide, A., Gilbreth, R. N., Esaki, K., Tereshko, V., and Koide, S. (2007) High-affinity single-
domain binding proteins with a binary-code interface. Proceedings of the National Academy of 
Sciences 104, 6632-6637 
89. Sha, F., Salzman, G., Gupta, A., and Koide, S. (2017) Monobodies and other synthetic binding 




90. Koide, A., Wojcik, J., Gilbreth, R. N., Hoey, R. J., and Koide, S. (2012) Teaching an old scaffold 
new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. J. Mol. Biol. 
415, 393-405 
91. Vazquez-Lombardi, R., Phan, T. G., Zimmermann, C., Lowe, D., Jermutus, L., and Christ, D. 
(2015) Challenges and opportunities for non-antibody scaffold drugs. Drug Discov. Today 20, 
1271-1283 
92. Martin, H. L., Bedford, R., Heseltine, S. J., Tang, A. A., Haza, K. Z., Rao, A., McPherson, M. J., 
and Tomlinson, D. C. (2018) Non-immunoglobulin scaffold proteins: Precision tools for studying 
protein-protein interactions in cancer. New Biotechnol. 45, 28-35 
93. Plückthun, A. (2015) Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for 
Research, Diagnostics, and Therapy. Annu. Rev. Pharmacol. Toxicol. 55, 489-511 
94. Škrlec, K., Štrukelj, B., and Berlec, A. (2015) Non-immunoglobulin scaffolds: a focus on their 
targets. Trends Biotechnol. 33, 408-418 
95. Koide, A., Bailey, C. W., Huang, X., and Koide, S. (1998) The fibronectin type III domain as a 
scaffold for novel binding proteins11Edited by J. Wells. J. Mol. Biol. 284, 1141-1151 
96. Albrecht, M., Renneberg, H., Wennemuth, G., Moschler, O., Janssen, M., Aumuller, G., and 
Konrad, L. (1999) Fibronectin in human prostatic cells in vivo and in vitro: expression, distribution, 
and pathological significance. Histochem. Cell Biol. 112, 51-61 
97. Katenkamp, K., Berndt, A., Hindermann, W., Wunderlich, H., Haas, K. M., Borsi, L., Zardi, L., and 
Kosmehl, H. (2004) mRNA expression and protein distribution of the unspliced tenascin-C 
isoform in prostatic adenocarcinoma. J. Pathol. 203, 771-779 
98. Inufusa, H., Nakamura, M., Adachi, T., Nakatani, Y., Shindo, K., Yasutomi, M., and Matsuura, H. 
(1995) Localization of oncofetal and normal fibronectin in colorectal cancer. Correlation with 
histologic grade, liver metastasis, and prognosis. Cancer 75, 2802-2808 
99. Hanamura, N., Yoshida, T., Matsumoto, E.-i., Kawarada, Y., and Sakakura, T. (1997) Expression 
of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in 
human colon adenomas and carcinomas. Int. J. Cancer 73, 10-15 
100. Gopal, S., Veracini, L., Grall, D., Butori, C., Schaub, S., Audebert, S., Camoin, L., Baudelet, E., 
Radwanska, A., Beghelli-de la Forest Divonne, S., Violette, S. M., Weinreb, P. H., Rekima, S., 
Ilie, M., Sudaka, A., Hofman, P., and Van Obberghen-Schilling, E. (2017) Fibronectin-guided 
migration of carcinoma collectives. Nature Comm. 8, 14105 
101. Lyons, A. J., Bateman, A. C., Spedding, A., Primrose, J. N., and Mandel, U. (2001) Oncofetal 
fibronectin and oral squamous cell carcinoma. Br. J. Oral Maxillofac. Surg. 39, 471-477 
102. Marsh, T., Pietras, K., and McAllister, S. S. (2013) Fibroblasts as architects of cancer 
pathogenesis. Biochim. Biophys. Acta 1832, 1070-1078 
103. Kalluri, R. (2016) The biology and function of fibroblasts in cancer. Nature Rev. Cancer 16, 582 
123 
 
104. Gulubova, M., and Vlaykova, T. (2006) Immunohistochemical assessment of fibronectin and 
tenascin and their integrin receptors α5β1 and α9β1 in gastric and colorectal cancers with lymph 
node and liver metastases. Acta Histochem. 108, 25-35 
105. Christofori, G. (2006) New signals from the invasive front. Nature 441, 444-450 
106. Lu, P., Weaver, V. M., and Werb, Z. (2012) The extracellular matrix: A dynamic niche in cancer 
progression. J. Cell Biol. 196, 395-406 
107. Nagaharu, K., Zhang, X., Yoshida, T., Katoh, D., Hanamura, N., Kozuka, Y., Ogawa, T., Shiraishi, 
T., and Imanaka-Yoshida, K. (2011) Tenascin C induces epithelial-mesenchymal transition-like 
change accompanied by SRC activation and focal adhesion kinase phosphorylation in human 
breast cancer cells. Am. J. Pathol. 178, 754-763 
108. Ou, J., Peng, Y., Deng, J., Miao, H., Zhou, J., Zha, L., Zhou, R., Yu, L., Shi, H., and Liang, H. 
(2014) Endothelial cell-derived fibronectin extra domain A promotes colorectal cancer metastasis 
via inducing epithelial–mesenchymal transition. Carcinogenesis  
109. Bae, Y. K., Kim, A., Kim, M. K., Choi, J. E., Kang, S. H., and Lee, S. J. (2013) Fibronectin 
expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in 
patients with invasive breast cancer. Hum. Pathol. 44, 2028-2037 
110. Yang, Z.-T., Yeo, S.-Y., Yin, Y.-X., Lin, Z.-H., Lee, H.-M., Xuan, Y.-H., Cui, Y., and Kim, S.-H. 
(2016) Tenascin-C, a Prognostic Determinant of Esophageal Squamous Cell Carcinoma. PLoS 
One 11, e0145807 
111. Spenlé, C., Saupe, F., Midwood, K., Burckel, H., Noel, G., and Orend, G. (2015) Tenascin-C: 
Exploitation and collateral damage in cancer management. Cell Adh. Mig. 9, 141-153 
112. Strohl, W. R. (2018) Current progress in innovative engineered antibodies. Protein & cell 9, 86-
120 
113. Forbes, N. S., Coffin, R. S., Deng, L., Evgin, L., Fiering, S., Giacalone, M., Gravekamp, C., 
Gulley, J. L., Gunn, H., Hoffman, R. M., Kaur, B., Liu, K., Lyerly, H. K., Marciscano, A. E., 
Moradian, E., Ruppel, S., Saltzman, D. A., Tattersall, P. J., Thorne, S., Vile, R. G., Zhang, H. H., 
Zhou, S., and McFadden, G. (2018) White paper on microbial anti-cancer therapy and prevention. 
J Immunother. Cancer 6, 78 
114. Linnebacher, M., Maletzki, C., Emmrich, J., and Kreikemeyer, B. (2008) Lysates of S. pyogenes 
serotype M49 induce pancreatic tumor growth delay by specific and unspecific antitumor immune 
responses. J. Immunother. 31, 704-713 
115. Maletzki, C., Linnebacher, M., Kreikemeyer, B., and Emmrich, J. (2008) Pancreatic cancer 
regression by intratumoural injection of live Streptococcus pyogenes in a syngeneic mouse 
model. Gut 57, 483-491 
116. Eisenstark, A., Kazmierczak, R. A., Dino, A., Khreis, R., Newman, D., and Schatten, H. (2007) 
Development of Salmonella strains as cancer therapy agents and testing in tumor cell lines. 
Methods Mol. Biol. 394, 323-354 
124 
 
117. Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W., and Vogelstein, B. (2001) Combination 
bacteriolytic therapy for the treatment of experimental tumors. Proceedings of the National 
Academy of Sciences 98, 15155-15160 
118. Saw, P. E., Kim, S., Lee, I.-h., Park, J., Yu, M., Lee, J., Kim, J.-I., and Jon, S. (2013) Aptide-
conjugated liposome targeting tumor-associated fibronectin for glioma therapy. J Mat. Chem. B 1, 
4723-4726 
119. Han, Z., and Lu, Z.-R. (2017) Targeting fibronectin for cancer imaging and therapy. Journal of 
Materials Chemistry B 5, 639-654 
120. Dobrovolskaia, M. A., and McNeil, S. E. (2007) Immunological properties of engineered 
nanomaterials. Nat Nano 2, 469-478 
121. Caswell, C. C., Barczyk, M., Keene, D. R., Lukomska, E., Gullberg, D. E., and Lukomski, S. 
(2008) Identification of the first prokaryotic collagen sequence motif that mediates binding to 
human collagen receptors, integrins α2β1 and α11β1. J Biol Chem 283, 36168-36175 
122. Naci, D., Vuori, K., and Aoudjit, F. (2015) α2β1 integrin in cancer development and 
chemoresistance. Semin. Cancer Biol. 35, 145-153 
123. Navab, R., Strumpf, D., To, C., Pasko, E., Kim, K. S., Park, C. J., Hai, J., Liu, J., Jonkman, J., 
Barczyk, M., Bandarchi, B., Wang, Y. H., Venkat, K., Ibrahimov, E., Pham, N. A., Ng, C., 
Radulovich, N., Zhu, C. Q., Pintilie, M., Wang, D., Lu, A., Jurisica, I., Walker, G. C., Gullberg, D., 
and Tsao, M. S. (2016) Integrin [alpha]11[beta]1 regulates cancer stromal stiffness and promotes 
tumorigenicity and metastasis in non-small cell lung cancer. Oncogene 35, 1899-1908 
124. Terao, Y. (2012) The virulence factors and pathogenic mechanisms of Streptococcus pyogenes. 
J. Oral Biosci. 54, 96-100 
125. Spanier, J. G., Jones, S. J., and Cleary, P. (1984) Small DNA deletions creating avirulence in 
Streptococcus pyogenes. Science 225, 935-938 
126. Scott, J. R., Cleary, P., Caparon, M. G., Heden, K. M. L., Musser, J. M., Hollingshead, S., and 
Podbielski, A. (1995) New name for the positive regulator of the M protein of group A 
Streptococcus. Mol. Microbiol. 17, 799 
127. Rasmussen, M., Edén, A., and Björck, L. (2000) SclA, a novel collagen-like surface protein of 
Streptococcus pyogenes. Infect. Immun. 68, 6370-6377 
128. Lukomski, S., Montgomery, C. A., Rurangirwa, J., Geske, R. S., Barrish, J. P., Adams, G. J., and 
Musser, J. M. (1999) Extracellular cysteine protease produced by Streptococcus pyogenes 
participates in the pathogenesis of invasive skin infection and dissemination in mice. Infect. 
Immun. 67, 1779-1788 
129. Lukomski, S., Nakashima, K., Abdi, I., Cipriano, V. J., Shelvin, B. J., Graviss, E. A., and Musser, 
J. M. (2001) Identification and characterization of a second extracellular collagen-like protein 






APPENDIX 1: SUPPLEMENTARY MATERIAL FOR CHAPTER 1 
SURFACE-EXPOSED LOOPS AND AN ACIDIC PATCH IN THE SCL1 PROTEIN OF 
GROUP A STREPTOCOCCUS ENABLE SCL1 BINDING TO WOUND-ASSOCIATED 
FIBRONECTIN 
Dudley H. McNitt, Soo Jeon Choi, Douglas R. Keene, Livingston Van De Water, Flavia 
Squeglia, Rita Berisio, Slawomir Lukomski 
Published in The Journal of Biological Chemistry 2018 293(20): 7796-7810. 
 
Table S1: Synthetic double stranded DNA blocks (gBlocks) and primer nucleotide 
sequences used in this study. 
 



































































(rScl.chi): recombinant chimeric streptococcal collagen-like protein.
GCCTCCAAAGGcTAGAAGGACGGCAGCGGCTGAGGTTAGCCCGTAGCGCCAGA
CTAGTTTGTTGAGATTATGGTGCTTTGATGTC 
Primer – pSL600_insert_1F 
ACACCATCGAATGGCCAGATG 
Primer – pSL600_insert_1R 
TTTACCAGCGAGACCATCAAGG 
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(Publication was part of invited review on biomarkers of disease. I wrote on the merits of utilizing the 
streptococcal collagen-like proteins 1 and 2 as biomarkers for group A Streptococcus infections) 
 
ABSTRACT 
Group A Streptococcus (GAS) infections are responsible for significant morbidity and 
mortality worldwide. The outlook for an effective global vaccine is reduced because of 
significant antigenic variation among GAS strains worldwide. Other challenges in GAS 
therapy include the lack of common access to antibiotics in developing countries, as well 
as allergy to and treatment failures with penicillin and increasing erythromycin resistance 
in the industrialized world. At the portal of entry, GAS binds to newly deposited 
extracellular matrix, which is rich in cellular fibronectin isoforms with extra domain A (EDA, 
also termed EIIIA) via the surface adhesin, the streptococcal collagen-like protein 1 
(Scl1). Recombinant Scl1 constructs, derived from diverse GAS strains, bind the EDA 
loop segment situated between the C and C’ β-strands. Despite the sequence diversity 
in Scl1 proteins, multiple sequence alignments and secondary structure predictions of 
Scl1 variants, as well as crystallography and homology modeling studies, point to a 
conserved mechanism of Scl1-EDA binding. We propose that targeting this interaction 
may prevent the progression of infection. A synthetic cyclic peptide, derived from the EDA 
C-C’ loop, binds to recombinant Scl1 with a micromolar dissociation constant. This review 
highlights the current concept of EDA binding to Scl1 and provides incentives to exploit 





“A biomarker is any measurement reflecting an interaction between a biological system 
and a potential hazard, which may be chemical, physical, or biological. The measured 
response may be functional and physiological, biochemical at the cellular level, or a 
molecular interaction.” (1). In the case of pathogens, typical biomarkers are genes or 
surface proteins/components that are expressed during the infection. Biomarker 
identification and characterization aid in the understanding of pathogenesis and can be 
used for diagnosis or treatment (2), e.g., the surface adhesin HBHA of Mycobacterium 
tuberculosis, as biomarker to distinguish between latent and active tuberculosis infections 
(3). The identification of novel biomarkers is a compelling need for many bacterial 
pathogens, including highly virulent bioterrorism threat pathogens, such as Francisella 
tularensis and Burkholderia spp. (4,5), or pathogens with antibiotic resistance concerns, 
such as Staphylococcus aureus and group A Streptococcus (6). 
  Group A Streptococcus (GAS) is a human-adapted pathogen that is responsible 
for over 700 million infections worldwide each year (7). Diseases linked to GAS infection 
range in severity from non-invasive superficial pharyngitis and impetigo to severe and 
invasive diseases like necrotizing fasciitis or streptococcal toxic shock syndrome (7). 
Additionally, post-infectious autoimmune sequelae include rheumatic fever and rheumatic 
heart disease, acute poststreptococcal glomerulonephritis, and pediatric autoimmune 
neurologic disorder associated with streptococci, also known as PANDAS (8-10). Invasive 
and autoimmune diseases account for approximately 500,000 deaths globally each year 
(7). GAS can transiently colonize barrier tissue sites, such as throat mucosa and the 
surface of the skin (11). When the barrier is breached, the resultant wound provides GAS 
with a portal of entry into host tissues and the interstitium. Once inside the wound, GAS 
adheres to exposed extracellular matrix (ECM) and cells, thus enabling colonization of 
the host. These essential first steps of infection that are critical to colonization are 
augmented by several GAS surface adhesins, such as a prominent GAS surface adhesin 
and key virulence factor, the M protein (12). DNA sequence encoding the outermost 
amino-terminal end of the M protein is hypervariable and is used for GAS typing, resulting 
in more than 220 emm types of GAS reported globally (13). Two other major GAS surface 
proteins are the streptococcal collagen-like proteins 1 (Scl1/SclA) and 2 (Scl2/SclB), 
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which are ubiquitous among GAS strains (14-18). In vitro assays and animal model 
experiments show that Scl1 contributes to host colonization and biofilm formation within 
tissues by binding to host extracellular matrix proteins, cellular fibronectin (cFn), and 
laminin (19,20). Scl1 binds to wound-enriched isoforms of cFn, containing the extra 
domain A (EDA, also termed EIIIA), which is a unique target and distinct from other GAS 
fibronectin adhesins (21). The ubiquitous presence of Scl1 in GAS strains across different 
M types and the distinctive binding to the EDA/cFn isoforms within the wound 
microenvironment make Scl1 a potential biomarker for GAS infections.  
  GAS infections are initially identified in physician’s offices, using a Rapid Antigen 
Detecting Test based on the original Lancefield’s concept to detect group A carbohydrate 
surface antigen (22). More recent methods target nucleic acids, such as GASDirect 
hybridization test, which identifies rRNA sequences specific to S. pyogenes in tissue 
swabs (23), and a PCR-based method was developed to detect GAS within clinical 
isolates (24); more information can be found elsewhere (25). In this review, we will discuss 
the merit of Scl1 and Scl2 proteins as potential GAS biomarkers, their unique functions in 
GAS pathogenesis, and strategies to utilize the Scl1-EDA interaction to target diverse 
and epidemiologically important GAS M types. The long-term goal is to disrupt wound 
colonization and prevent the spread of infection.  
 
2. SCL1 AND SCL2 AS BIOMARKERS OF GAS INFECTION  
A hallmark of a pathogen biomarkers is that it is expressed by all strains of the organism 
and during critical stages of infection. Both scl1 and scl2 genes have been identified in 
many epidemiologically important M types of GAS (14-17,26). scl1 expression is 
positively regulated by the multiple-gene regulator, Mga (14,15,27). Mga is a major 
virulence-associated transcriptional regulator expressed in all GAS strains (28-31). It 
controls the expression of key GAS virulence factors, including the M and M-like proteins, 
C5a peptidase, Sic, and Scl1 (14,15,32-34). Elevated transcription of scl1 has been found 
in GAS isolates from both non-invasive and invasive infections (26,35), underscoring the 
premise of Scl1 as a biomarker. Unlike Scl1, expression of full-length Scl2 protein is 
controlled during polypeptide translation by phase variation, which is associated with 
varying numbers of pentanucleotide CAAAA repeats located downstream of the scl2-start 
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codon (15-17). Like scl1, scl2 transcription has been observed during GAS infection, but 
protein expression varies between strains due to the aforementioned phase variation 
(15,36). The invasive M3-type GAS strains (37-39) show elevated levels of scl2 
transcripts and low levels of scl1 transcripts, compared with strains of several other M 
types (40). Therefore, Scl2 protein is a better biomarker in M3 organisms.  
  Detection of specific antibodies elicited during infection is commonly used in 
diagnostic assays. Host seroconversion to Scl1 and Scl2 antigens has been documented 
in humans and experimental murine models. Convalescent and acute-phase sera were 
positive for anti-Scl1 and anti-Scl2 antibodies following infections with M1-type and M28-
type strains. M1 GAS is a global pandemic M type, linked with both noninvasive and 
invasive infections across the globe (41,42). M28 GAS strains have historically been 
associated with puerperal sepsis and neonatal infections (43-45), but also with current 
cases of pharyngitis and invasive infections worldwide (46-49). Retrospective 
examination of sera from patients with known previous infection by M1 GAS strains 
detected anti-Scl1 antibodies in 64% of samples (50). Examination of acute and 
convalescent sera from pediatric patients with non-invasive M1 and M28 GAS infections 
identified broad presence of anti-Scl1 antibodies, whereas anti-Scl2 antibodies 
associated with M28 infections were detected with lower frequency; the Scl2 antigen is 
not expressed in M1 GAS strains due to an off-phase effect associated with CAAAA 
repeats (15,40). Others have reported the presence of both anti-Scl1 and anti-Scl2 
antibodies in patient sera infected by GAS strains of various M types that were collected 
from cases of pharyngitis and impetigo, as well as acute rheumatic fever (51)1. 
Interestingly, antibody levels against Scl1 and Scl2 antigens in patients suffering from 
severe and invasive infections (toxic shock and necrotizing fasciitis) with M1, M3, and 
M28 GAS were significantly lower than in patients with non-severe bacteremia, 
suggesting that humoral adaptive immunity plays an important role in the protection 
against severe invasive diseases (52). In murine models of pharyngitis and impetigo, mice 
administered intranasally and subcutaneously, respectively, with M1 and M28 strains 
seroconverted to Scl1 antigen, apparently expressed during infections (50). 
                                                          
1 SL unpublished data 
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Comparatively, there was moderate seroconversion for Scl2 antigen in mice infected with 
M28 GAS. Altogether, utilization of anti-Scl1 and anti-Scl2 antibodies as biomarkers 
depends on the type of GAS infection (e.g., throat versus skin infection and superficial 
versus invasive infection). Furthermore, variation in the primary Scl1 and Scl2 sequences 
across GAS strains pose additional diagnostic challenge. Alternative approaches, utilizing 
ligands that target Scl1 and Scl2 variants in multiple M types could circumvent these 
challenges.  
 
2.1. SCL1 AND SCL2 STRUCTURE 
Both Scl1 and Scl2 proteins have similar structural organization (53) (Figure 1A). Both 
are homotrimeric, with an N-terminal globular, sequence-variable (V) domain, followed by 
the collagen-like (CL) domain and a C-terminal cell wall-anchoring domain. The CL 
domain of both Scl1 and Scl2 is composed of varying numbers of Gly-Xaa-Yaa collagen 
repeats, analogous to triple-helical mammalian collagen (54,55). Structurally, the triple 
helix is a motif characterized by the association of three distinct polypeptide chains 
wrapped around a common axis, where each chain assumes a polyproline-II (PPII)-type 
conformation (56-59). However, the CL domain does not contain hydroxyproline, which 
provides the main stabilizing contribution to triple-helix structure in mammalian collagens 
(60-64). Indeed, bacteria lack the prolyl-hydroxylase, an enzyme necessary for post-
translational modification of Pro to Hyp. Despite the lack of Hyp, however, Scl1- and Scl2-
CL domains form triple-helix structures with a stability ranging between 35 and 40ºC, 
similar to mammalian collagens (54,65-68). Instead, alternative stabilization mechanisms 
are employed in bacteria that secure triple-helix stability, such as hydration networks, 
electrostatic interactions between side chains, and specific stabilization repeats (55,68).  
The primary sequences of V domains differ both between and within Scl1 and Scl2 
variants originating from strains of different M types (53). Despite sequence differences, 
secondary-structure prediction algorithms identified two conserved α-helices interspaced 
by a hypervariable segment (14,69). This prediction was validated by crystallography data 
of the recombinant protein, corresponding to the Scl2-V domain from an M3-type GAS 
(70,71) (Figure 1A). The crystal structure showed that the Scl2-V domain folds into a 
trimeric six-helical bundle, forming a cylinder that is 30 Å in diameter and 60 Å in height, 
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which is stabilized by a hydrophobic core and salt bridges. The inner core of this bundle 
consists of a parallel, trimeric structure in which helices are wrapped in a gradual left-
handed superhelix. Three further helices wrap antiparallel to the internal helices in a left-
handed direction around the exterior of the central trimer. The pairs of anti-parallel α-
helices are each connected with PPII-type loop segments. Structural and biophysical data 
suggested that V domains of Scls display dichotomous functions by first acting as triple-
helix stabilization domains through facilitating proper folding and refolding of the collagen 
triple-helix (72) and second, by mediating host-pathogen interaction (73-75). 
Consistently, recombinant collagen-domain constructs cannot refold following thermal 
denaturation (54,72). 
  This crystal structure served as the basis for homology models of sequence-
diverse Scl1- and Scl2-V domains (76) (Figure 1B). Homology models predicted with 
confidence that both the Scl1- and Scl2-V domains adopt similar six-helical bundle 
structures, where a flexible loop segment connects each α-helix pair. Crystal structure 
and homology models revealed two important features found in Scl1- and Scl2-V domains 
that are essential for EDA-fibronectin binding. First, the electrostatic potential surface of 
ligand-binding-positive Scl1 protein displays a negatively charged region in the center of 
the Scl1-V trimer, which is surrounded by neutral and positively charged residues. In 
contrast, the electrostatic surface of the binding-negative Scl2 protein displays a uniform 
negative surface charge throughout the crown of the Scl2-V domain (76). The 
arrangement of the electrostatic surface potential observed in the Scl1-V domains was 
associated with a pattern of conserved negatively charged amino acids, primarily E46, 
47(Scl1.1) and D48(Scl1.1), located at the C-terminus of the loop sequence at the junction with 
the α-helices forming the inner core of the Scl1.1-V bundle. Second, productive ligand 
binding is further due to the surface-exposed loops of the Scl1-V domain. Surface-
exposed loops and a characteristic distribution of charged residues are proposed as the 
key molecular determinants that generate the long-range interactions needed for ligand 




2.2. FIBRONECTIN WITHIN THE WOUND MICROENVIRONMENT 
Scl1 binds to several ligands found in tissue and blood, compared with Scl2; the latter’s 
function in GAS pathogenesis is less clear (reviewed in (53)). The collagen domain of 
Scl1 can bind and activate human collagen integrin receptors (73,74,77), whereas the V 
domain is responsible for the majority of ligand binding (19,69,77-80). Interestingly, Scl1 
mutants of M1-type GAS were attenuated in a mouse skin infection model, but not 
following intraperitoneal inoculation(18), conceivably due to differences in the capacity to 
evade innate immune defenses between wild type and mutant strains (18,81). In contrast, 
Scl1 mutants of two other M types exhibited increased lesion size in mouse skin (40). 
Here we focus on the interaction between Scl1 protein and the human ECM protein, 
cellular fibronectin (19,21).  
  GAS utilizes a wounded portal of entry to gain access to host tissues, initiating host 
colonization and subsequent infection. One of the essential measures during wound 
healing is the deposition of new distinct matrices that participate in tissue remodeling and 
signal pro-inflammatory responses. These complex processes engage macrophages and 
neutrophils in clearing out tissue debris and keratinocytes in facilitating wound closure 
(82,83). One of the major constituents of these matrices is fibronectin (Fn) (84-86). Fn is 
a high-molecular weight glycoprotein that exists in two main forms within the body, e.g., 
as a plasma fibronectin (pFn) secreted by hepatocytes into the blood stream and as a 
cellular fibronectin (cFn) secreted by cells within tissues (87). Both forms of fibronectin 
originate from the same gene, FN1, and are composed of three different types of 
repeating domains: types I, II, and III (87,88)(Figure 2A). cFn-mRNA can be alternatively 
spliced, resulting in more than 20 different isoforms found within the body (88-90). This 
alternative splicing leads to the inclusion of extra domains that are found in cFn, but not 
pFn. The alternatively spliced type III domains are known as extra domain A (EDA/EIIIA) 
and extra domain B (EDB/EIIIB), as well as different combinations of the type III 
connecting segment (IIICS), also known as the variable domain (90). The EDA-containing 
cFn isoforms (EDA/cFn) are highly expressed during embryonic development but only at 
negligible levels within healthy adult tissues (91-93). On the other hand, EDA/cFn 
isoforms are deposited in high quantities within inflamed and wounded tissue 
environments in adults and play essential roles in wound healing (92,94-96). EDA adopts 
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the prototypical type III repeat structure, which is composed of two β-sheets, forming a β-
sandwich consisting of seven β-strands (i.e. A, B, C, C’, D, E, and F) connected by loop 
segments (97,98)(Figure 2B). An important role for EDA/cFn within wounded tissue is to 
support host cell attachment, achieved by the interactions between the C-C’ loop of EDA 
and cellular integrin receptors, α9β1 and α4β1, as well as α4β7, which binds EDA by an 
unknown mechanism (99-101). Integrin α9β1 is upregulated by keratinocytes during tissue 
injury (94,102). Integrins α9β1, α4β1, and α4β7 through their attachment to EDA/cFn 
regulate important repair mechanisms, such as cell migration, angiogenesis, 
myofibroblast differentiation, growth factor secretion, and tissue remodeling 
(94,96,101,103,104).  
  Wound keratinocytes express α9β1, which exerts a “trans-dominant” inhibitory 
effect on α3β1 during angiogenesis in healing wounds (96). On keratinocytes, α3β1 binds 
to laminin-332, and this binding mediates endothelial cell migration and angiogenesis 
through the secretion of growth factors (105,106). Binding of α9β1 to EDA/cFn controls 
α3β1-mediated angiogenesis by modulating growth factor secretion, thereby reducing 
endothelial cell migration and survival during angiogenesis (96). Inhibition of α3β1 by α9β1 
occurs through changes in Src-mediated phosphorylation of focal adhesion kinase (96). 
The temporal expression of EDA/cFn, during wound healing, suggests that the α9β1-to-
α3β1 integrin cross-talk is important for controlling the level of angiogenesis. Given that 
Scl1 and integrin α9β1 bind to the same peptide region of the EDA segment, these findings 
suggest that α3β1-mediated effects in keratinocytes could be perturbed by Scl1-mediated 
streptococcal adhesion. 
One of the critical steps of wound healing is tissue remodeling, which is fostered 
by matrix metalloproteinases, which are secreted by both resident tissue cells and 
infiltrating immune cells (86,107). EDA/cFn fragments generated by this proteolysis 
activate toll-like receptor 4 (TLR4) on dermal fibroblasts, as well as monocytes and 
dendritic cells (101,107,108). This interaction induces the NF-κB signaling cascade, 
promoting pro-inflammatory responses, such as production of cytokines IL-8 and TNFα 
(108). EDA-mediated activation of TLR4 is dependent on the TLR4-co-receptor, MD-2, 
and evidence suggests that activation of TLR4 is enhanced by synergy from neighboring 




2.3. SCL1 BINDING TO WOUND FIBRONECTIN  
The Scl1 proteins of several different M types of GAS bind to the C-C’ loop of EDA, 
promoting GAS wound-specific recognition and tissue microcolony (in vivo biofilm) 
formation (21). The Scl1-EDA interaction is different from other fibronectin-binding 
proteins of GAS, such as PrtF1 and F2, Fba, FBp54, etc. These proteins bind to the N-
terminal fibronectin module composed of type I repeats, which is found in both pFn and 
cFn (110-113) (Figure 2A). Adherence to the N-terminal type I repeats occurs through a 
β-zipper mechanism, where the adhesin contributes an additional β-strand to one of the 
β-sheets of the type I Fn repeat (112). In contrast, Scl1 binding to the type III repeat of 
cFn, the EDA, engages the surface-exposed loops and negatively charged cleft of the 
Scl1-V domain (76).  
  Although not demonstrated experimentally, the Scl1-EDA/cFn interaction may alter 
normal wound-healing responses. First, Scl1 binding to EDA was mapped to the C-C’ 
loop (21) at or near the binding site of interaction with host cell integrin receptor α9β1 (99). 
By competing with the host’s integrins, Scl1 binding to EDA/cFn could lead to alterations 
of the dynamic wound-healing process, such as changes in angiogenesis (Figure 3). In 
addition, Scl1 could prevent or delay the formation of fibrosis by blocking α4β1-mediated 
attachment to EDA/cFn. It is currently not known, whether Scl1 binding to EDA affects 
TLR4 function. In such a scenario, Scl1 action could reduce the production of pro-
inflammatory cytokines and infiltration of neutrophils to the site of infection, thereby 
adding a new immune evasion strategy to the GAS repertoire (Figure 3). Ongoing 
experiments will test this hypothesis. Altogether, Scl1 plays essential roles in the 
pathogenesis of GAS and has the potential to alter host functions during infection.  
 
3. DIFFERENT STRATEGIES FOR TARGETING GAS INFECTIONS 
Currently, GAS infections are treated either with penicillin or erythromycin in patients with 
a penicillin allergy (114). Alarmingly, several studies documented penicillin treatment 
failure, with up to 30% of pharyngitis patients showing persistence of GAS following 
treatment (115-117). Additionally, there is an increasing frequency of erythromycin 
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resistance among GAS strains circulating in the industrialized world (118,119), again 
underscoring the need for new alternative strategies to treat GAS infection. 
  Considerable efforts have been undertaken by research laboratories in search of 
vaccine targets to prevent GAS infections and the development of a universal GAS 
vaccine. The immunogenic surface M protein serves as the basis for most GAS vaccine 
candidates, as it confers M type-specific immunity (120). Historically, cross-reactive 
antibody concerns between M protein and cardiac tissue impeded development of GAS 
vaccines for years; however, current methods utilize peptides corresponding to the N-
terminal hypervariable region, thereby avoiding autoreactive portions (121,122). A 26-
valent vaccine, which is composed of N-terminal hypervariable region peptides derived 
from 26 different M-protein types, has completed stage I/II clinical trials in the United 
States  (123). Still, other challenges exist, such as the high number of M protein types, 
the lack of vaccine protection from throat infections, and differences in M-type distribution 
across the globe (124,125). 
Antibodies against the Scl1 antigen may possibly be developed as a strategy to 
treat GAS infections. In general, anti-Scl1 antibodies could be opsonic or may well block 
the interactions between Scl1 and EDA/cFn, thus, preventing GAS colonization. Although 
infection with GAS can lead to the production of anti-Scl1 cross-reactive autoantibodies 
(outlined in section 2), others have found that recombinant Scl1-based collagen proteins 
are non-immunogenic (126). Variability of the amino acid sequence of the Scl1 V-domain 
would face challenges similar to those concerning the M protein-based vaccine. 
Therefore, targeting GAS with C-C’ loop-derived peptides could hypothetically overcome 
this hurdle. 
 
3.1. POTENTIAL PROBLEMS AND SOLUTIONS 
Inasmuch as utilizing peptides derived from the C-C’ loop of EDA is a rational premise for 
treating GAS infections, there are significant challenges that need to be overcome.  
 
3.1.1. BINDING AFFINITIES 
First, the binding affinities between C-C’-loop circular peptide and two different 
recombinant Scl1 variants, originating from M1- and M3-type GAS, were in a range of 
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40–60 µM KD, as estimated through surface plasmon resonance and tryptophan 
fluorescence binding assays (Fig. 2 C) (40). This binding is relatively weak, especially 
when compared with the binding affinity of an antibody. EDA-derived peptides can be 
improved for Scl1 binding by first systematically determining the minimum amino acids 
involved in the critical binding, using alanine scanning mutagenesis. After the minimum 
pharmacophore is found, then synthetic modifications of peptidomimetics can be 
generated and tested for binding; these compounds will incorporate natural and unnatural 
amino acids (e.g., D-amino acid, α-α-disubstituted amino acids, macrocycles, etc.) (127-
129). 
 
3.1.2. OFF-TARGET BINDING EFFCTS 
Second, off-target binding effects of the C-C’ loop peptide directly to host cell integrin 
receptor α9β1 could lead to dysregulation of the dynamic wound-healing processes, such 
as dysregulation in tissue angiogenesis (Figure 3). To address these challenges, the 
optimized C-C’ loop peptide must be tested for the potential recognition by host cell 
integrins and other receptors. 
 
3.1.3. STRAINS THAT DO NOT EXPRESS SCL1 
Third, although all strains carry the scl1 gene, a small subset of strains do not express 
Scl1, such as M3-type GAS (40). In these strains, however, Scl2 protein would serve as 
an alternative target.  
 
3.1.4. INCREASED INVASIVENESS 
Fourth, the C-C’ loop-peptide could increase bacterial spread via microcolony dispersion. 
Nevertheless, sessile GAS cells will be susceptible to drugs or C-C’ loop-derived peptide 
conjugated to an antimicrobial peptide, like LL-37 (130,131). 
 
4. CONCLUSIONS 
 The scl1 and scl2 genes are found in every strain of GAS, and both Scl1 and Scl2 
proteins elicit humoral immunity during infection. These factors make Scl1 and Scl2 
promising biomarkers of GAS infection.  
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 The Scl1-V domain structure is conserved among diverse GAS M types, and several 
rScl1 constructs bind to the C-C’ loop of EDA through the same mechanism. The 
conserved Scl1 structure and function in strains of epidemiologically important M types 
serve as the foundation for effective targeting of GAS.  
 EDA/cFn is highly upregulated within wounded tissues and plays important healing 
roles. Scl1 binds to the C-C’ loop of EDA, and this interaction stimulates wound-specific 
colonization of GAS, by facilitating pathogen adherence and tissue microcolony 
formation. Scl1 binding probably impedes the important wound-healing functions that are 
normally executed by EDA/cFn isoforms 
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Figure 1: Scl1 and Scl2 structure. (A) Top, Schematic representation of the common domain organization 
of Scl1 and Scl2 proteins. Domains: V, the N-terminal globular sequence-variable domain; CL, the collagen-
like domain; G+, the C-terminal cell-wall-anchor domain. Bottom insert, Cartoon representation of Scl2-V-
CL structure. This structure has been obtained by combining the crystal structure of the Scl2-V domain, 
with the modeled structure of the CL domain, generated using the structure of the collagen peptide (Pro-
Pro-Gly)10 as a template; only the first 15 Gly-X-Y repeats is shown for clarity. (B), Homology model of the 
Scl1-V domain. Left, Side view of the Scl1-V domain, showing the six-helix bundle fold, with three pairs of 
anti-parallel α-helices and connecting loop segments. The N-terminus and C-terminus of a single 
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representative α-helix pair is marked. Right, Top-down view of the Scl1-V domain. The three helix-pairs are 
shown, wrapped in a left-handed orientation. Negatively-charged amino acids, and their positions within the 
Scl1-V domain, are marked. These residues are conserved in EDA-binding-positive Scl1 proteins. The 
homology model is based on the crystal structure of the Scl2-V domain originating from M3-type group A 








Figure 2: Scl1 binds to cellular fibronectin that contains extra domain A. Schematic of fibronectin, 
model of EDA, and fluorescence binding data between C-C’ loop peptide and recombinant Scl1 (rScl1) 
proteins. (A) Schematic of fibronectin, with fibronectin type I, II, and III repeat domains denoted by squares, 
ovals, and hexagons, respectively. Regular Fn domains are shown in light grey and are numbered, 
constitutively, whereas alternatively spliced extra domains A, B and IIICS are shown in dark gray. Scl1-
EDA binding is marked with an arrow and binding regions for several GAS Fn-binding proteins (PrtF1, 
FbaA, SOF, etc.) are also indicated. (B) Cartoon representation of the EDA domain of fibronectin. Model 
(PDB accession code: 1J8K) shows the β-sandwich structure, with each β-strand marked (A, B, C, C’, D, 
E, F); the C-C’ loop is shown in ball-and-stick style and the corresponding amino acid sequence is shown 
below. (C) Binding assay based on tryptophan fluorescence for the Scl1-EDA interaction. Binding was 
assessed between a synthetic C-C’ loop-derived cyclic peptide and recombinant Scl1 forms derived from 
M1 (Scl1.1V) and M3-type (Scl1.3V) GAS. Tryptophan fluorescence quenching analysis shows the dose-
response curve of the fluorescence values for both Scl1.1V and Scl1.3V at 333 nm versus the concentration 





Figure 3: Modulation of host responses by GAS Scl1 during wound colonization. In this model, GAS 
gains access to the host via the portal of entry, shown here as a breach in protective epidermis (i.e. skin 
and throat mucosa). The wound microenvironment ECM is enriched with EDA/cFn isoforms. The globular 
V domain of Scl1 binds to the C-C’ loop of EDA, facilitating GAS biofilm formation and wound colonization. 
Neutrophils (NT) and keratinocytes (KC) bind to the C-C’ loop of EDA via integrin receptor α9β1, regulating 
important wound-healing functions. EDA/cFn also activates TLR4 on monocytes (MC) and dermal 
fibroblasts (DF) to stimulate the production of pro-inflammatory cytokines, TNFα and IL-8, through the NF-
κB signaling cascade. The Scl1-EDA/cFn interaction may alter several important wound-healing functions. 
Designed C-C’ loop-derived peptides could prevent GAS wound colonization and reverse potentially 
adverse effects of the Scl1-EDA/cFn interaction. 
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(Publication demonstrated that the lack of surface expression of Scl1 from M3 serotype of group A 
Streptococcus contributes to the invasiveness of this M type. I constructed and assisted in the 
construction of two plasmids used in this study - pSl503, pSL514) 
 
ABSTRACT 
The streptococcal collagen-like proteins 1 and 2 (Scl1 and Scl2) are major surface 
adhesins that are ubiquitous among group A Streptococcus (GAS). Invasive M3-type 
strains, however, have evolved two unique conserved features in the scl1 locus: (i) an 
IS1548 element insertion in the scl1 promoter region and (ii) a nonsense mutation within 
the scl1 coding sequence. The scl1 transcript is drastically reduced in M3-type GAS, 
contrasting with a high transcription level of scl1 allele in invasive M1-type GAS. This 
leads to a lack of Scl1 expression in M3 strains. In contrast, while scl2 transcription and 
Scl2 production are elevated in M3 strains, M1 GAS lack Scl2 surface expression. M3-
type strains were shown to have reduced biofilm formation on inanimate surfaces coated 
with cellular fibronectin and laminin, and in human skin equivalents. Repair of the 
nonsense mutation and restoration of Scl1 expression on M3-GAS cells, restores biofilm 
formation on cellular fibronectin and laminin coatings. Inactivation of scl1 in biofilm-
capable M28 and M41 strains results in larger skin lesions in a mouse model, indicating 
that lack of Scl1 adhesin promotes bacterial spread over localized infection. These 
studies suggest the uniquely evolved scl1 locus in the M3-type strains, which prevents 
surface expression of the major Scl1 adhesin, contributed to the emergence of the 
invasive M3-type strains. Furthermore these studies provide insight into the molecular 
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Group A Streptococcus (GAS) or Streptococcus pyogenes is a human-specific Gram-
positive pathogen responsible for significant morbidity and mortality worldwide (1,2). The 
clinical outcomes resulting from GAS infection range from superficial pharyngitis and 
impetigo to severe life-threatening diseases, such as streptococcal toxic shock syndrome 
and necrotizing fasciitis, as well as post-infectious sequelae, including rheumatic fever, 
rheumatic heart disease, and post-streptococcal glomerulonephritis (3). Historically, GAS 
has been a significant cause of puerperal sepsis, scarlet fever, erysipelas, and pharyngitis 
(4). GAS strains are epidemiologically subtyped based on nucleotide sequence variation 
at the 5’-end of the emm gene, reflecting differences in the hypervariable N-terminal 
region of the anti-phagocytic surface protein M. Over 240 M-types have been identified 
(http://www.cdc.gov/abcs/index.html), and certain M-types have been shown to have 
nonrandom associations with specific disease outcomes (3,5). Since the 1980’s there has 
been resurgence in invasive GAS diseases in the U.S. and other parts of the world. 
Numerous epidemiology studies conducted in the U.S. (6-11), Canada (12-15), and 
Europe (16-19) have found associations between infections with M1- and M3-type strains 
and invasive diseases. Specifically, M3-type strains have been associated with severe 
invasive disease (6,19) and fatal outcomes (14,16,17).  
These epidemiological observations have spurred significant whole genome 
sequencing efforts aimed at identification of the underlying genetic basis for virulence in 
M3-type GAS. The complete annotated genomes of invasive M3 strains MGAS315 and 
SSI-1 have been reported (20,21). These studies have revealed that differing phage 
elements, insertion sequences, and the large-scale chromosomal inversion identified in 
SSI-1, contributed to much of the genetic variation between M3 and other M-types. 
Acquisition of prophages and SNP’s drive the expansion of different M3 subclones during 
epidemic waves of infection (22,23). Additionally, strains causing pharyngitis and those 
causing invasive infections are derived from the same pool of M3 strains (24). In addition, 
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genetic variation in virulence regulators, including RopB and CovRS, which are “hot-
spots” for the accumulation of mutations, also contributes to the hypervirulence of M3 
strains (23-28). The cause of the hyper-invasive phenotype of M3 strains is multifactorial 
and involves multiple virulence factors controlled by complex regulatory networks that 
continually undergo remodeling.  
The streptococcal collagen-like proteins 1 and 2, or Scl1 and Scl2 (also known as 
SclA and SclB), are major GAS surface adhesins known to contribute to pathogenesis. 
Both Scl proteins contain an N-terminal variable region, followed by a collagen-like region 
containing Gly-X-Y repeats and a cell-wall-anchored C-terminal region (29-33). 
Transcription of scl1 is positively regulated by the multiple gene regulator Mga (30,32,34). 
Scl1 binds cellular fibronectin and laminin (35), and contributes to the formation of biofilm 
by strains of multiple M-types (36,37). GAS adherence and biofilm formation is enhanced 
on extracellular matrix (ECM) coatings and on fibroblast-deposited ECM network (37,38), 
supporting a role for Scl1 in tissue-microcolony formation described during GAS skin 
infection (39). While the scl1 gene has been found in every GAS strain tested (29,32), the 
scl1.3-allele in M3-type strains harbors a null mutation within the coding sequence (29). 
A rare natural reversion of this polymorphism was identified in a small subset of M3 carrier 
strains (40). 
Scl2-protein expression is regulated during translation by varying numbers of short 
CAAAA repeats downstream of the start codon that determine whether the protein-coding 
sequence is in-frame or translation will be prematurely terminated (30,31); genome 
sequencing indicates majority of the M3-type strain contain in-frame scl2.3 alleles (18,22). 
Scl2 has been shown in some strains to bind the human thrombin-activatable fibrinolysis 
inhibitor (41) and contribute to adherence to fibroblasts (31), although its role in GAS 
pathogenesis is less understood. Recently, the crystal structure of the Scl2.3 globular 
domain, which is structurally conserved between Scl1 and Scl2, has been reported 
(42,43) providing insight into the potential binding interactions with host ligands.  
In this study, we show that invasive M3-type GAS harbor two unique conserved 
features of the scl1 locus including the IS1548 insertion in the promoter region and the 
null mutation in the coding sequence, which results in a secreted instead of cell-attached 
Scl1 protein. We demonstrate significantly different expression patterns of scl1 and scl2 
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in M3-type GAS compared to representative strains of M1-, M28- and M41-types. We 
demonstrate that the expression of the Scl1 adhesin is deficient in serotype M3 strains, 
as opposed to M1-, M28-, and M41-type strains. However, the Scl2 protein is upregulated 
in M3 strains compared to M1, M28, and M41 GAS. The M3 strains lacked significant 
biofilms on cellular fibronectin and laminin coatings, compared to M41-type GAS, and did 
not form tissue microcolonies in a wounded pseudo-organ skin equivalent model of 
infection. Recombinant Scl1.3 specifically bound cellular fibronectin and laminin, and 
restoration of surface expression of Scl1.3 conferred significant biofilm formation by M3 
strains. Inactivation of Scl1 expression in biofilm-capable M28- and M41-type GAS 
resulted in larger skin lesions produced by the mutants in a mouse model of subcutaneous 
infection, supporting a role for Scl1 in maintaining a localized infection. Our model 
advocates that the lack of surface-associated Scl1 adhesin in M3-type strains causes 
decreased tissue adherence and decreased capacity for stable microcolony formation, 
thus, promoting bacterial spread over localized nidus of infection.  
 
EXPERIMENTAL PROCEDURES 
1. Bacterial strains and growth – MGAS315 and MGAS10870 are fully sequenced 
invasive M3-type strains (20,23). MGAS315 was isolated from a patient with streptococcal 
toxic syndrome in the 1980’s (6) and MGAS10870 was isolated from a patient with soft 
tissue infection in Ontario in 2002 (23). Additional strains from epidemiologically diverse 
M-types were used for comparison: MGAS6183 (M41), MGAS5005 (M1), and MGAS6143 
(M28). The MGAS6143∆scl1-, MGAS6183∆scl1-, and MGAS10870∆scl1-inactivated 
mutant strains have been previously described (40,44,45). Group A Streptococcus 
cultures were grown in Todd-Hewitt broth (Becton Dickinson and Co.) supplemented with 
0.2% yeast extract (THY medium) and on Brain Heart Infusion agar (Becton Dickinson 
and Co.) at 37°C in an atmosphere with 5% CO2. For antibiotic selection, erythromycin (5 
µg mL-1), chloramphenicol (10 µg mL-1), kanamycin (200 µg mL-1), and spectinomycin 
(100 µg mL-1) were added to the medium.  
Cloning experiments were performed in XL-1 Blue and TB1 E. coli cells, while 
protein expression experiments were performed in BL21 and TB1 E. coli cells grown in 
Luria-Bertani media (Difco Laboratories) at 37°C. For antibiotic selection, 
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chloramphenicol (10 µg mL-1), kanamycin (50 µg mL-1), spectinomycin (100 µg mL-1), and 
ampicillin (100 µg mL-1) were added to the medium. 
 
2. PCR assays 
 
2.1. Analytical PCR 
 
2.1.1. Detection of IS element upstream of scl1 in GAS strains – The presence of 
IS1548 upstream of scl1 was determined by PCR with primers IS1548F and Scl1R 
(Figure 1) using Qiagen Taq DNA polymerase (Qiagen, Germantown, MD) as follows: 
95°C, 5 min-[95°C 1 min, 62°C 1 min, 72°C 1 min] x30 cycles- 72°C, 10 min. Sequences 
of primers used in all PCR assays are listed in Table S1. 
 
2.1.2. PCR amplification of scl1.3 and scl2.3 alleles – PCR was performed on genomic 
DNA isolated from M3 strains with primer pairs 232 Up/ 232 Rev for scl1.3 amplification 
and sequencing, and Scl2.3 F/R and SclUp/ SclRev for length polymorphism analysis and 
sequencing of scl2.3, respectively. Amplification was performed using Qiagen Taq DNA 
polymerase as follows: scl1.3: 95°C, 5 min-[95°C 1 min, 55°C 1 min, 72°C 1 min] x30 
cycles- 72°C, 10 min; scl2.3: 95°C, 5 min-[95°C 1 min, 51°C 1 min, 72°C 1 min 45 sec] 
x30 cycles- 72°C, 10 min. All PCR products were analyzed in a 1% agarose gel with 1 kb 
Plus DNA ladder as a molecular size marker (Life Technologies, Grand Island, NY). 
 
2.2. Quantitative reverse transcription PCR (qRT-PCR) 
 
2.2.1. RNA isolation – Total RNA was isolated from the logarithmic phase (OD600 0.5) 
GAS cultures using RNeasy Protect Bacteria Mini kit (Qiagen), employing an additional 
pretreatment step with 250 µg lysozyme, 100 µg proteinase K, and 12.5 U mutanolysin 
per sample to augment cell wall disruption. Trace genomic DNA was removed by 
incubation with TurboDNase enzyme (Ambion). RNA quality was assessed in 1% agarose 
gel and spectrophotometrically; A260/280 and A260/230 ratios of >1.8 were considered 
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acceptable. RNA was used immediately in cDNA synthesis or stored at -80°C for no more 
than 1 week.  
 
2.2.2. Determination of transcription by qRT-PCR – Synthesis of cDNA was performed 
using iScript Select cDNA synthesis kit (Bio-Rad) with 1 µg of RNA per reaction and 
random primer mix. For each sample, a no reverse transcriptase control was performed, 
containing only RNA, reaction buffer, and random primer mix, to ensure the absence of 
genomic DNA. Incubations were carried out on a Bio-Rad C1000 Touch Thermal cycler: 
25°C 5 min, 42°C 30 min, 85°C 5 min, and cDNA was stored at -20°C until used in qRT-
PCR. qRT-PCR reactions were performed with 250 nM primers using SsoAdvanced 
SYBR Green Universal Supermix (Bio-Rad). For each qRT-PCR reaction, template 
cDNA, diluted 1:20, control genomic DNA, or no reverse transcriptase control were used. 
PCR was performed using the following conditions on a Bio-Rad CFX96 Thermal cycler: 
95°C 2 min- [95°C 5 sec, 60°C 30 sec]x30- [65°C- 95°C, 5 sec, 0.5°C/ step]. Standard 
curves were generated for each primer set using cDNA from MGAS315 to determine the 
linear range and estimate reaction efficiency. Gene expression of scl1, scl2, emm, and 
mga was normalized against the expression of tufA gene, which has previously been 
identified and validated as an appropriate endogenous control (46). The ∆∆Ct method 
was utilized to compare gene expression between MGAS315 and other M3 strains, as 
well as M1, M28, and M41-type strains. Data was averaged from three independent 
experiments, each containing three technical replicates. Statistical significance was 
determined using an unpaired t-test. 
 
3. Recombinant Scl (rScl) proteins 
 
3.1. Cloning, expression, and purification of M3-derived rScl proteins – The rScl 
proteins were generated using the Strep-tag II cloning, expression and purification system 
(IBA-GmbH, Gottingen, Germany). Proteins were expressed with a C-terminal affinity tag 
and purified on Strep-Tactin sepharose, as described (47). rScl proteins rScl1.3V and 
rScl1.3FL are derived from MGAS315, whereas rScl2.3 protein is derived from the M3 
strain MGAS3375. The recombinant Scl2.3V protein has been described previously (42). 
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Construct containing the recombinant full-length Scl1.3FL (rScl1.3FL) protein was 
previously described (40). Briefly, the scl1.3 coding region from MGAS315 was cloned 
into the E. coli/GAS shuttle vector pJRS525 (48), generating plasmid pSL501. PCR 
mutagenesis was used to convert the internal TAA stop codon into a GAA glutamate 
codon, resulting in plasmid pSL502 with continuous full-length scl1.3FL allele. This 
sequence was subsequently cloned into the pASK-IBA2 expression vector for 
recombinant Scl1.3FL protein production; each clone was verified by sequencing. Protein 
expression constructs are listed in Table 1. 
Protein expression was induced by the addition of anhydrotetracycline at 0.2 µg 
mL-1 for 3 hours. Cells were centrifuged and resuspended in high sucrose buffer (100 mM 
Tris-HCl, 1 mM EDTA, pH 8.0, 500 mM sucrose) or Cell Lytic B Buffer (Sigma), for 
separation of the periplasmic fraction and subsequent affinity purification. Proteins were 
dialyzed against 25 mM HEPES, pH 8.0, and analyzed by SDS-PAGE stained with 
RAPIDstainTM (G-Biosciences). Protein sequence was confirmed using mass 
spectrometry (University of Nebraska Medical Center) and N-terminal Edman 
Degradation sequencing (Iowa State University).  
 
3.2. Electron microscopy of rotary shadowed rScl proteins – Electron microscopy 
visualization of the rotary shadowed preparations of rScl1.3FL and rScl2.3 was used to 
assess the domain organization of rScl proteins, as employed previously (49). The rScl 
proteins were dialyzed against 0.1 M ammonium bicarbonate and mixed with glycerol to 
a final concentration of 70% (vol:vol). Samples were nebulized onto mica chips with an 
airbrush and rotary-shadowed with carbon/platinum using an electron beam gun. 
Photomicrograph images were acquired using a transmission electron microscope FEI 
G2 operated at 80KV. 
 
3.3. Mass spectrometry analysis – Samples from in-gel trypsin digested proteins were 
cleaned using a Millipore µC18 ZipTip, then resuspended in 0.1% formic acid. Samples 
were fractionated on a Eksigent cHiPLC column (75 µm x 15 cm ChromXP C18-CL 3 µm 
120 Å), and resulting peptides were sequenced using 5600 TripleTOF (typical gradient 2-
60% ACN in 60 minutes). Peptides identified were searched against the NCBI protein 
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database with Protein Pilot software employing the following settings: search effort, 
thorough; taxonomy, none. Positive identification was considered as the identification of 
two or more unique peptides at high confidence ≥95%, FDR=0.05, 0.01, or 0.001, which 
matched the same protein entry in the database searched.  
 
3.4. Binding of rScl proteins to extracellular matrix proteins and synthetic peptide 
 
3.4.1. ELISA binding assays – Binding of rScl proteins to extracellular matrix proteins, 
cellular fibronectin (cFn) and laminin (Lm), was tested by ELISA (35). rScl proteins were 
immobilized onto Strep-Tactin® coated microplate wells (IBA GmbH) at 0.5 µM at room 
temperature for 1.5 hours, then blocked with Tris-buffered saline (TBS) containing 1% 
bovine serum albumin (BSA) overnight at 4°C. The cellular fibronectin from human 
foreskin fibroblasts (Sigma) and murine laminin (Invitrogen) were added to the wells at 1 
µg per well and incubated at room temperature for 1 hour. Bound ECM proteins were 
detected with rabbit anti-laminin at 1:100 (Sigma) and anti- human fibronectin at 1:4,000 
(Sigma) polyclonal antibodies. Secondary antibody goat anti-rabbit IgG (H+L) HRP 
conjugate (Bio-Rad) was next used with 1-step ABTS substrate (2,2'-Azinobis [3-
ethylbenzothiazoline-6-sulfonic acid]-diammonium salt) (ThermoScientific). Absorption 
was measured using Spectramax 190 at a wavelength of 415 nm. Statistical analysis is 
based on three independent experiments each containing three technical replicates, 
using an unpaired t-test.  
 In antibody inhibition assay, the IST-9 mAb targeting the C-C’ loop of EDA domain 
was utilized (37). cFn was either untreated or pre-treated with increasing concentrations 
of IST-9 blocking mAb (0.1 µg- 1.0 µg), and added to Strep-Tactin®-coated microplate 
wells immobilized with rScl proteins, then incubated for 1 hour. Bound ECM proteins were 
detected as above. 
 
3.4.2. Design and synthesis of the C-C’ cyclic peptide – The C-C’ cyclic peptide was 
designed based on the crystal structure of the EDA domain of cFn (PDB code 1J8K). In 
particular, the region, which was reported to be involved in Scl1 binding, connecting to 
two β-strands C and C’ of EDA was elongated to the whole C-C’ β-hairpin by allowing the 
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formation the electrostatic interaction between Arg33 and Glu45. The terminal Tyr32 and 
Pro48 were mutated to Cys to stabilize the β-hairpin by introducing a disulfide bond 
(Figure S4). The obtained sequence, CRVTYSSPEDGIHELFC (molecular weight: 
1997.1 Da), endowed with a cyclic structure to mimic the structure of this region in EDA, 
was acetylated and amidated at the N- and C-terminus, respectively. Synthesis of the 
designed peptide was performed employing the solid phase method on a 50 μmol scale 
initially following standard Fmoc strategies (50). Due to aspartimide formation during 
traditional acylation reactions, peptide synthesis was carried out employing microwave 
technology (51). Cyclization was achieved by treating the peptide at 0.1 mg/mL (to avoid 
intermolecular disulphide formation) with buffer carbonate 50 mM, pH=9, overnight. The 
peptide was purified by RP-HPLC and the identity and purity (> 97%) was assessed by 
LC-MS (data not shown). 
 
3.4.3. Surface plasmon resonance (SPR) experiments – Real time binding assays 
were performed at 25 °C on a Biacore 3000 Surface Plasmon Resonance (SPR) 
instrument (GE Healthcare). For immobilization, rScl1.3FL protein containing the C-
terminal Strep-tag II was injected at a concentration of 40 µM on streptavidin-coated 
sensor chip, SA Biacore, until the desired level of immobilization was achieved 
(averaged value of 100 RU). Binding assays were carried out by injecting the C-C’ cyclic 
peptide at concentrations ranging between 10-500 µM. Experiments were carried out in 
HBS buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, pH 7.4). The association 
phase (kon) was followed for 270 s, whereas the dissociation phase (koff) was followed 
for 300 s. The reference chip sensorgrams were subtracted from sample sensorgrams. 
Experiments were carried out in duplicates. Kinetic parameters were estimated 
assuming a 1:1 Langmuir binding model and using version 4.1 Evaluation Software (GE 
Healthcare).  
 
3.4.4. Fluorescence binding analysis – rScl1.3FL protein, at a concentration of 30 μM, 
was incubated with increasing concentrations of C-C’ cyclic peptide (0 - 300 μM) at 25.0 
°C, using an excitation wavelength of 298.0 nm and a fluorescence emission wavelength 
ranging from 300 to 400 nm. The acquisition parameters were set as follows: excitation 
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and emission slits at 5 nm; 120 nm/min scan rate; 1.00 nm data interval averaging time 
at 0.500 s, PMT voltage at “high”. Fluorescence values were recorded at 333 nm, and 
subtracted from the fluorescence intensity of the ligand-free protein, generating -
∆fluorescence. The -∆fluorescence values were plotted against the peptide 
concentration. (52). Experiments were carried out in duplicates. A control assay was 
carried out employing the buffer as titrant to assess that the dilution effect was under 3%, 
not affecting the results.  
 
4. Complementation of GAS strains with full-length Scl1.3FL – For trans-
complementation experiments, plasmid pSL502, encoding full-length cell-associated 
Scl1.3FL protein, was electroporated into MGAS315 WT and MGAS6183Δscl1 
electrocompetent cells. The pJRS525 vector was electroporated as a control. 
Transformants were selected on BHI agar containing 100 µg mL-1 spectinomycin, and 
plasmids were re-sequenced. For MGAS10870∆scl1, which contains a spectinomycin 
resistance cassette in place of the scl1.3 allele, the spectinomycin resistance marker in 
pSL502 was replaced with a kanamycin resistance, generating the plasmid pSL518 and 
colonies were selected on BHI agar containing 150 µg mL-1 kanamycin.  
 
4.1. Determination of Scl1.3- and Scl2.3-protein expression in wild-type and 
complemented GAS strains 
 
4.1.1. Western blot analysis – Expression of the Scl1.3 and Scl2.3 proteins was 
determined by western immunoblotting of the bacterial cell wall and culture supernatant 
protein fractions, as described before (29,30). Briefly, bacterial cultures were grown to an 
OD600 of 0.5 and cells were harvested by centrifugation. Culture supernatant proteins 
were precipitated with trichloroacetic acid (Sigma) to a final concentration of 10% (vol:vol). 
The cell wall protein fraction was obtained after cell digestion with lysozyme and 
mutanolysin in a high sucrose buffer. A total of 10 µg of protein samples were separated 
by SDS-PAGE and transferred to a nitrocellulose membrane. Detection of Scl1.3, Scl2.3, 
and M3 proteins was performed using the same sample preparations with rabbit 
polyclonal antibodies generated against the truncated rScl1.3WT protein (anti-Scl1 
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1:15,000 dilution, reported in (40)) and the rScl2.3V region (anti-rScl2.3V 1:2,500; 
generated by Proteintech (43)). Horseradish peroxidase-conjugated goat anti-rabbit IgG 
(H+L) secondary antibody (Bio-Rad), combined with PierceTM ECL western blotting 
substrate (Thermo Scientific) was used for detection. Images were acquired using a 
ChemiDoc Touch Imaging System (Bio-Rad). 
 
4.1.2. Flow cytometry analysis – Surface detection of Scl1.3 and Scl2.3 proteins was 
determined by flow cytometry. Bacteria grown to an OD600 of 0.5 were harvested by 
centrifugation, and washed with flow cytometry buffer (sterile phosphate-buffered saline 
containing 10% Todd-Hewitt broth supplemented with 0.2% yeast extract). Cells were 
incubated with polyclonal antibodies against Scl1.3 and Scl2.3 described above at a 
dilution of 1:100 for 30 minutes on ice, then washed and incubated with Allophycocyanin 
(APC)-conjugated donkey anti-rabbit IgG (H+L) (Jackson ImmunoResearch) for 30 
minutes on ice. Cells were washed and fixed in 0.4% paraformaldehyde, and stored at 
4°C until analysis. Before analysis, cells were washed twice and resuspended in flow 
cytometry buffer. Cells were analyzed using a BD LSRFortessa, and 50,000 events were 
collected per sample. Data was analyzed using the FCS Express Flow 5 software.  
 
5. Assessment of biofilm formation 
 
5.1. Crystal violet staining assay – Wild-type, mutant, and complemented strains were 
grown to OD600 of 0.5 and seeded into 24-well culture plates coated with ECM at 2 µg per 
well, then incubated at 37°C with 5% CO2 for 24 hours. Wells were washed with PBS 
followed by the addition of 0.5 mL 1% crystal violet solution (Fisher Scientific) diluted in 
PBS and incubation at room temperature for 30 minutes. Wells were rinsed twice with 
PBS and stain was solubilized with 0.5 mL of 75% ethanol. Spectrophotometric readings 
were taken for each sample at OD600. Statistical analysis is shown based on three 





5.2. Confocal laser scanning microscopy (CLSM) – To visualize GAS by CLSM, 
bacterial cells were transformed with a GFP-encoding plasmid pSB027 (53), as before 
(36). 15-mm glass cover slips were placed into 24-well tissue culture plate wells and 
coated with 2 µg of cFn or Lm per well. Bacterial cultures grown to logarithmic-phase 
were added to the wells and allowed to form biofilms for 24 hours. Wells were rinsed with 
PBS and bacterial cells were fixed with 3% paraformaldehyde at room temperature for 30 
min. Wells were washed again and coverslips were mounted onto slides using ProLong 
Gold Antifade Mountant (Thermo Scientific). Confocal images were acquired using a 
63×/1.40 Plan-Apochromat objective and a Zeiss LSM 510 laser scanning confocal 
microscope.  
 
6. In vitro and in vivo GAS infection models 
 
6.1. GAS infection of in vitro cultured human skin equivalents – Wounded full-
thickness skin equivalents, EpiDerm-FT (MatTek, Boston, MA) were used. The tissues 
are discs 8 mm in diameter, which are provided in transwells. A 3-mm wound is generated 
by performing a punch biopsy to remove the keratinocyte layer. Immediately upon arrival, 
tissues were equilibrated in antibiotic-free manufacturer’s medium overnight at 37°C in 
atmosphere with 5% CO2. Wounds were infected with 10 µL of GFP-expressing log-phase 
group A streptococcal inocula and incubated in a humid environment at 37°C with 5% 
CO2 in daily-fresh media; a total of 4 experiments were performed and variables included 
the inoculum size of 3 x 106 -1.8 x 107 CFU and collection time points between 1-5 days. 
Tissues designated for histopathological evaluation were fixed in 10% formalin, whereas 
tissues for two-photon fluorescence (TPF) microscopy imaging were fixed in 4% 
paraformaldehyde for several hours and then transferred to petri dishes containing PBS. 
For visualization of glycocalyx produced by GAS strains, tissues were permeabilized with 
0.1% Triton X-100 in 1 x PBS and blocked with 0.05% Triton X-100 in 1x PBS with 1% 
BSA before staining with concanavalin A- tetramethylrhodamine (Molecular Probes). 
Tissues were then rinsed and stored in PBS at 4°C until TPF imaging was performed. For 
TPF analysis, an Olympus 60x/ 1.2NA water dipping objective was used. Fixed tissues 
were imaged by two-photon microscopy with the Ti:sapphire laser (Mira, Coherent) 
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intensity at 60 mW and input wavelength of 850 nm. Laser scanning images were 
collected at 0.5- 1 µm incremental depths using ScanImage (Janelia Farms, HHMI). 
Images were saved in a single TIFF file with 16 bit depth. Deconvolution of the images 
was performed using AutoQuant x3 and 3D models of z-stacks were generated using 
Imaris software. 
 
6.2. Mouse model of soft tissue infection – Animal experiments were conducted in 
compliance with the regulations and standards under the Animal Welfare Act, the Public 
Health Service Policy on Humane Care and Use of Laboratory Animals, and the Guide 
for the Care and Use of Laboratory Animals. The protocol was approved by the West 
Virginia University Institutional Animal Care and Use Committee (IACUC). 
Subcutaneous infections of mice were carried out as described previously (54). 
Briefly, 5-week-old male, immunocompetent, hairless mice (strain Crl:SKH1-hrBR) were 
used (Charles River, Wilmington, MA). Groups of 10-15 mice anesthetized with isoflurane 
were infected subcutaneously at the right flank with ~109 GAS CFU of WT or scl1-mutant 
strains, and mice were observed for 14 days. The weight and abscess dimensions (length 
[L] and width [W]) of each mouse were recorded daily during the first week and every 
other day thereafter. To analyze differences between mice infected with WT and scl1-
mutant GAS, the area of each abscess was calculated with the equation for the area (A) 
of an spherical ellipsoid: A=(L/2)x(W/2); statistical differences were calculated using the 
student’s t-test. At the conclusion of the experiments, mice were anesthetized and 
sacrificed by cervical dislocation. 
 
RESULTS 
M3-type GAS contain unique insertion of IS1548 element and nonsense mutation 
within the scl1.3 locus – Since the resurgence of invasive GAS infections in the 1980s 
and an advent of molecular epidemiology fostered by large-scale sequencing, significant 
efforts have been made to define the molecular basis for the invasive phenotype of M3-
type strains. In parallel to these advances, we identified two unique genomic traits in the 
scl1.3 locus, encoding streptococcal collagen-like protein 1: (i) the presence of an 
insertional sequence element, IS1548, in the promoter region and (ii) the presence of a 
167 
 
nonsense mutation within the coding sequence of scl1.3 allele that was absent in other 
M-types.  
Studies employing mga-inactivated mutants have indicated that Scl1 expression 
was positively regulated by the GAS-global transcriptional regulator, Mga (30,32). Two 
putative Mga binding sites were identified upstream of the scl1 coding sequence in the 
M1-type strain SF370 and experiments demonstrated that the Mga binding site distal to 
scl1 was responsible for transcription activation (34). Identical Mga binding sites I and II 
were also identified upstream of scl1.3 in the sequenced M3-type strain MGAS315 with 
IS1548 element inserted 38 bp upstream of the distal Mga I-binding site (Figure 1A). To 
determine if the IS1548 insertion was specific to M3 strains, we BLAST-searched this 
element in 45 completed GAS genomes representing 21 different M-types. We observed 
the presence of IS1548 in all strains searched with varying locations and occurrences 
from one to twelve per genome (Figure 1B). However, the IS1548 insertion upstream of 
the scl1.3 allele was only found in the sequenced genomes of M3-type strains MGAS315, 
SSI-1, and M3-b. Interestingly, a complete IS1548 element was not present upstream of 
scl1.3 in the recently reported genome of the M3 strain STAB902, which represents a 
non-invasive isolate (55); instead, a 34-bp remnant of IS1548, including the inverted 
repeat and additional 14 bp, was found. Based on this bioinformatics data, we examined 
the presence of the IS1548 element upstream of scl1 by PCR in a panel of 40 M3-type 
strains, using primers located in the IS1548 and scl1.3 sequences (IS1548F and Scl1R, 
Table S1). All M3-type strains examined were positive for the IS1548-scl1.3 amplicon, 
while M1, M41, and M28-type controls were negative (Figure 1C), demonstrating a broad 
and conserved presence of the IS1548 insertion in this location among M3-type GAS. 
 The nonsense mutation in the 11th Gly-X-Y repeat in the Scl1.3-CL collagenous 
region (Figure 1A, red box), presumably results in a truncated secreted variant, which 
consists of the Scl1-V variable region and 10 Gly-X-Y repeats but lacks the cell wall 
anchor. This polymorphism was originally identified in five M3-type invasive GAS strains 
but was absent in 45 other strains analyzed, representing 20 different M-types (29). It was 
later shown in 98.7% of 479 sequenced invasive M3-type isolates (40). We performed 
targeted PCR amplification of scl1.3 from 46 additional M3-type strains and observed 
identical amplicon sizes in all of them (Figure S1A). Sequencing showed that all tested 
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strains harbored an identical scl1.3 allele, containing 25 Gly-X-Y repeats in the 
collagenous domain with the null mutation in the 11th repeat (Data Set S1). A complete 
lack of genetic variation within scl1.3 is surprising and differs from the length variation 
that is commonly observed among scl alleles from other M-types (29,32,33). These 
results demonstrate that the IS1548 insertion and null mutation we identified in the scl1.3 
locus are unique to and conserved among M3-type GAS. Based on these results, we 
hypothesized M3 strains produce a truncated, but potentially biologically active Scl1.3 
variant, which is secreted instead of being cell-attached. 
 
scl1.3 expression is diminished in M3-type GAS – Original reports showed scl1 
transcripts in northern blots, as well as full-length Scl1 proteins (both cell-associated and 
cell-free fractions) in western blots for strains of emm types 1, 28, 52, and 41 
(29,30,32,45). To analyze the expression of the truncated Scl1.3 protein in M3-type GAS, 
western blot analysis was performed on cell-wall (CW samples) and culture-supernatant 
(Sup samples) protein fractions of several M3-type strains grown to exponential phase 
(Figure 2A). The expected truncated Scl1.3 protein was not detected by anti-Scl1 
antibodies, whereas the rScl1.3V positive control, corresponding to the V region of Scl1.3 
variant, produced the expected immunoreactive band of ~8.3 kDa. In an additional control 
experiment, the same panel of M3 strains was tested for Scl1.3 on the cell surface using 
flow cytometry (Figure 2B). No shift in median fluorescence intensity was observed in M3 
strains incubated with anti-Scl1 antibody compared to a secondary-only antibody control, 
indicating a lack of Scl1 on the cell surface among M3 strains.  
Given the unique IS1548-scl1.3 location and the lack of truncated Scl1.3 products 
in culture supernatants, we investigated scl1.3 expression by qRT-PCR. Total RNA was 
isolated from exponential phase cultures of 5 M3-type strains, as well as from previously 
characterized control strains of emm types 1, 28, and 41 (29,30,32,45). Expression of 
scl1 from each strain was compared to scl1.3 transcription in M3 strain MGAS315 (Figure 
2C). Each non-M3-type strain tested had significantly higher transcription level of 
respective scl1 allele compared to MGAS315. The M1 strain had the most increased 
expression by 21-fold, while M28 and M41 strains exhibited 6-fold and 8-fold higher scl1 
expression, respectively. Interestingly, the scl1.3 transcripts examined in four additional 
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M3-type MGAS strains 158, 335, 1313, and 10870 were significantly reduced as 
compared to MGAS315, with a range of 25-45-fold decrease. Overall, we observed that 
M3-type GAS harboring the IS element upstream of scl1.3 have drastically decreased 
scl1.3 transcript levels and lack the Scl1 protein product, as assessed by western blot 
and flow cytometry.  
Since scl1 is regulated by the transcriptional activator Mga, we investigated 
whether the decreased scl1.3 transcripts in M3 strains were due to lack of mga gene 
expression in these strains. In parallel, we assessed transcript levels of the emm gene 
encoding the M surface protein, a key virulence factor regulated by Mga. For comparison, 
we included the M1 strain, which had significantly increased scl1 expression compared 
to the M3 strains. With the exception of MGAS335, which had significantly downregulated 
mga and emm expression, we found no significant differences in either mga or emm gene 
expression between MGAS315 and the other M3 strains or M1 strain (Figure 2D). 
Furthermore, M3 protein was highly expressed, as it was found in both cell wall and 
supernatant fractions, except for the MGAS335 strain, consistent with transcription data 
(Figure 2E). These results demonstrate that the striking downregulation of scl1.3 in M3-
type GAS is not due to decreased mga expression or non-functional Mga protein, as emm 
is normally expressed in these strains. 
 
scl2.3 is expressed in M3-type GAS – Scl2 shares a similar structure with Scl1 but its 
biological function is poorly understood. One study demonstrated in a different M-type 
background that isogenic mutant devoid of Scl2.55 variant had lower adhesion to human 
skin fibroblasts (Rasmussen and Bjӧrck, 2001); however, the Scl2.3 variant present in 
M3-type GAS has not been investigated for expression and ECM binding. Therefore, we 
next assessed scl2.3/Scl2.3 expression in M3 strains. PCR amplification and sequencing 
showed that the majority of M3 strains contained in-frame scl2.3 allele (Figure S1B, Table 
S2).  
Western blot analysis of cell wall (CW samples) and supernatant (Sup) protein 
fractions found Scl2.3 protein was expressed by M3 strains MGAS315, 10870, 158, 9517 
and 1313, whereas samples obtained from strain MGAS335, which contains an out-of-
frame scl2.3 allele, generated no immunoreactive band; rScl2.3V control produced the 
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expected 10.1-kDa band (Figure 3A). Mass spectrometry confirmed the identity of the 
presumed immunoreactive Scl2.3-protein band from MGAS315 (Table S3). Consistently, 
Scl2.3 was detected on the surface of all five M3 strains containing in-frame scl2.3 alleles 
by flow cytometry, with a positive shift in median fluorescence intensity ranging in 67-131-
fold change, as compared to the secondary-only antibody control (Figure 3B). We next 
compared the scl2-transcription level in M3 strain MGAS315 with scl2-transcription levels 
in M1-, M28-, and M41-type strains. In striking contrast to the pattern of scl1.3 
transcription, scl2 transcripts were significantly decreased in the M1-type strain by 13-
fold, as well as in the M28 (6-fold) and M41 (3-fold) strains (Figure 3C). Additionally, there 
was no significant difference between scl2 expression in MGAS315 and the M3 strains 
MGAS158, 335, 1313, and 10870 (Table S4). These results confirm that the M3 scl2.3 
allele is transcribed at high levels, resulting in considerable expression of the Scl2.3 
protein. These results suggested that Scl2 has an important biological function in M3 
strains and warranted subsequent experiments assessing Scl2.3 function.  
 
GAS infection disseminates through human tissue and inhibits wound healing – A 
wounded human skin equivalent, devoid of an inflammatory component, was utilized as 
a “mechanistic model” of GAS tissue colonization. The epidermal wound of each skin 
equivalent was infected with GFP-expressing M3-type invasive strain MGAS315 or M41-
type non-invasive strain MGAS6183, and analyzed after 1-5 days by standard 
histopathology (H&E and Gram’s stain) and using two-photon fluorescence (TPF) 
microscopy. H&E of uninfected tissue controls harvested at day 0 showed the absence 
of a keratinocyte layer where the punch biopsy was performed (Figure 4A). Complete 
healing of the wound was observed after 5 days, with a newly-generated intact 
keratinocyte layer covering the punch biopsy site (Figure 4B). In contrast, tissue infected 
with either GAS strain exhibited delayed wound closure as late as day 5 post-infection 
(Figure 4E, H). H&E staining of skin equivalents infected with either M3 or M41 after 24 
hours revealed bacterial colonization of the exposed dermal surface, as well as bacterial 
invasion into puncture-associated defects extending deep into the dermal layer, largely 
located at the wound edges (Figure 4D, G). Notably, extensive bacterial growth and 
spread was largely confined to tissue crevices in the dermis, whereas the presence of 
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large bacterial colonies directly below the wound bed was rarely seen on microscopic 
examination. By day 5 of infection, bacterial invasion via these dermal defects extended 
to the bottom of the dermis for both strains, presenting both vertical and lateral spread of 
bacteria (Figure 4E, H). Gram stain of infected tissues showed the formation of superficial 
colonies near dermal surfaces, as well as biofilm formation on the surface of exposed 
dermis (Figure 4J-L). Additionally, epidermal tissue neighboring the wound bed exhibited 
~60% decreased thickness of the viable keratinocyte layer in tissues infected with 
MGAS315 and MGAS6183 by day 5, relative to uninfected tissues (Figure 4C, F, I). This 
suggests bacterial infection of the wound affects epidermal cells distant from the site of 
infection in this model.  
 TPF analysis was then performed on whole infected skin equivalents on day 5 
post-infection in order to assess bacterial spread directly below the wound bed. This 
method allowed us to visualize bacterial structures within tissue that were not apparent in 
H&E or Gram-stained sections. Tissue microcolonies were observed in samples infected 
with M41 GAS (Figure 4N), whereas M3 cells had a scattered appearance (Figure 4P). 
TRITC-concanavalin A (TRITC-conA) was utilized to visualize glycocalyx associated with 
bacteria. TRITC-conA stain colocalized with bacterial microcolonies formed by the M41 
GAS (Figure 4O, Figure S3), indicating microcolonies were encased in a glycocalyx, 
much like a classic biofilm. In contrast, TRITC-conA stain was associated with scattered 
M3-GAS chains located at the bottom cell layer in MGAS315-infected skin equivalents 
(Figure 4Q). These results indicate that M41 GAS, but not the M3 GAS, forms 
microcolonies in the tissue during a human skin infection that are encased in a glycocalyx, 
consistent with the observation that M41, but not M3, GAS forms robust biofilm in vitro on 
ECM coatings. In addition, M3 GAS disseminates in a form of scattered chains or single 
cells through the tissue.  
 
M3-type GAS strains form poor biofilms on extracellular matrix coatings – It was 
previously reported that M3-type strains have no substantial biofilm formation in vitro on 
an inanimate surface (36). Here, we tested biofilm formation on cellular fibronectin (cFn) 
and laminin (Lm) coatings by a panel of representative M3 strains isolated from invasive 
cases of GAS disease, as compared to the non-invasive biofilm-capable M41-type model 
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strain MGAS6183. As expected, wells coated with either cFn or Lm supported robust 
biofilm formation by the M41 strain, whereas significantly less bacterial biomass was 
measured for all M3-type GAS on both ECM coatings (Figure 5A). There was also no 
correlation between Scl2 expression and biofilm formation. We hypothesized that M3-
type GAS, devoid of Scl1 adhesin, have decreased binding to cFn and Lm ECM 
components, thus, preventing the formation of tissue microcolonies, and that restoration 
of full-length Scl1.3 (Scl1.3FL) on the GAS cell surface will confer binding to host ECM, 
as well as biofilm capacity in vivo (Figure 5B).  
 
Full-length recombinant Scl1.3 binds cellular fibronectin and laminin – To test this 
hypothesis, we: (i) constructed Scl1.3- and Scl2.3-derived recombinant proteins, (ii) 
characterized their structural organization, and (iii) assessed their ECM-binding 
capacities.  
First, rScl1.3FL and rScl2.3 proteins were assessed for purity and integrity by SDS-
PAGE (Figure 6A). The expected 20.6-kDa rScl1.3FL migrated at ~34 kDa, which is 
consistent with previous reports of aberrant migration of rScl proteins (29,30), whereas 
the rScl2.3 protein migrated according to the expected molecular mass of 16.2 kDa; both 
proteins were verified by mass spectrometry (Table S3). Rotary shadowed rScl1.3FL and 
rScl2.3 constructs, exhibited the characteristic lollipop-like structural organization (Figure 
S2), as observed for previously characterized rScl proteins (47,49). Interestingly, 
rScl1.3FL formed aggregates that were mediated by the intermolecular interactions 
between the globular domains; such interactions, however, were not observed between 
rScl2.3 molecules. The appearance of Scl1-Scl1 aggregates implies an attractive 
hypothesis that V-to-V-region interactions between the Scl1 molecules, but not between 
the Scl2 molecules, on the surface of neighboring GAS chains may support biofilm 
structure, as proposed in our model (Figure 5B).  
It has been established that Scl1 proteins selectively bind cellular, but not plasma, 
fibronectin and laminin (35), and that selective cFn binding is achieved by a unique 
binding mechanism involving the C-C’ loop of the extra domain A in cFn (EDA-cFn) (37). 
Here, we pre-incubated cFn with increasing concentrations of EDA-blocking IST-9 mAb 
(0.1, 1.0 µg), then added to wells containing immobilized rScl proteins and allowed for 
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binding. We observed significant dose-dependent inhibition of cFn binding to rScl1.3FL, 
with a 36% inhibition at 0.1 µg and a 60% inhibition at 1.0 µg of IST-9 (Figure 6B). In 
addition, the rScl2.3 protein did not bind cFn, which is consistent with our previous data 
employing several different rScl2 proteins (35). Surface plasmon resonance (SPR) 
measurements of binding affinity between rScl1.3FL and EDA-derived C-C’ cyclic peptide 
provided a dissociation constant of KD= 63.3 µM (Figure 6C). To corroborate the 
rScl1.3FL-EDA binding affinity, an in-solution fluorescence binding assay was performed, 
in which the variation in tryptophan fluorescence of rScl1.3FL was recorded as a measure 
of positive binding to the C-C’ cyclic peptide. Tryptophan fluorescence emission at 333 
nm showed a dose-response quenching upon addition of the C-C’ cyclic peptide and - 
fluorescence intensity was plotted against peptide concentration (Figure 6D). Data were 
fitted with a 1:1 model of interaction, providing a KD = 44.54 ±9 μM, in agreement with 
SPR data (56). 
We next assessed binding of rScl1.3FL and rScl2.3 proteins to laminin (Lm) by 
ELISA. We determined rScl1.3FL had significant Lm binding, whereas rScl2.3 had not 
(Figure 6E), consistent with previous findings that Scl1-derived recombinant proteins, but 
not the Scl2-derived, bind ECM proteins (35). Collectively, these results demonstrate 
specific binding of Scl1.3FL to the EDA domain of cFn and to Lm and its capacity of being 
surface adhesin. 
 
Homologous complementation of M3 strains with full-length surface-exposed 
Scl1.3 adhesin confers biofilm formation on ECM – To assess the effect of cell-surface 
Scl1.3FL expression on the capacity to form biofilm, an in-trans complementation of two 
representative invasive M3 strains was performed, MGAS315 wild-type (WT) strain, 
naturally lacking Scl1.3 expression, and a previously generated scl1-inactivated mutant 
of MGAS10870 (10870Δscl1), with plasmids pSL502 (SpR) and pSL518 (KmR), 
respectively, both encoding the full-length Scl1.3FL protein. As a control, MGAS315 was 
complemented with a shuttle vector pJRS525. The cell wall-associated expression of 
Scl1.3FL in complemented M3-type GAS was first tested by western blot analysis of the 
cell wall protein fractions and on the GAS-cell surface by flow cytometry. An expected 
~35-kDa immunoreactive band in complemented strains was observed, which was absent 
174 
 
in the parent strains (Figure 7A). Mass spectrometry analysis of the corresponding bands 
extracted from the gel confirmed they represented the Scl1.3FL protein, with five unique 
peptides identified with 17% sequence coverage for complemented MGAS315 and four 
unique peptides identified with 11% sequence coverage for complemented MGAS10870 
(Table S3). A 6.8-fold increase in median fluorescence intensity of Scl1.3FL-
complemented MGAS315 cells was measured by flow cytometry, as compared to the 
vector-complemented and WT control strains (Figure 7B). The Scl1.3FL-complemented 
10870Δscl1 exhibited a 2.2 -fold increase in median fluorescence intensity, as compared 
to the mutant control (Figure 7B). These results indicate the Scl1.3FL is indeed expressed 
and surface-exposed in the complemented M3-type strains. 
 Biofilm formation by the complemented and parent strains was then assessed after 
24 hours following crystal violet staining and using confocal laser scanning microscopy 
(CLSM). Scl1.3FL-expressing MGAS315 showed significantly increased biomass on both 
cFn and Lm coatings compared to the WT parent organism, as well as vector-
complemented control; 3.6 or 2.5- and 2.5 or 2.1-fold OD600 increases on cFn and Lm, 
respectively, were measured compared to MGAS315 WT or to vector-complemented 
MGAS315 (Figure 7C). Significantly thicker biofilm formed by Scl1.3FL-complemented 
MGAS315 was imaged by CLSM. We observed on average a 2.8-fold (P= 0.0002) and 
2.6-fold (P= 0.0002) increased biofilm thickness on cFn and Lm, respectively, compared 
to MGAS315 WT, and a 2.0-fold (P= 0.0036) and 4.8-fold (P= 2.1x10-5) increased biofilm 
thickness on cFn and Lm, respectively, compared to vector-complemented MGAS315 
(Figure 7D and E, representative images). Similar results were obtained for the 
complemented 10870Δscl1 mutant, which had 1.7-fold increase in biomass staining on 
both cFn and Lm compared to the MGAS10870 WT strain, and 2.2- and 2.6-fold increase 
in biomass staining on cFn and Lm, respectively, compared to the 10870Δscl1 mutant 
strain (Figure 7C). CLSM data, however, could not be rendered for MGAS10870 strains 
due to poor GFP expression for unknown reasons. Altogether, it was demonstrated that 
null mutation in the scl1 gene, which ablates surface Scl1.3 protein and is unique to M3-
type GAS, is responsible for the decreased biofilm capacity since restoration of the full-




Heterologous complementation of M41 Δscl1 mutant strain with full-length surface-
exposed Scl1.3 restores biofilm formation on ECM – In a previous study we showed 
that scl1.41-inactivation in a non-invasive biofilm-rich M41 strain MGAS6183 resulted in 
significantly decreased biofilm capacity, which was restored to wild-type level by 
complementation with surface Scl1.41 (37). Notably, this M41 strain expresses at least 
one additional major Fn-binding protein, protein F2 (45), which binds both plasma and 
cellular fibronectin by a mechanism different from Scl1 (57). Here, we hypothesized that 
expression of rScl1.3FL in the heterologous M41 GAS will confer biofilm formation. 
Western immunoblotting of the cell wall protein fractions detected the ~35-kDa 
immunoreactive band, corresponding to full-length Scl1.3, associated with complemented 
cells, while the M41Δscl1 mutant and WT cells were signal-negative (Figure 8A). Mass 
spectrometry of the corresponding band extracted from the gel confirmed Scl1.3FL 
expression, with 3 unique peptides identified, covering 13% of the amino acid sequence 
(Table S3). In addition, we showed the expression of the larger Scl1.41 variant in the cell 
wall of M41 WT, but not in the ∆scl1 mutant, by re-probing a portion of the blot with anti-
rScl1.41 antibody, using rScl1.41 protein as a positive control. 
 Similarly to complementation with homologous Scl1.41 protein, the heterologous 
complementation of the M41Δscl1 mutant with Scl1.3FL also restored biofilm to M41 WT 
levels on cFn and Lm (Figure 8B-D). Crystal violet staining showed increased bacterial 
biomass (Figure 8B) and confocal microscopy revealed significantly thicker biofilms, on 
average 3-fold increased, as compared to the parental M41Δscl1 mutant strain on both 
cFn (Figure 8C) and Lm (Figure 8D) coatings (cFn, P= 0.0105; Lm, P= 0.0011).  
 
Expression of Scl1 adhesin attenuates GAS during subcutaneous infection – We 
have previously shown that an M3 strain harboring a carrier scl1.3 allele, producing a 
shorter cell-attached Scl1.3 variant, had an attenuated phenotype in a murine model of 
necrotizing fasciitis (40). Here, we tested our hypothesis that Scl1 adhesin in biofilm-rich 
M28 and M41 background promotes stable colonization and localized infection, using a 
murine skin infection model. Hairless, immunocompetent SKH1 mice were 
subcutaneously infected with ~109 GAS CFU of the M28 and M41 wild-type (WT) or their 
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isogenic scl1-inactivated mutant (scl1) strains (44,45), and mice were assessed for 
changes in gross pathology of the skin. 
Skin lesions caused by both the WT and scl1 strains were observed as early as 48 
hours post-infection, and the lesions began to regress after day 7 with complete resolution 
of the lesion by the completion of the experiment. The areas of the skin lesions calculated 
for mice infected with the scl1 mutant strains were significantly larger than those of WT-
infected mice (Figure 9A; 96 hour time-point is shown); images of lesions of 
representative mice demonstrate differences in lesion severity between WT- and scl1-
GAS infected mice for both the M28- and M41-infected groups (Figure 9B). Thus, the in 
vivo data, using GAS strains expressing surface Scl1 proteins and producing rich biofilms, 
support our hypothesis that decreased adhesion and biofilm formation, due to the 
absence of Scl1.3 on the surface of M3 strains, bears an inverse correlation to the 
invasive potential of the infecting GAS strain.  
 
DISCUSSION 
Since the resurgence of invasive GAS disease in the 1980’s, and emergence of invasive 
M3-type isolates, significant efforts have been made to determine the molecular basis for 
the invasive phenotype of M3-type strains. Numerous whole-genome sequencing 
projects have identified specific genomic features of M3 strains that were correlated with 
their potential to cause invasive infections. In this study, we show that Scl1-negative M3-
type GAS have reduced adhesion and biofilm formation within host tissue, and therefore 
are predisposed to invasive spread over superficial infection (Figure 10).  
 
Unique topography and expression patterns of scl loci – First, the insertion of IS1548 
element in the promoter region of scl1 exclusively found in the M3-type strains is an 
intriguing observation, given the abundance of IS1548 insertions across GAS genomes 
representing a variety of M-types. IS elements are known to cause genomic 
rearrangements and affect the expression of important genes that contribute to bacterial 
virulence (58). For example, the insertion of IS1548 element (59) into the scpB-lmb 
intergenic region in group B Streptococcus has been shown to upregulate lmb-gene 
transcription and Lmb-adhesin surface expression, resulting in enhanced laminin binding 
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(60). The IS1548 insertion in the scl1.3 promoter was conserved in the genomes of 
sequenced M3 strains MGAS315, SSI-1, and M3-b, as well as in 40 additional M3 strains 
tested by PCR. However, the recently sequenced STAB902 M3 strain (55), which 
represents a non-invasive isolate, contained a 34-bp IS1548 remnant, suggesting that M3 
circulating strains exist with this polymorphism. We hypothesize that the proximity of the 
IS1548 insertion to the Mga I binding site in M3 strains affects scl1.3 transcription. 
Comparative qRT-PCR analysis showed significantly higher levels of scl1 transcription, 
particularly in M1, as well as in M28 and M41 strains, relative to M3-type strains analyzed.  
Variation in the Mga coding sequence and autoregulated mga promoter has been 
reported to significantly affect Mga-dependent gene expression and virulence properties 
in GAS (26,27,61). For example, a 12-bp deletion of a single repeat in the VNTR region 
of the mga promoter is present in M3 carrier strains and absent in the invasive M3 strains, 
causing a downregulation of Mga expression and Mga-regulated genes in the carrier 
strains (27). We identified an analogous 12-bp deletion in the VNTR of the mga promoter 
of the M1-type MGAS5005 and in M3 strains, MGAS335 and MGAS1313, but not in 
MGAS315, MGAS158 and MGAS10870. It is likely that the variation observed in the 
VNTR region impacts Mga expression but could not, alone, explain differences in scl1 
transcription patterns observed in this work. Consequently, qRT-PCR analyses showed 
mga and emm transcripts (emm is second downstream target of Mga within the Mga 
regulon) were expressed at similar levels in MGAS5005 and M3 strains, except for the 
MGAS335, indicating a mechanism of scl1 downregulation in M3 strains, which is 
independent from the level of Mga transcription. The presence of emm transcripts and 
M3-protein products indicate that Mga is present and functional in the majority of M3 
strains tested, and therefore the polymorphism we observed in the mga promoter did not 
affect Mga expression or activity of Mga-controlled scl1.3 promoter. Altogether, our data 
hint at the insertion of the IS1548 in the downregulation of scl1.3 expression, specifically 
in M3-type GAS, although additional studies are required to firmly establish whether the 
IS element insertion is responsible. 
It is intriguing that scl1 and scl2 expression patterns were drastically different 
between M1 and M3-type GAS, both associated with invasive infections. The scl1.3 
transcript was decreased by 21-fold in MGAS315, and even further in the remaining M3 
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strains studied (additional 20-45 fold), as compared to the M1-type strain MGAS5005. 
The upregulation of scl1 in M1-type GAS has previously been shown in invasive M1 
isolates, including MGAS5005, as compared to pharyngeal M1 isolates (62). Studies 
comparing wild-type and isogenic scl1.1 mutants in M1-type GAS reported that Scl1.1 
contributed to immune evasion by inhibiting neutrophil extracellular trap production and 
by protecting bacteria from the cathelicidin LL-37 (63). We conclude the differences we 
observed in scl1 expression are related to different pathogenicity requirements for Scl1 
protein in M1- versus M3-type strains. In contrast, Scl2 expression is highly upregulated 
in M3-type strains, as compared to invasive M1-type GAS. While the majority of M3-type 
strains contain in-frame scl2.3 alleles, all 21 M1 strains we analyzed contained out-of-
frame scl2.1 alleles (unpublished data). Although the Scl2.3 human ligands are not 
known, it may have an unidentified biological function, which is important for pathogenesis 
of M3, but not M1, strains. Hence, we are reporting striking differences in the expression 
and features of the Scl1 and Scl2 proteins that evolved in the invasive M1 and M3 strains. 
 
Scl1-mediated adhesion and biofilm formation in vitro – Scl1 mediates binding to 
human extracellular matrix components, cellular fibronectin and laminin, as well as biofilm 
formation (35-37). Previous work identified that Scl1 binds specifically to the C-C’ loop of 
the type III-repeat EDA domain of cellular fibronectin (37). This represents a novel 
mechanism of fibronectin binding, which is distinct from the mechanism employed by 
other GAS fibronectin-binding proteins that bind to the N-terminal type I repeats of 
fibronectin (64). Here, we determined that rScl1.3FL binds to cellular fibronectin via the 
same C-C’ loop-dependent mechanism. It is important for our overall model to 
acknowledge that the EDA-cFn isoform is specifically produced during embryogenesis 
and during wound healing in adult tissue (65-67), which indicates Scl1 evolved with a 
unique function for targeting wounded tissue, a presumed pathogen portal of entry. We 
also demonstrate significant binding of rScl1.3FL to laminin, a major basement membrane 
protein at the epidermal-dermal junction; none of those ECM ligands were bound by 
rScl2.3, consistent with previous knowledge that Scl1, but not Scl2, variants exhibit 
binding to cFn and Lm (35). These studies show that full-length Scl1.3, if expressed on 
the M3-GAS cell surface, would bind ECM, contributing to tissue colonization.  
179 
 
 The diminished Scl1.3 expression and poor biofilm formation, led us to hypothesize 
that lack of surface-expressed Scl1 in M3-type GAS reduces host ECM binding and stable 
microcolony formation in tissue, thus, shifting the balance towards invasive spread, 
augmented by other virulence factors expressed by these strains. Recombinant rScl1.3FL 
formed aggregates that were mediated by the V-to-V region interactions, which could 
represent a mechanism of biofilm and microcolony stabilization by Scl1 molecules on 
adjacent GAS cells. Two representative invasive M3 isolates, MGAS315 and 
MGAS10870, acquired biofilm formation on cFn and Lm when homologous 
complementation was performed with surface-attached Scl1.3FL. MGAS315 has been 
shown to contain a missense mutation in the covS gene, causing upregulation of CovRS-
regulated virulence genes and enhanced virulence during subcutaneous infection of mice, 
compared to an isogenic strain containing the WT covS allele (68). Additionally, 
MGAS315 contains a mutation in the regulator of protein B allele, ropB, which produces 
a nonfunctional RopB variant, while MGAS10870 contains a wild-type covR/S and ropB 
alleles (28), allowing us to demonstrate the effect of Scl1.3FL function in the presence of 
differing regulatory networks. Similarly, heterologous complementation with surface 
Scl1.3FL in a scl1.41-mutant of the non-invasive biofilm-capable strain M41-type 
MGAS6183, restored its biofilm capacity to the wild-type level. These results indicate that 
M3-derived Scl1.3FL variant has the full capacity to support biofilm formation to a similar 
degree as Scl1 from a divergent M-type. The robust biofilm observed in vitro on ECM 
coatings validates the concept that biofilm capacity combined with adherence to the 
surrounding host ECM would reinforce the formation of stable tissue microcolonies in 
vivo.  
  
In vitro skin equivalent model of wound colonization and microcolony formation – 
We observed inhibition of wound re-epithelization by GAS infection of wounded skin 
equivalents, as well as the thinning of the viable epidermal layer at sites distant from the 
infected wound. In addition to our study, others have reported changes in skin 
histopathology and wound healing, resulting from bacterial infections. An in vivo study 
has reported epidermal defects as a result of GAS infection in a humanized mouse model 
with human skin graft (69). Previous study of M3-type GAS infection using a skin 
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equivalent model showed that hyaluronic acid capsule interactions with CD44 receptor 
on keratinocytes induced intracellular signaling, resulting in cytoskeletal rearrangement 
and monolayer disruption (70). Infection of an in vitro skin model containing a burn wound 
with Pseudomonas aeruginosa caused a loss of the keratinocyte layer and basement 
membrane, while intact epidermis was observed in burned but uninfected tissue (71). 
Impairment of wound healing has also been demonstrated by staphylococcal infections. 
Infection of dermal wounds in rabbit ears with Staphylococcus aureus showed the 
formation of biofilm, production of a persistent, low grade inflammatory response, and 
significantly delayed wound healing (72). Similarly, delayed wound healing by both S. 
aureus and S. epidermidis biofilms was observed in a mouse model of cutaneous wounds 
(73). The inhibition of wound healing we describe here is by and large consistent with 
reports by other laboratories generated using in vivo animal and in vitro human skin 
infection models. 
Microcolonies have been identified within human streptococcal impetigo lesions 
(39) and in tonsils from patients with recurrent GAS pharyngeal tonsillitis (74), and likely 
represent a superficial or persistent state of GAS colonization. However, streptococcal 
infections can result in invasive disease due to biofilm disruption and bacterial 
dissemination (75,76). We observed large rounded microcolonies formed in tissue during 
infection with M41 strain, while M3 GAS remained scattered throughout the tissue as 
single cells and chains. Microcolony formation has been previously observed with S. 
aureus infection in organotypic skin model (77). Moreover, wound infection in rabbit ears 
with S. aureus produced mature biofilms encased in exopolysaccharide, as revealed by 
concanavalin A staining (72). Similarly, we also demonstrated that microcolonies in M41-
infected tissue were encapsulated in bacterial-associated glycocalyx. However, a lack of 
glycocalyx-encapsulated microcolonies was associated with infection by M3-type GAS.  
These results support our hypothesis that biofilm-poor M3 strains are abolished in 
stable microcolony formation in vivo, in part due to a lack of the ECM-binding Scl1 protein 
and an overall lack of surface adhesins, although they likely express the FbaB protein, 
identified in M3 GAS to be involved in the adherence and invasion into epithelial and 




In vivo mouse model of skin infection – Recent study reported that a small proportion 
of non-invasive M3-type strains (~1.3%) were found to harbor the scl1.3 “carrier allele”, 
which resulted from an in-frame deletion in the collagenous region, encompassing the 
null mutation, producing a shorter cell-attached Scl1.3 variant. This MGAS10870 strain 
containing the scl1.3 carrier allele was attenuated following intramuscular infection (40). 
In this study, we utilized the M28- and M41-type strains, representing biofilm-rich 
producers, for subcutaneous inoculation. We observed that scl1.28- and scl1.41-
inactivated isogenic mutants produced significantly larger skin lesions as compared to the 
wild-type parent strains. These results, again, support the hypothesis that lack of Scl1 
surface adhesin destabilizes focused nidus of infection, resulting in a shift towards 
increased tissue spread. However, previous studies performed in a M1 GAS background, 
utilizing scl1.1-mutants for subcutaneous infection, reported smaller skin lesions in the 
mutant groups, which likely reflects a differing predominant function of Scl1.1 in M1-type 
GAS (29,63). Investigations using intranasal and intraperitoneal mouse infection models 
of Streptococcus pneumoniae have shown that culture-grown bacteria disseminated to 
the ear and lungs, while biofilm-grown bacteria stably colonized the nasopharynx (81,82). 
A similar study on Streptococcus pyogenes showed that bacteria grown in biofilms have 
downregulated virulence genes and tend to colonize the nasal associated lymphoid tissue 
of mice, while culture-grown bacteria had significantly increased dissemination and were 
more virulent in a septicemia model (83). Previous studies reported that inactivation of 
some GAS genes resulted in increased skin pathology produced by the mutants 
compared to their wild-type organisms, and these genes often encoded surface proteins, 
including SpyCEP (84), Mrp (85), protein F1 (86), and Spy0128, encoding a major pilus 
subunit (87). Similarly, the covS mutant of group A streptococcal M1T1 strain with 
upregulated SpeB-protease activity was hypervirulent and had reduced capacity to bind 
human epithelial cells and fibronectin, and also to form biofilm due to increased cleavage 
of surface proteins (88). Altogether, the concept that expression of a surface adhesin, 
such as Scl1, involved in biofilm formation and host tissue attachment, is inversely related 
to strain invasiveness has gained support from several studies, including this study.   
We show the invasive M1- and M3-type GAS evolved scl1 and scl2 alleles with 
opposite expression patterns, with scl1 downregulated and scl2 upregulated in M3 
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compared to M1 GAS. We show M3-type GAS, devoid of surface-expressed Scl1.3, 
lacked biofilm formation on ECM coatings and microcolony formation during infection of 
in vitro wounded skin equivalent. Complementation with surface Scl1.3FL restored biofilm 
capacity of M3-type GAS on ECM coatings. Mouse infection with the isogenic scl1 
mutants of biofilm-rich M28- and M41-type GAS produced larger lesions, supporting the 
role of Scl1 in a localized tissue infection. Lastly we developed a model for Scl1-mediated 
microcolony formation (Figure 10), whereby Scl1 expressed on the GAS surface 
strengthens host colonization by attachment to cFn and Lm expressed within wounded 
tissue, as well as biofilm formation via Scl1-Scl1 interactions, resulting in a local, 
stabilized microcolony. Conversely, when Scl1 is absent on the GAS cell surface, as is 
the case for M3-type GAS, bacteria lack stable anchoring in the surrounding host ECM, 
as well as structural strength within microcolony, promoting cells to disperse more freely.  
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Figure 1: M3-type GAS strains harbor unique polymorphisms in the scl1.3 locus. (A) Schematic 
representation and nucleotide sequence are based on the scl1.3 locus in the M3-type strain MGAS315 
genome. The scl1.3 promoter region contains two putative Mga binding sites, Pscl1-I with Mga I and Pscl1-
II with Mga II. IS1548 is inserted 38 bp upstream of the preferred *Pscl1-I/Mga I promoter, which was shown 
to be necessary for scl1 transcription. Transcriptional start site (solid dot), -10 and -35 boxes are shown 
upstream of scl1.3 coding sequence. Scl1 regions are designated as follows: SS, signal sequence; V, 
variable region; CL, collagen-like region; L, linker region; WM, wall-membrane region; LPATG, cell-wall 
anchor. The null mutation in the 11th Gly-X-Y repeat of the CL region is depicted by the red box, presumably 
resulting in a truncated secreted Scl1.3 protein. Relative location of primers, IS1548F and Scl1R, used to 
generate amplicons in (C) are shown. (B) IS1548 insertion upstream of scl1.3 is unique to M3 genomes. 
BLAST search in the NCBI nucleotide (nr/nt) database using IS1548 (1,317 bp) sequence as query 
identified insertions in 45 GAS genomes representing 21 different M-types. Only genomes of M3-type 
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strains harbored IS1548 element upstream of the scl1 allele (bold text). (C) IS1548 insertion upstream of 
scl1.3 is conserved among M3 strains. Genomic DNA was isolated from a collection of 40 M3-type strains 
and analyzed by PCR for the presence of IS1548 upstream of scl1 using primers IS1548F and Scl1R 
(located in conserved scl1 signal sequence). Additional M1-, M41-, and M28-type control strains, and a no 
template control (NTC) are included. Expected amplicon size, 963 bp; M, 1 kb Plus DNA Ladder. MGAS 








Figure 2: Assessment of Scl1.3 expression. (A) Assessment of Scl1.3 production by M3-type GAS. Cell 
wall (CW) and culture supernatant (Sup) protein fractions prepared from exponential phase cultures of 
several M3-type strains were analyzed by western immunoblotting, using anti-Scl1 rabbit polyclonal 
antibody. Recombinant protein rScl1.3V, corresponding to the variable region of Scl1.3, was used as a 
positive control. Expected molecular masses: Scl1.3, 11.4 kDa; rScl1.3V, 8.3 kDa. M, PageRulerTM Plus 
Prestained Protein Ladder. (B) Detection of Scl1.3 on the surface of M3-type GAS. Flow cytometry analysis 
of several M3-type strains is shown using anti-Scl1 antibody described in part (A) (color-shaded histograms) 
or a secondary only control (2o sample, black outlined histogram). Median fluorescence intensities (MFI) 
are shown in parentheses for each strain. (C) Assessment of scl1 transcription. Fold-change of scl1 
transcript levels are shown compared to scl1.3 transcription in M3-type strain MGAS315. qRT-PCR was 
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performed on RNA obtained from exponential phase cultures. Results are shown from three independent 
experiments, each performed in triplicate wells. Standard errors and statistical analysis were computed 
from averaged ΔCt values for each biological replicate prior to normalization against the endogenous 
reference gene tufA; *P≤0.05, **P≤0.01, ***P≤0.001 (student’s t-test). (D) Assessment of mga and emm 
transcription. Relative expression levels of mga and emm genes were compared between MGAS315 and 
four additional M3 strains or the M1 strain MGAS5005. Results are shown from three independent 
experiments, each performed in triplicate wells. Standard errors and statistical analysis were computed 
from averaged ΔCt values for each biological replicate prior to normalization against the endogenous 
reference gene tufA; **P≤0.01. (E) Assessment of M3-protein production by M3-type GAS. The same cell 
wall (CW) and culture supernatant (Sup) protein samples prepared from exponential phase cultures of M3-
type strains (used in panel A) were analyzed by western immunoblotting, using anti-M3 protein rabbit 







Figure 3: Characterization of the scl2.3 locus in M3-type GAS. (A) Assessment of Scl2.3 production by 
M3-type GAS. The same cell wall (CW) and culture supernatant (Sup) protein samples prepared from 
exponential phase cultures of several M3-type strains (used in Fig. 2A, E) were analyzed by western 
immunoblotting, using anti-rScl2.3V rabbit polyclonal antibody. Recombinant protein rScl2.3V, 
corresponding to the variable region of Scl2.3 protein, was used as a positive control. Expected molecular 
masses based on MGAS315: Scl2.3, 52.5 kDa; rScl2.3V, 10.1 kDa. Aberrant migration of detected Scl2.3 
variants is characteristic of Scl proteins. M, PageRulerTM Plus Prestained Protein Ladder. (B) Detection of 
Scl2.3 on the surface of M3-type GAS. Flow cytometry analysis of several M3-type strains is shown using 
anti-rScl2.3V rabbit polyclonal antibody (color-shaded histograms) or a secondary-only control (2o sample, 
black outlined histogram). Median fluorescence intensities (MFI) are shown in parentheses for each strain. 
(C) Assessment of scl2 transcription. Fold-change of scl2 transcription levels are shown compared to scl2.3 
transcription in M3-type MGAS315. qRT-PCR was performed on reverse-transcribed RNA obtained from 
exponential phase cultures. Results are shown from three independent experiments, each performed in 
triplicate wells. Standard errors and statistical analysis were computed from averaged ΔCt values for each 







Figure 4: In vitro skin equivalent model of GAS infection. (A-I) H&E stained sections of uninfected (A-
C) or infected (D-I) wounded skin equivalents at 40x magnification; scale bar: 1000 µm. Uninfected wound 
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at day 0 (A) shows a lack of the epidermal layer where biopsy punch was performed, which healed by day 
5 (B). At day 1, infection of wounded skin equivalents with M3 and M41 GAS revealed superficial 
colonization of the wound bed, as well as invasion into the defects formed at the wound edge (D, G, arrows). 
By day 5, bacteria had disseminated throughout tissue laterally and vertically (arrows), reaching the bottom 
of the dermis layer (E, H). (C, F, I) H&E stained sections of the keratinocyte layer of intact skin surrounding 
the biopsy punch; scale bar: 100 µm. The thickness of the viable keratinocyte layer outside the wound (C, 
double arrow) was significantly reduced in tissues infected with M3 (F) and M41 (I) by day 5. (J, L) Gram 
stained sections of wounded tissue, corresponding to boxed areas in panels D and H, show tissue 
microcolonies (arrows) and superficial bacterial colonization (arrowheads). (J, scale bar: 400 µm; L, scale 
bar: 200 µm). (K, M) 1000x magnification micrographs of surface biofilms shown in J and L (scale bar: 10 
µm). (N-Q) Two-photon fluorescence microscopy analysis of infected skin equivalents. Vertical 
dissemination through the wound bed and glycocalyx formation by the GFP-expressing M41- (N-O) and 
M3-type (P-Q) GAS at day 5. 3D projections of z-stacks are shown from the top view of the z-stack (top 
panels) or the side view (bottom panels). Multi-channel images show GFP fluorescence of GAS cells (N, 







Figure 5: In vitro biofilm formation and hypothetical model of microcolony formation by invasive 
M3-type GAS. (A) Limited in vitro biofilm formation by invasive M3 strains on coatings with cellular 
fibronectin and laminin. A panel of invasive M3-type strains was compared to a non-invasive biofilm-capable 
M41-type strain MGAS 6183. Crystal violet staining was used to assess biomass formed after 24 hours of 
growth in wells coated with cellular fibronectin (cFn) and laminin (Lm); results represent averaged values 
from at least 3 independent experiments performed in triplicate wells. **P≤0.01 (student’s t-test). (B) 
Hypothesis model. Top: Infection of wounded skin with wild-type M3-type GAS. Inherent lack of surface-
expressed Scl1.3 causes decreased binding to cFn and Lm expressed in wounded tissue, and reduces 
biofilm and tissue microcolony formation by M3-type bacteria (red circles). Bottom: In-trans 
complementation of M3-type GAS with full-length cell-associated Scl1.3, Scl1.3FL, restores binding to cFn 








Figure 6: Construction and binding characterization of recombinant full-length Scl1.3FL and Scl2.3 
proteins. (A) Affinity purified rScl1.3FL and rScl2.3 proteins were analyzed by 4-20% gradient SDS-PAGE; 
expected molecular masses: rScl1.3FL, 20.6 kDa and rScl2.3, 16.2 kDa. (B-D-) Binding of rScl1.3FL to 
extra domain A (EDA) of cellular fibronectin. (B) IST-9 antibody inhibition identifies rScl1.3FL binding to the 
C-C’ loop of EDA-cFN. Inhibition of rScl1.3FL binding to EDA-cFn was tested by ELISA following pre-
incubation of cFn with blocking IST-9 mAb specific to the C-C’ loop. Significance of inhibition by 0.1 and 
1.0 µg of IST-9 mAb was determined by student’s t-test as compared to the untreated cFn. A lack of 
significant cFn binding by rScl2.3 was evident, as compared to rScl1.3FL-cFn binding; student’s t-test. (C) 
rScl1.3FL binding to a cyclic peptide mimicking the C-C’ loop of EDA using surface plasmon resonance. 
Overlay of sensorgrams for the interaction between immobilized rScl1.3FL and EDA-derived C-C’ cyclic 
peptide is shown. The experimental curves corresponding to different concentrations of peptide (10-500 
μM) were fitted according to a single binding model with 1:1 stoichiometry. (D) rScl1.3FL binding to a C-C’ 
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cyclic peptide using tryptophan fluorescence assay. Tryptophan fluorescence quenching analysis shows  
the dose-response curve of the fluorescence values of rScl1.3FL at 333 nm plotted against the 
concentration values of C-C’ cyclic peptide. (E) Laminin binding to rScl1.3FL and rScl2.3 by ELISA. 
Recombinant rScl proteins were immobilized onto Strep-Tactin-coated wells and incubated with laminin. 
Bound laminin was detected with specific primary pAbs and HRP-conjugated secondary Abs. Laminin 
binding was compared between rScl1.3FL and rSc2.3 and evaluated statistically using student’s t-test. 
Results for panels C and F represent averaged values from at least 3 independent experiments performed 






Figure 7: Homologous complementation of M3-type GAS with full-length surface-expressed Scl1.3 
protein confers biofilm formation. (A) Western blot detection of full-length Scl1.3 in cell wall fractions of 
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MGAS315 and MGAS10870∆scl1 complemented in-trans with the scl1.3FL allele. Parent strains were 
included as negative controls and rScl1.3FL was used as a positive control for detection. (B) Flow cytometry 
detection of Scl1.3FL on the GAS cell surface. Left: Fluorescence intensity of Scl1.3FL-complemented 
MGAS315 WT strain was compared to vector-complemented or WT parent strain. Right: Fluorescence 
intensity of Scl1.3FL-complemented MGAS10870∆scl1 was compared to WT and ∆scl1 parent strains. 
Median fluorescence intensities are shown in parentheses for each strain. (C) Crystal violet assessment of 
bacterial biomass after 24 hours of growth in cFn- or Lm-coated wells. MGAS315 WT complemented in-
trans with pJRS525 (SpcR vector) or pSL502 (Table 1) harboring the scl1.3FL allele was compared to WT 
parental strain. Spectinomycin resistant MGAS10870∆scl1 mutant was complemented in-trans with KanR 
pSL518 (Table 1), harboring the scl1.3FL allele. Biofilm biomass of the complemented strain was compared 
to MGAS10870 WT and scl1-inactivated parental strains. Results represent averaged values from at least 
3 independent experiments performed in triplicate wells. *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001; students t-test. 
(D, E) Confocal laser scanning microscopy analysis of biofilm formation by GFP-expressing MGAS315 
vector and scl1.3FL- complemented strains. Biofilms were grown for 24 hours on cFn-coated (D) or Lm-
coated (E) coverslips. Maximum intensity projections of GAS biofilms with cross-sectional views (left 
panels) are representative of z-stacks from ten fields within a single experiment. Average vertical thickness 







Figure 8: Heterologous complementation of scl1-deficient mutant of M41-type GAS with full-length 
Scl1.3 restores biofilm formation. (A) Left blot: western blot detection of full-length Scl1.3 protein in cell 
wall fraction of M41∆scl1::scl1.3FL using anti-Scl1 polyclonal antibody. The M41∆scl1 and M41 WT strains 
were included as negative controls, and rScl1.3FL was included as a positive control. Right blot: western 
blot detection of Scl1.41 in M41∆scl1 and M41 WT strains using anti-rScl1.41 antibody and rScl1.41 as a 
positive control. (B) Crystal violet assessment of biofilm biomass after 24 hours of growth in cFn- or Lm-
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coated wells. M41 scl1-inactivated (M41∆scl1) mutant was complemented in-trans with either homologous 
scl1.41 allele harbored on pSL230 or with heterologous scl1.3FL allele harbored on pSL502 (Table 1). M41 
WT, ∆scl1 mutant and two complemented mutant strains were assessed for biofilm formation and statistical 
significance was assessed by students t-test as compared to M41∆scl1; *P≤ 0.05, **P≤ 0.01. (C, D) 
Confocal laser scanning microscopy analysis of biofilm formation by GFP-expressing M41∆scl1 or 
M41∆scl1:: scl1.3FL. Biofilms were grown for 24 hours on cFn-coated (C) or Lm-coated (D) coverslips. 
Maximum intensity projections of GAS biofilms with cross-sectional views (top panels) are representative 
of z-stacks from ten fields within a single experiment. Average vertical thickness is indicated in micrometers. 







Figure 9: Skin pathology of SKH1 hairless mice infected subcutaneously with wild-type and scl1-
inactivated mutants of M28- and M41-type GAS. (A) Mean area of skin lesions in mice infected with M28- 
or M41-type isogenic GAS strains. The severity of skin lesions was compared following infection with wild-
type (WT) or scl1-mutant (scl1) GAS; 96-hour time-point is shown. The mean lesion area and standard 
deviation were calculated and compared between experimental groups. Data represents mean lesion size 
from at least 10 mice per experimental group. Statistical differences were calculated using the student’s t-
test; **P≤ 0.01, ***P≤ 0.001. (B) Gross pathology of the skin lesions. Digital images of the skin lesions of 
representative animals infected with either WT or scl1-mutant GAS. The images show skin lesions 








Figure 10: Model of Scl1-mediated GAS adhesion, biofilm formation, and host colonization. M28- 
and M41-type GAS express full-length cell-attached Scl1, which mediates adherence to cFn and Lm. ECM 
binding promotes biofilm formation in wounded tissue and allows the formation of superficial tissue 
microcolonies resulting in non-invasive colonization. On the contrary, in M3-type GAS, naturally lacking full-
length cell-attached Scl1.3 adhesin, bacterial cells have reduced adherence to cFn and Lm and reduced 
capacity for biofilm formation, thereby circumventing the formation of localized tissue microcolonies; 
infection balance is shifted towards dissemination through tissue, promoting invasive spread. 
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Figure S1. Analytical PCR of scl1.3 and scl2.3 in M3-type GAS. (A) PCR of scl1.3 in 42 M3-type strains 
was performed with primers 232Up and 232Rev flanking the scl1 locus (Table S1). Expected size based 
on MGAS315: 1,010 bp. M, 1 kb Plus DNA Ladder. (B) PCR of scl2.3 in 42 M3-type strains was performed 
with primers Scl2.3 F and Scl2.3 R flanking the scl2.3 collagen-like region (Table S1). Expected size based 
on MGAS315 genome is 1,125 bp. M, 1 kb Plus DNA Ladder. MGAS designation applies to all strain 









Figure S2. Domain organization of rScl1.3FL and rScl2.3 proteins. Rotary shadowing of rScl proteins 
demonstrates the conserved lollipop-like domain organization. Aggregates mediated by the interactions 
between V regions of rScl1.3FL are seen in the top panels (depicted by arrows). No apparent aggregation 
was observed in the rScl2.3 preparation (single lollipops are depicted by arrowheads). All scale bars reflect 









Figure S3. Colocalization of glycocalyx staining with GFP-expressing M41-type GAS during in vitro 
infection of skin equivalent. Representative TPF gallery image of z-stack layers from 3D projection 
(Figure 5 of manuscript), showing colocalization of TRITC-concanavalin A staining of glycocalyx (red) with 








Figure S4. Strategy for C-C’ loop peptide design. Cartoon model of the EDA domain of cFn (PDB code 
1J8K) used for the C-C' peptide design. The designed peptide includes the C-C' beta-hairpin (orange). The 
terminal residues of the beta-hairpin (magenta) were mutated to cysteine to induce a disulfide bond and 
mimic the conformation of the peptide in the protein. The key residue for recognition, Asp41, is reported in 
ball-and-stick along with the residues Arg33 and Glu45, which form a salt bridge, and the terminal residues 






Table 1. Constructs used in this study 
Plasmid Description Source 
pJRS525 E. coli / S. pyogenes shuttle vector  McIver and Scott. 1997 
pSL230 pJRS525 with scl1.41 allele  Caswell et al. 2007 
pSL501 pJRS525 with scl1.3WT allele  Flores et al. 2015 
pSL502 pSL501 with repaired allele scl1.3FL  Flores et al. 2015 
pSL518 pSL502 with KanR in place of SpcR  This study 
pASK-IBA2 E. coli expression vector IBA, Göttingen 
pSL154 pASK-IBA2 encoding rScl1.3V This study 
pSL503 pASK-IBA2 encoding rScl1.3FL Flores et al. 2015 
pSL514 pASK-IBA2 with rScl2.3  This study 





Supplementary Table 1: Primers used in this study 
Primer name Sequence (5’-3’) Use  
Analytical PCR   
IS1548F GCCGTCTGCGTGCCCATTGCGTCTA Detection of 
IS1548  Scl1 R ACTAGATCTGAGATTATGGTGCTTTGATGTC 
232 Up CTCCACAAAAGAGTGATCAGTC Amplification 
of scl1.3 232 Rev TTAGTTGTTTTCTTTGCGTTT 
Scl2.3 F AGGCATACAAGATCATGTCCTTGA Amplification 
of scl2.3  Scl2.3 R TTTGGTGTATGTGGTGCGGT 
Scl Up CTTTCAATGGATGACGATACC Amplification 
of scl2.3 Scl Rev ACTTTCCATCAGTTAGGTAGC 
   
Cloning   





232 Up CTCCACAAAAGAGTGATCAGTC Cloning of 
scl1.3WT  ME7 TCAGTGAATTCTCTTTAGAGGATTAG 




Scl1.3 M3VF GAGATGGCCGAGACTCCTATGACATCAAAGG Cloning of 
scl1.3FL  Scl1.28WMR GTCAAGCTTATTATTTTTCGAACTGCGGGTGGCTC
CAAGGTTTTTCTGGAGCTGGAGTTACC 






Scl2 M3VF GAGATGGCCGATGGTGAAGATGCCCAAAAAAG Cloning of 
scl2.3  Scl2.28_WMR GTCAAGCTTATTATTTTTCGAACTGCGGGTGGCTC
CAT 
   
qRT-PCR analysis   
tufA_F CAACTCGTCACTATGCGCACAT qRT-PCR of 
tufA tufA_R GAGCGGCACCAGTGATCAT 
Scl1_WMR_exp_F TGCTGACAAAGAAGCTAACCAAAC qRT-PCR of 
scl1  Scl1_WMR_exp_R GTGGTTGTTGGCTACAGGTGTCT 
Scl2_WMR_exp_F TCCTAAAACACCAGAGGTCC qRT-PCR of 
scl2  Scl2_WMR_exp_R2 TGTGTGTGTCGTGAGCTGC 
emm3_exp_F2 AACAAATCTCAGACGCAAGCCGTC qRT-PCR of 
emm  emm3_exp_R2 TTCAAGCTCTTTGTTWAGTTTTTCAAG 
Mga_TMF CAAGTCAACAGTGGAGAGAACTAAAATT qRT-PCR of 
mga  Mga_TMR ATGGAGATGTTGAGAGCTTTGCT 




a Bolded GAA in primer ME6 indicates codon for glutamine in place of the original TAA 




Supplementary Table 2: Variation in scl2.3 gene among M3 strains 
Strain  No. of GXY 
repeats 









MGAS274 ~125 ~1125 ~1206  8 yes 
MGAS315   116   1044   1125  5 yes 
MGAS335 ~135 ~1215 ~1296  4 no 
MGAS1313 ~119 ~1071 ~1152  8 yes 
AM3 ~129 ~1161 ~1242  10 no 
MGAS3375   17   153   234   5 yes 
MGAS9517   113   1017   1098 8 yes 
MGAS9622   111   999   1080 11 yes 
MGAS9631   113   1017   1098  18 no 
MGAS9716   110   990   1071 14 yes 
MGAS9726   111   999   1080 11 yes 
MGAS9739   119   1071   1152 5 yes 
MGAS9760   113   1017   1098 11 yes 
MGAS9780   106   954   1035 14 yes 
MGAS9842   139   1251   1332 9 no 
MGAS9852   103   927   1008 8 yes 
MGAS10080   117   1053   1134 5 yes 
MGAS10118   119   1071   1152 5 yes 
MGAS10220   110   990   1071 12 no 
a Amplicons were generated using primers Scl2.3 F/ R (Table S1) 




Supplementary Table 3: Mass spectrometry identification of rScl and native Scl 
proteinsa 








rScl1.3V 4 EENSQEELK 99% 40% yes 
EENSQEELKNFTEER 99%   
LKEILDLIEK 99%   
WYGTYFKEENSQEELK 99%   
rScl2.3 2 GIQDHVLDGQDGDR 99% 18% yes 
EELLSALIDGTSR 98.13%   
      
MGAS315 WT 
Scl2.3 in Sup 12 DVTPAPQNPSN 99% 17% yes 
DVTPAPQNPSNR 99%   
EELLSALIDGTSR 99%   
GEAGPAGPR 99%   
GIQDHVLDGQDGDR 99%   
GIQDHVLDGQDGDRGEAGPA
GPR 
99%   
GLNKPQTQGGNQL 99%   
GLNKPQTQGGNQLAK 99%   
NKPQTQGGNQLAK 99%   
REELLSALIDGTSR 99%   
TPEVPQKPDTAPHTPK 99%   
TPQIPGQSK 99%   
Scl2.3 in CW 7 DVTPAPQNPSNR 99% 15% yes 
EELLSALIDGTSR 99%   
GIQDHVLDGQDGDR 99%   
GIQDHVLDGQDGDRGEAGPA
GPR 
99%   
GLNKPQTQGGNQLAK 99%   
REELLSALIDGTSR 99%   
TPEVPQKPDTAPHTPK 99%   
 
Scl1.3FL- complemented GAS 
315WT :: 
scl1.3FL 
5 EENSQEELKNFTEER 99% 17% yes 
EILDLIEK 99%   
GDKGETGLAGPVGPAGK 99%   
GETGLAGPVGPAGK 99%   
LKEILDLIEK 99%   
10870∆scl1 :: 
scl1.3FL 
4 EILDLIEK 99% 11% yes 
GDKGETGLAGPVGPAGK 99%   
GETGLAGPVGPAGK 99%   
LKEILDLIEK 99%   
M41∆scl1 :: 
scl1.3FL 
3 EENSQEELKNFTEER 99% 13% yes 
GDKGETGLAGPVGPAGK 99%   
GETGLAGPVGPAGK 99%   
a Protein identification is confident by the presence of at least two distinct peptides with 




Supplementary Table 4: Summary table of fold-changes in scl1 and scl2 
expressiona 
Strain Gene Fold change +SE - SE P value Significance 
M1 scl1 21.05195084 -2.33583 -2.62734 0.001184755 **  
scl2 -23.6920597 -1.97551 -1.82347 0.01549836 * 
M28 scl1 6.237987683 -1.1098 -1.34997 0.01395444 * 
 scl2 -7.25032516 0.960352 1.106978 0.034822349 * 
M41 scl1 7.787441864 -0.82018 -0.91673 0.004897482 ** 
 scl2 -3.22615419 0.376259 0.425935 0.141911016 N.S. 
M3 MGAS: 
10870 scl1 -25.2160816 1.366976 1.445328 5.48581E-06 *** 
 scl2 -1.84753589 -0.01174 -0.01166 0.077646106 N.S. 
158 scl1 -45.8489636 -0.86051 -0.84465 0.000121468 ***  
scl2 1.077129939 0.059307 0.056212 0.753558444 N.S. 
335 scl1 -42.9309881 -4.03211 -3.68593 5.18378E-05 ***  
scl2 -2.44408041 -1.65928 -0.98832 0.283398851 N.S. 
1313 scl1 -43.929358 0.938527 0.959016 5.45812E-06 ***  
scl2 -3.89390614 -2.38312 -1.47835 0.117229672 N.S. 
aFold-changes in scl1 and scl2 expression relative to M3 MGAS315 are shown for each 
strain. Data is based on qRT-PCR analysis of RNA isolated during exponential growth 
phase and expression is normalized to the expression of tufA gene. +SE, positive 
standard error; -SE, negative standard error. Significance is calculated based on three 
independent experiments, each performed in triplicate wells. *P<0.05, **P<0.01, 
***P<0.001; student’s t-test.  
 
 
